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ABSTRACT 
 
Introduction: Pre-exposure prophylaxis (PrEP) can alter antibody kinetics resulting in 
delayed antibody binding avidity and reduced titres during the early post-HIV infection 
period. Data from the RV144 vaccine trial have underscored the protective role of non-
neutralizing antibodies (nNAbs), likely Fc-mediated, in HIV prevention. Previously published 
data from the CAPRISA 1 % tenofovir gel trial, showed distinct antibody profiles in the 
genital tracts, distinguished women with prior tenofovir gel use. The effect of prior PrEP on 
subsequent nNAb function was explored to elucidate whether IgG-specific nNAb functions 
were altered in the plasma and genital tracts of women in the tenofovir compared to those 
in the placebo arm post-HIV infection.   
Methods: An in-vitro neutrophil-based antibody dependent cellular mediated phagocytic 
functions (ADCP) assay and a novel intracellular cytokine staining NK cell activated antibody 
dependent cellular cytotoxicity (ADCC) assay at 3, 6 and 12 months post-infection in the 
tenofovir (n = 24) and placebo arms (n = 24), were conducted for gp120, gp41, p66 and p24 
IgGs in the plasma and genital tracts of women who seroconverted. Statistical analyses 
involved Wilcoxon Sum Rank test, Wilcoxon Singed rank test and Spearman R correlations. 
Results and Conclusions: HIV-specific ADCP and NK cell activated ADCC were detected in 
both the plasma and genital tract compartment. Gp70 V1V2 ADCP was higher in the plasma, 
while p66 and p24 specific ADCP was higher in the genital tract of women in the tenofovir 
arm compared to the placebo arm (P < 0.01; P < 0.1). Gp41 and p66 specific NK cell 
activated ADCC activity in the genital tract evolved significantly in women in the tenofovir 
arm (P < 0.1), in contrast to ADCP responses which were similar for both compartments (P > 
0.05) and specificities. Gp120 ADCP and NK cell activated ADCC remained higher in plasma 
compared to the genital tract (P < 0.001). Prior topical tenofovir gel did not diminish Fc-
mediated effector ADCP and NK cell activated ADCC functions, as evidenced by the higher 
NK cell activated ADCC and ADCP specific activity in the genital tract. Together, these data 
inform combination prevention strategies that parallel PrEP usage can influence humoral 
immunity and may even enhance; the diverse antibody-mediated effector functions post 
HIV vaccination, at the site of vulnerability, the genital tract. 
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CHAPTER 1 
 
Introduction 
 
Despite strides made in HIV prevention, HIV continues to be a global health challenge. 
Approximately 1.8 million [1.6 million-2.1 million] new infections occur annually, of which 
an estimated 64% of these new infections, occur in sub-Saharan Africa (Unaids, 2014b). 
Despite HIV prevention strategies, the number of new infections is declining too slowly to 
meet the UNAIDS goal of ending AIDS by 2030 (Unaids, 2017b). Young women (aged 15-24 
years) in particular, are more susceptible to HIV infection and account for 26% of new HIV 
infections despite only making up 10% of the population (Unaids, 2017b).  
 
Pre-exposure prophylaxis is currently one of the most promising biomedical HIV prevention 
tools.  In 2010, results from the CAPRISA 004 1% Tenofovir gel trial, provided evidence that a 
topical vaginal gel, used as PrEP, can confer protection (Abdool Karim et al., 2010). Several 
subsequent oral trials proved that oral PrEP could protect against HIV acquisition. However, 
PrEP efficacies have varied in women ranging from -49 to 75% with sub-optimal adherence 
being a key factor. Despite this fact, PrEP has been recommended in combination with other 
HIV prevention strategies and is currently being scaled up in several countries. 
 
Therefore the development of an HIV vaccine, particularly one that can overcome the 
current adherence challenges and induce a functional protective antibody response against 
HIV, remains the ultimate HIV prevention strategy for this global epidemic [as reviewed 
(Safrit and Koff, 2016, Plotkin, 2010)].  
 
Vaccine development, however, has proven challenging. Various factors such as waning 
antibody response following vaccination, the ability of the induced response to act against 
viral escape mutants, consensus on whether a vaccine should include multiple or single HIV 
epitopes, or target conserved or variable regions, contribute to the challenges associated 
with the development of an HIV vaccine (Rubens et al., 2015, Richman et al., 2003). The 
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RV144 vaccine trial is, to date, the only HIV vaccine trial, that achieved a modest 31.2% 
protection from HIV infection (Rerks-Ngarm et al., 2009). In recent years, vaccine research 
has also focussed on broadly neutralizing antibodies (bNAbs), which bind to various regions 
of the virus preventing HIV from infecting the cell, by inhibiting viral and target cell 
membrane or CD4 receptor fusion (Fauci et al., 2008). However, eliciting bNAbs through 
vaccination has been elusive. Particularly because bNAbs develop slowly, usually 2-3 years 
after HIV infection and require extensive levels of somatic hypermutation (SHM) in order to 
develop the breadth and potency required to neutralize various HIV virions (Mikell et al., 
2011, Burton et al., 2012, Haynes et al., 2012b).  
 
Interestingly, the observed efficacy in the RV144 trial was achieved in the presence of 
binding or non-neutralizing antibodies (nNAbs). Analysis of the immune correlates of 
protection, attributed protection to the induction of gp120 V1V2 specific nNAbs (Haynes et 
al., 2012a), which mediated antibody dependent cell-mediated cytotoxicity (ADCC) (Yates et 
al., 2014). Furthermore, ADCC can coordinate polyfunctional effector functions, a 
characteristic that correlated with HIV risk reduction in the RV144 trial (Chung et al., 2014, 
Chung et al., 2015). In addition to ADCC, a non-human primate study has shown evidence 
for the role of other nNAb functions, such as antibody dependent cellular phagocytosis 
(ADCP) as a correlate of protection (Barouch et al., 2013a). These findings underscore an 
important role of Fc-mediated functions in HIV protection.   
 
Antibodies in the genital tract generally show close concordance with circulating systemic 
antibodies, however their relative abundance differ between compartments. Previously 
published data from Archary et al., (2016) reported that HIV-1 specific binding antibodies to 
gp120, gp41, p66 and p24, IgG and IgA, were present in plasma and genital tract, in women 
who experienced breakthrough HIV infections, whilst using 1% tenofovir microbicide gel. 
Furthermore, HIV specific T cell responses were preserved and significantly increased 
magnitudes and frequencies of HIV-specific nNAbs were detected in the blood and genital 
tracts of women who used the tenofovir gel prior to coitus, compared to those women in 
the placebo arm (Archary et al., 2016). These data support the notion that exposure to PrEP, 
modulates immune responses in the genital and blood compartments (Castillo-Mancilla et 
al., 2015, Kersh et al., 2012, Archary et al., 2016). The Fc effector cell interaction in relation 
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to systemically and mucosally detectable nNAbs of women, are largely unknown. Therefore, 
the objective of this study is to understand if detectability and magnitudes of HIV-specific 
nNAbs have a functional cytotoxic and phagocytic advantage, in the context of prior topical 
PrEP exposure. This data may then enable us to tease apart putative immune correlates of 
protection, which may be highly desirable to elicit and block infection at the site of HIV 
exposure.  
 
Elucidating the effects of PrEP on functional antibody  such as IgG mediated ADCP and NK 
cell activated ADCC activity, may inform on future combination strategies aimed at 
increasing the qualitative and quantitative humoral immune response [as reviewed in 
(Corey et al., 2015)], ultimately leading to improved HIV prevention strategies that confer 
protection and prevent HIV acquisition, such as PrEP with vaccination.    
 
  
5 
 
CHAPTER 2 
Literature Review  
 
2.1 HIV epidemic worldwide and in sub-Saharan Africa 
 
HIV is a global epidemic affecting approximately 36.7million [34.0–39.8 million] people with 
a global prevalence rate of 0.8% (Figure 1) (Unaids, June 2016). Sub-Saharan Africa is home 
to approximately 64% of the world's new HIV infections (Unaids, 2014a). According to the 
most recent UNAIDS report South Africa bears the brunt of the HIV epidemic with 
approximately 7.1 million [6.4-7.8 million] HIV infected people living in South Africa (Unaids, 
2017b). 
 
FIGURE 1: World Map illustrating the global adult prevalence of (Unaids, 2017b). 
 
In an effort to reduce new infections, initiatives to increase the distribution of antiretroviral 
treatment have reduced global new infections by 16% from 1.8 million [1.6-2.1 million] 
between 2005-2013, respectively (Kharsany and Abdool Karim, 2016). Despite these figures, 
South Africa is off track to meet the 2030 target of fewer than 500 000 annual new 
infections, with current estimates at 270 000 [ 240 000- 290 000] (Unaids, 2017a). Women 
between the ages of 15-24 years of age account for approximately 26% of new infections in 
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South Africa and are particularly vulnerable to HIV infection (Abdool Karim et al., 1992, 
Shisana et al., 2009, Unaids, 2017b). 
 
In South Africa, the highest HIV prevalence rates are in the eThekwini district of Kwa-Zulu 
Natal (KZN) and the Ekurhuleni district in Gauteng. In Durban, KZN, the incidence rate is 6.3 
per 100 women years, in woman under the age of 25 years, underscoring the need for 
effective combination prevention strategies, particularly in these vulnerable populations 
(Shisana et al., 2009).  
 
Several social, behavioural and biological factors have been identified as contributors to 
women’s susceptibility to HIV infection (Adimora et al., 2013). Multiple sex partners, HIV 
viral load of the partner, gender based violence, sexually transmitted infections (STIs), the 
vaginal microbiome and age disparate sexual pairing, increases the  HIV acquisition risk in 
women (Kokab et al., 2010, Gianella et al., 2013, Lisco et al., 2012, Taha et al., 1998, 
Gregson et al., 2002, Van Der Straten et al., 1998, Dunkle et al., 2004, Abdool Karim, 2011, 
De Oliveira et al., 2017). HIV can be transmitted in several different ways, such as mother to 
child transmission, needle stick injuries, transmission by intravenous drug users and blood 
transfusions (Spinner et al., 2016). However, sexual transmission is the most frequent mode 
of HIV transmission and predominantly occurs via  mucosal portals of entry, such as the 
genital tracts of  females and males, as well as via the rectal mucosa [as reviewed in 
(Iwasaki, 2010)].  Additionally, biological factors in women, such as the mucous consistency 
in the female reproductive environment and surface area, may also influence HIV 
acquisition (Nicolosi et al., 1994). Factors such as endogenous hormones, the menstrual 
cycle and the use of injectable or oral hormonal contraceptives have been shown to 
influence the mucosal environment and may contribute to an increased risk of HIV infection 
(Tucker et al., 2012, Ralph et al., 2015, Morrison et al., 2015). In vitro and non-human 
primate (NHP) studies, have shown that depot-medroxyprogesterone acetate (DMPA), 
which causes epithelial thinning of the squamous epithelial layer, compromises epithelial 
barrier integrity (Poonia et al., 2006, Hadzic et al., 2014, Ngcapu et al., 2015). Furthermore, 
DMPA use in women, alters the innate immune profile of the female genital tract, acting as 
an immune-suppressive agent further increasing the risk of HIV acquisition in women 
(Ngcapu et al., 2015). However, such findings of the biological and cellular changes 
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associated with DMPA use, are yet to be confirmed in human studies designed to answer 
these questions and remains a topic of ongoing debate (Hild-Petito et al., 1998, Marx et al., 
1996, Mitchell et al., 2014, Bahamondes et al., 2014, Mauck et al., 1999, Miller et al., 2000).  
Therefore, due to the disproportionate risk and burden of HIV in women, strategies to 
reduce the risk of HIV acquisition in the absence of male partner co-operation are key to 
limit and control the spread of HIV (Adimora et al., 2013, Mabala, 2006, Ramjee, 2013). 
Various clinical trials investigating the efficacy of PrEP in the form of oral ARV drugs, 
subcutaneous ARV administration and topical ARV-containing microbicide gels have been 
conducted; are still on-going or are in the developmental pipeline, in order to identify the 
most effective modality of protection for high risk populations, especially women (Table 1) 
(Abdool Karim et al., 2010, Mccormack et al., 2016, Gunawardana et al., 2015, Thomson et 
al., 2016, Baxter and Abdool Karim, 2016). Although protection from HIV infection has yet to 
be fully achieved, current trials focussing on improving adherence through convenience and 
multipurpose prevention technologies (MPT) for women in resource-limited countries, are 
being investigated (Baxter and Abdool Karim, 2016). MPT strategies aim  to address various 
health concerns, such as protection from HIV, other sexually transmitted infection (STI’s) 
and  unintended pregnancies simultaneously (Fernández-Romero et al., 2015, Malcolm et 
al., 2014, Malcolm et al., 2016, Malcolm and Fetherston, 2013, Woodsong and Holt, 2015, 
Romano et al., 2013).  
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2.2 PrEP in prevention  
 
While MPT strategies are in the pipeline, effective PrEP administration, dosing and 
combinations, are still being investigated  in order to protect young women who continue to 
be a high-risk population (Baxter and Abdool Karim, 2016).  
 
The efficacy of PrEP in providing adequate protection from HIV is disparate between men 
and women (Table 1). PrEP studies in men have achieved good levels of protection, with 
oral administration providing up to 86% (95% CI: 39% to 99%) protection from HIV infection 
(see Table 1) (Patterson et al., 2011). However, inconsistent results have been observed for 
PrEP trials involving women. Various trials have reported no to low efficacy and others 
range from -49% to 75%) effectiveness against HIV (Table 1) (Spinner et al., 2016, Rees et 
al., 2015, Marrazzo et al., 2015).  
 
The CAPRISA 004 1 % tenofovir gel trial had the highest efficacy of 39%, compared to all 
other PrEP gel trials in women (Van Damme, 2012, Marrazzo et al., 2015, Donnell et al., 
2014, Gomez, 2013, Thigpen et al., 2012, Mujugira et al., 2011, Abdool Karim et al., 2010). 
Poor adherence to PrEP is a major factor impacting PrEP efficacies, as seen with the CAPRISA 
004 trial and other studies, which reported high tenofovir gel adherence conferred a 53% 
efficacy (Van Damme, 2012, Marrazzo et al., 2015, Donnell et al., 2014, Gomez, 2013, 
Thigpen et al., 2012, Mujugira et al., 2011, Abdool Karim et al., 2010, Baeten et al., 2016). 
Detectable concentrations of tenofovir or any other PrEP agent, in the blood are key in 
protection from infection, as this factor was associated with >85% protection in the Partners 
PrEP study (Table 1) (Donnell et al., 2014). Additionally, in an effort to overcome adherence 
the Ring and ASPIRE trials investigated the potential of a monthly intravaginal ring 
containing dapivirine. Observed efficacies were between 27-31%, respectively (Baeten et al., 
2016, Palanee-Phillips et al., 2015). Further, post-hoc analysis revealed that older women, 
>21 years of age had higher rates of protection compared to younger women, <21 years, 56 
%( 95% CI, 31 to 71) vs -31% (95% CI 1 to 31%) (P < 0.001) (Baeten et al., 2016).  
 
The discrepant efficacies in women emphasize the need to understand the biological 
mechanisms that affect PrEP efficacies (Spinner et al., 2016, Baxter and Abdool Karim, 
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2016). Besides adherence, the low levels of protection observed may have been influenced 
by hormonal contraceptive use (as previously mentioned), immature mucosae of the young 
women, high viral load in partners, increased levels of pro-inflammatory cytokines, which 
recruit target cells and higher exposure of the vaginal surface area to virus (Celum et al., 
2015, Chen et al., 2007, Van Damme, 2012, Yi et al., 2013, Nicolosi et al., 1994). 
Interestingly, a further analysis of the CAPRISA 004 trial revealed that the vaginal 
microbiome also effects efficacy of tenofovir containing PrEP agents (Klatt et al., 2017). In 
that sub-study, women with bacterial vaginosis, which is associated with a dysbiotic vaginal 
microbiome, resulted in reduced efficacy of the tenofovir gel. This was attributed to the 
presence of Gardnerella vaginalis and other anaerobic bacteria, which metabolized 
tenofovir at a higher rate than the cells, thereby reducing the active metabolite available to 
inhibit HIV reverse transcriptase activity (Klatt et al., 2017, Abdool Karim et al., 2010, De 
Clercq, 2007).  
 
Taken together, these factors emphasize the importance of better understanding the 
vaginal mucosae and contributing risk factors, as these factors have been shown, to 
significantly, alter the outcome of intended protective modalities. Ultimately, these 
prevention strategies and outcomes of PrEP trials emphasize the need for an HIV vaccine, 
which can ultimately overcome these challenges, eliminate new infections all together and 
provide complete protection from HIV, in both men and women. Furthermore, despite the 
strides made in some of the PrEP trials in certain populations, due to the relative newness of 
PrEP, the long-term biological effects are not well described (Pattacini et al., 2015). 
Following the approval of Truvada® as PrEP and the recent WHO recommendation for PrEP 
as an additional prevention strategy in high risk populations, knowledge regarding humoral 
immune responses, in the presence of PrEP is limited (Archary et al., 2016). A recent study 
by Archary et al., (2016) demonstrated that in women with HIV infection who used the 
topical 1% tenofovir gel prior to infection; distinct mucosal and blood antibody profiles 
differentiated them from women in the placebo arm were detected. Therefore, determining 
the functional abilities of antibody responses, other than neutralization, in the context of 
PrEP is of paramount importance.
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TABLE 1: Overview of the prospective systemic oral PrEP, topical and other HIV prevention studies [adapted from Kharsany and Karim (2016)]. 
Study Risk population PrEP Agent Effect size (95% CI) 
CAPRISA 004 (Abdool Karim et al., 2010) Women TFV gel 39% (6; 60) 
MTN 003 VOICE (Marrazzo et al. 2015) Women TFV gel 15% (-21;40) 
FACTS 001 – peri-coital tenofovir gel (Rees et al., 2015) Heterosexual women TFV gel 0% (-40;30) 
MTN020-ASPIRE Intravaginal Ring (Palanee-Phillips et al., 2015) Women Dapivirine Ring 27% (1;46) 
IPM 027(Nel et al., 2014) Heterosexual Dapivirine Ring 30.7% (0.90;51.5) 
IPERGAY (Molina et al. 2015) MSM TDF/FTC 86% (39;99) 
PROUD (McCormack et al. 2016) MSM TDF/FTC 86% (62;96) 
Partners PrEP daily (TDF/FTC) (Baeten et al. 2012) HIV-discordant couples TDF/FTC 75% (55;87) 
Partners PrEP daily Tenofovir (Baeten et al. 2012) HIV-discordant couples TDF 67% (44;81) 
TDF2 (Thigpen et al. 2012) Heterosexual couples TDF/FTC 62% (22;83) 
iPrEX (Grant et al. 2010) MSM TDF/FTC 44% (15;63) 
Bangkok Tenofovir Study (Choopanya et al. 2013) IDU TDF 49% (10;72) 
Fem-PrEP (Van Damme et al. 2012) Heterosexual women TDF/FTC 6% ( -52;41) 
MTN003/VOICE daily (TDF/FTC) (Marrazzo et al., 2015) Heterosexual women TDF/FTC -4% (-49;27) 
MTN003/VOICE daily (Tenofovir) (Marrazzo et al., 2015) Heterosexual women TDF -49% (-129;3) 
*Note: TFV – tenofovir; PrEP – pre exposure prophylaxis; TDF/FTC – truvada (tenofovir disoproxil fumarate and emtricitabine); IDU- intravenous drug users 
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2.3 Biological drivers of HIV acquisition and the effect of PrEP on immune parameters 
 
Immune activation, genital tract inflammation and the recruitment of activated target T cells 
are known immunological factors that drive HIV infection risk and HIV disease progression 
(Masson et al., 2015). The concept of dampening immune responses in the genital tract, to 
decrease the risk of infection is a topic of ongoing debate [as reviewed in (Card et al., 
2013),(Naranbhai et al., 2012). Furthermore, in preclinical studies, macaques on oral PrEP 
showed a reduced inflammation profile and a reduced level of CD4+ T cell loss during 
breakthrough SIV infections, compared to controls (Kersh et al., 2012). The study 
demonstrated that despite HIV infection, prior PrEP improves early immune parameters, 
which may then impact on the rate of disease progression (Kersh et al., 2012, Castillo-
Mancilla et al., 2015, Naranbhai et al., 2012). Similar findings in a sub-study of CAPRISA 004 
women were found, reporting the preservation of HIV-specific CD4+ T cells (Mureithi et al., 
2012). CD4+ T cells play an important role in determining antibody avidity and therefore 
contribute to shaping the adaptive immune response (Morita et al., 2011, Boswell et al., 
2014). Furthermore, in an animal study, topical rectal application of tenofovir gel, 
reportedly primed T cell responses, supporting the role of PrEP as a prime/boost strategy 
(Cranage et al., 2008).  
 
Although some studies have shown no evidence of immunological changes in HIV uninfected 
individuals on oral PrEP (Baeten et al., 2012), other studies report reduced levels of systemic 
immune activation in HIV-uninfected individuals on oral PrEP (Castillo-Mancilla et al., 2015). 
Additionally, studies investigating the effect of topical tenofovir gel, reported a reduced 
immune activation identified as a reduction in activated CD4 T target cells and biomarkers of 
inflammation (Vibholm et al., 2012, Mcgowan et al., 2013), known factors associated with 
HIV infection risk and disease progression (Masson et al., 2015). The influence of the 
reduced immune activation on antibody functionality have however, not been described. 
 
Interestingly, studies have also reported that PrEP delays antibody avidity but has no effect 
on time to seroconversion, in those experiencing breakthrough HIV infection (Curtis et al., 
2011, Laeyendecker et al., 2015). However, decreased antibody titres have been associated 
with the use of ARV’s during HIV infection, but the functionality of these antibodies in the 
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presence of low antibody titres remains unresolved. (Hare et al., 2006, O'sullivan et al., 
2002, Payne et al., 2015).  
 
Breakthrough HIV infection amongst those who participate in PrEP trials can directly inform 
on the effects of PrEP on the immune responses. This is important in order to, better inform 
on the potential impact of prior PrEP usage on vaccine efficacy, particularly in an era where 
combination prevention strategies using both vaccines and PrEP are likely. Furthermore, the 
immune responses that prevail at the female genital mucosal regions, especially in the 
context of combination therapy, such as vaccines and PrEP, is not well described (Archary et 
al., 2016). 
 
2.4 Humoral immune responses and HIV 
 
Antibodies develop at least 1-week post HIV infection in the presence of detectable viremia, 
however, these antibodies appear to have no effect on modulating viremia due to escape 
variants  (Tomaras et al., 2008). This is due to autologous, strain-specific antibodies, which 
have narrow breadth and do not neutralize virus isolated from other individuals as well as 
those that arise through mutation and immune pressure. Transmission of HIV from  infected 
mothers to their infants is not inhibited by neutralizing antibodies (NAbs), due to the 
transmission of escape variants (Dickover et al., 2006, Wu et al., 2006). Surprisingly, non-
neutralizing antibodies showed a role in decreasing transmission of HIV to infants and 
increasing mortality, due to the activity of antibody mediated cellular cytotoxicity (Mabuka 
et al., 2012, Milligan et al., 2015). These data add to the mounting evidence that non-
neutralizing antibodies may play a role in modulating HIV transmission. In order to 
understand the role of non-neutralizing antibodies in HIV infection, the developmental 
process of antibodies and the potential role of a polyfunctional immune response, needs to 
be explored.  
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2.4.1 The Development of Antibodies 
 
When pathogens are encountered by the immune system the innate immune cells like 
macrophages, engulf the invading pathogen (Figure 2). Macrophages are professional 
antigen presenting cells (APC) and present certain parts of the pathogen via MHC class II 
proteins to naïve T cells, which bind and subsequently produce IL-1, resulting in activation of 
the naïve T cell (Figure 2). Once activated, the naïve T cell differentiates and proliferate, and 
become either a cytotoxic T cell or a T helper cell. The cells produce IL-2, which stimulates T 
cell proliferation. The T helper cell then activates the mature naïve B cells by stimulation 
with APC’s. B cells, which migrate into the dark zone of the germinal center (GC) located in 
the lymph nodes (Figure 2), undergo clonal expansion, somatic hypermutation (SHM), pre-
clonal selection, selection, class switching and differentiation (Figure 2). This process 
ultimately results in the production of antigen specific antibodies  (Georgiou et al., 2014). 
Each of these B cells express unique B cell receptors (BCR) which recognize specific antigens. 
Inside the dark zone, the B cell forms centroblasts, where affinity maturation occurs by SHM 
of the fragment binding region (Fab), selecting for the B cell with the highest affinity for a 
specific antigen (Figure 2).  
 
FIGURE 2: The various stages involved in the development of an antigen-specific B cells responses 
to a foreign antigen or pathogen in the lymph node [adapted from (Georgiou et al., 2014)]. 
 
During SHM, the expressed BCR mutates via genetic recombination of the genes- which 
form the VDJ complex- and the BCR, in order to generate the best fit to the pathogen [as 
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reviewed in (Haynes and Mcelrath, 2013)]. Throughout this process, T follicular helper cells 
aid in antibody avidity maturation, selecting against auto reactive B cells, however, this 
process of tolerance is not fully understood (King et al., 2008). Following SHM, the 
centroblast moves to the light zone becoming a centrocyte, undergoes class switching of the 
fragment crystallizable (Fc) portion, after which it will proliferate and become either a 
plasma cell or memory cell (Figure 2). These GCs generate antibodies that are long-lived, 
with a high antigen affinity to a specific pathogen, usually spanning the lifespan of the 
individual. After the immune response has concluded, which is usually associated with 
pathogen clearance, the B cells contract to form memory B cells. Upon reinfection, memory 
B cells will be stimulated to undergo clonal expansion, to produce many pathogen/antigen-
specific antibodies [as reviewed in (Mouquet, 2014), (Georgiou et al., 2014)] . 
 
In the context of HIV infection, the pathogenic characteristics of HIV poses a challenge for 
the immune system to develop antibodies that are capable of clearing the infection. HIV-1, 
has rapidly mutating envelope spikes that differ 35-40% in their amino acid sequence 
between subtypes (Lynch et al., 2009, Gaschen et al., 2002). In addition, the strain-specific 
antibodies and ensuing  immune pressure, creates viral escape mutants, adding to the 
challenge of developing a vaccine [as reviewed in (Mouquet, 2014)]. The high recombination 
rate of HIV in vivo and lack of a proofreading polymerase enzyme, introduces mutations into 
the genome, which ultimately affects the expression of the glycoprotein (Ramirez et al., 
2008, Zhuang et al., 2002). Effective NAbs require the recognition of a functional HIV-
epitopes that are vulnerable to the neutralization. This is often difficult due to  highly 
variable regions and glycosylation which masks envelope (Env) epitopes (Kwong et al., 1998, 
Richman et al., 2003, Herrera et al., 2003, Chackerian et al., 1997, Wei et al., 2003, Bunnik et 
al., 2008)]. The carbohydrates or glycans, that cover HIV-1, form rapidly shifting glycan 
shields (Figure 3), which prevent antibodies from binding, through masking recognition of 
key sites and stearic hindrance, resulting in immune evasion [as reviewed in (Overbaugh and 
Rudensey, 1992, Wyatt, 1998), (Haynes et al., 2012b, Richman et al., 2003, Herrera et al., 
2003, Wei et al., 2003, Chackerian et al., 1997)]. Furthermore, the envelope of HIV can 
present various faces to the immune system with non-functional spikes etc., often baiting 
the immune system and resulting in antibodies that are inept against the virus (Figure 3) 
(Moore et al., 2006). 
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FIGURE 3: Various conformational structures of the HIV envelope. HIV presents different 
immunogenic faces to the immune system including shifting glycan shields, conformational masking, 
non-functional envelope stumps and a low level of Env expression on the surface of the virus that 
contribute to the virus’ pathogenicity, immune evasion and immune dysfunction [adapted from 
(Mouquet, 2014)]. 
When HIV is transmitted, the virus encounters CD4+ T cells and undergoes several  
conformational changes, which enables binding of the gp120 spike of the Env trimer, to CD4 
and CCR5 co-receptors on CD4+ T cells (Burton et al., 2004, Burton et al., 1994). At this point, 
the virus may be vulnerable to various antibodies, that can neutralize and prevent binding, 
therefore presenting optimal sites to target for NAbs [as reviewed in (Overbaugh and 
Morris, 2012)]. These regions are conserved due to their functional importance in receptor 
binding between the virus and target cell (Hendrickson et al., 1998, Wyatt, 1998, Calarese et 
al., 2003, Huang et al., 2007, Zhou et al., 2007). Effective antibodies require immense 
breadth (able to recognize a variety of diverse strains), potency (needing small amounts to 
be effective) and should have high affinity to conserved and their cognate epitopes (Klein et 
al., 2013, Barouch et al., 2013a, Burton et al., 2004). B cells often produce a large variety of 
antibodies that often target a wide array of HIV viral proteins. 
 
Env proteins which are expressed on the surface of the virus, are composed of three 
heterodimers of gp120, anchored into the viral membrane by a gp41 stalk (Figure 3) 
(Stamatatos et al., 2009). Gag proteins also known as p24 antigen, compose the capsid 
protein structure of the HIV virus (Figure 3) and is a marker of infection (Fiebig et al., 2003), 
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disease progression (Wolf et al., 1988) and immune responses to infection (Mcrae et al., 
1991). Other internal proteins include p66 which is produced by the Pol gene that encodes 
for the reverse transcriptase enzyme (Figure 3)- the protein responsible for the replication 
of viral RNA [as reviewed in (Jacobo-Molina and Arnold, 1991), (Di Marzo Veronese et al., 
1986). Nonnucleoside reverse transcriptase inhibitors (ARV drugs), target the enzyme, 
inhibiting its ability to bind and synthesize new copies of proviral DNA [as reviewed in (De 
Clercq, 1998), (Sluis-Cremer et al., 2000)]. These viral proteins represent potential targets 
for HIV vaccine development where both neutralizing antibodies and antibodies mediating 
Fc-related functions may be exploited.  
 
NAbs which develop months after infection, generally target the variable glycosylated 
region of HIV-1 Env (Rong et al., 2009, Moore et al., 2009). However, antigenic variability 
prevents recognition between the antibody Fab region and the antigen epitope, also arising 
from in vivo recombination events between envelopes of HIV quasispecies or in some cases, 
superinfection (Preston et al., 1988, Mansky and Temin, 1995).  
 
These characteristics of the HIV virus, as well as others such as virus size [as reviewed in 
(Parren and Burton, 2001)], the proximity of Env surface proteins to each other, the 
characteristics of the viral proteins i.e. whether one Env surface protein can mediate viral 
entry, as well as the number of viral surface proteins (Zhu et al., 2003), influence vaccine 
design. HIV has between 8-10 viral envelope spikes expressed on its surface. But, every 
single one of these Env spikes need to be blocked or neutralized in order to prevent 
infection, as one spike can mediate viral entry (Yang et al., 2005b, Zhu et al., 2003). BNAbs 
capable of neutralizing a variety of epitopes, in particular, have the ability to directly inhibit 
or obstruct the virus and target cell co-receptor from engaging despite mutational 
differences, between virus envelope proteins (Walker, 2009, Blish et al., 2009). BNAbs in 
particular have the ability to directly inhibit or obstruct the virus and target cell co-receptor 
from engaging and these are known as entry inhibitors like VRC01 (Wu et al., 2010). Other 
bNAbs include, IgG1 b12 a CD4 binding antibody (Saphire et al., 2001), fusion inhibiting 
MPER antibodies e.g. 4E10, which directly obstruct fusion between the target cell and HIV 
virus membrane (Zwick et al., 2001, Zwick et al., 2005, Cardoso et al., 2005). 
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2.4.2 Broadly Neutralizing Antibodies  
BNAbs have two characteristics that distinguish them from other neutralizing antibodies- 
breadth and potency (Moore et al., 1996, Moog et al., 1997, Beirnaert et al., 2000, Binley et 
al., 2008, Piantadosi et al., 2009, Sather et al., 2009, Gray et al., 2011, Simek et al., 2009).    
 
However, current knowledge of bNAbs, have reported that these types of antibodies take  
2-3 years to develop and furthermore are only present in 20-30% of HIV infected individuals, 
therefore not providing immediate protection (Binley et al., 2008, Doria-Rose et al., 2009, 
Sather et al., 2009, Simek et al., 2009, Li et al., 2009). Thus, emphasising the need for novel 
innovative, scientific approaches that overcome current challenges associated with bNAb 
development. Novel approaches include, reverse engineering. An approach that involves 
mimicry  of cognate epitopes, the sequence footprint and structure of an HIV envelope,  to 
elicit protective bNAbs [as reviewed in (Burton, 2002, Koff, 2012)].  
 
The ealry 1990’s revealed the discovery of what is now known as first generation bNAbs, 
which included IgG1b12 (b12), 2G12, 2F5 and 4E10, with each antibody binding to different 
regions of the virus (Walker et al., 2011).  B12 binds to a conserved region on the CD4 
binding site (Walker et al., 2011, Saphire et al., 2001), 2G12 targets an area rich in mannose 
residues present on the glycan shield having a unique domain-exchange structure (Trkola et 
al., 1996, Trkola et al., 1995), 4E10 targets a linear epitope (NWFDIT) in the membrane 
proximal external region (MPER) of gp41 (Stiegler et al., 2001), and 2F5 targets a ELDKWA 
motif ectodomain of gp41 (Figure 4) (Corti et al., 2010).  
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FIGURE 4: A schematic diagram of HIV-1 and the regions of the surface glycoproteins targeted by 
various broadly neutralizing antibodies. These include 2G12, the PGT series -targets the N-linked 
glycan on V3. PG9/16, CAP256 VRC26.25, PGT 141-145-targets the glycans on the V1V2 loops. The 
CD4 binding site antibodies (b12, VRC01 etc., VRC series and the 3BNC117) and the CH antibodies, 
the PGT151-158 and 8ANC195 that target the glycans on gp120/gp41 interface. Lastly, the MPER 
antibodies that include 2F5, 4E10, Z13, m66 and 10E8  3BNC176 binding site remains as yet 
undefined [adapted from (Mouquet, 2014)].   
 
The development of assays like the microneutralization assay, high throughput single cell, B 
cell receptor amplification and novel Env selection tools, have resulted in an explosion in the 
discovery of  second generation antibodies, which exhibit increased potency and 
neutralization breadth [as reviewed in (Koff, 2012)]. These second generation antibodies 
target CD4 binding site (VRC01, VRC07, 3BCN117) and conserved regions on the V1V2 Env 
gp120 protein and have given rise to antibodies like PG9 (Huang et al., 2012), PG16 (Walker, 
2009) (Figure 5) and other antibodies such as CAP256 VRC26.25 (Moore et al., 2011). 
CAP256 VRC26.25 is a V2 glycan dependent highly potent bNAb, with a bias towards 
subtype C and A virus neutralization, with exhibiting broadly cross neutralizing capacity 
against 76% of HIV strains  (Moore et al., 2011).  
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BNAbs are unique in that they undergo extensive SHM and some like the CAP256 VRC26.25, 
have long 30-33 amino acid complementary determining regions on the heavy chain 3 
(CDRH3), which likely contributes to the breadth (see Figure 6) (Moore et al., 2011). Another 
potent bNAb with a long CDR region is PGT121, a V3 glycan dependent antibody (Walker et 
al., 2011). However, in reality, the induction of such antibodies with long CDR regions are 
problematic, as the germline cells that produce such antibodies are selected against by 
check-points in the immune system, which function to prevent autoimmune reactivity 
(Doria-Rose et al., 2014, Mclellan et al., 2011, Wardemann et al., 2003). Insertions and 
deletions generated by SHM in these variable regions for antigen binding of the antibody, 
controls for the fit and affinity that occurs between these bNAbs and the cognate sites on 
the Env protein (Sok et al., 2013). Vaccines that strive to elicit the production of bNAbs have 
to overcome the high levels of SHM required in the B cell lineage in the germinal centre in 
order to develop antibodies with increased neutralization breadth and potency. 
 
FIGURE 5: HIV epitopes targeted by broadly neutralizing antibodies. Env spikes composed of a 
trimer of a heterodimer comprising gp120 and gp41 transmembrane glycoprotein are depicted in 
purple and grey respectively.  The gp120 trimer has variable loops made up of V1 and V3 as well as 
containing the site for CD binding. The diagram above outlines the regions targeted by the above 
mentioned broadly neutralizing antibodies, [adapted from(Koff, 2012)]. 
 
This would require long regimens of vaccine prime/boosts in order to induce sufficient SHM 
for generation of these bNAbs (Sok et al., 2013, Zhou et al., 2007, Xiao et al., 2009). Despite 
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these challenges, candidate modified Env immunogens are being pursued to generate these 
bNAbs, and testing of a potent bNAb or a combination of bNAbs passive administration to 
prevent HIV infections are currently underway (Rubens et al., 2015).   
 
In passive immunity studies the V3 glycan dependent bNAb PGT121 proved to be potent 
and able to neutralize approximately 70% of the virus reference strains, in intravaginally 
challenged macaques (Walker et al., 2011, Barouch et al., 2013a, Barouch et al., 2013b). 
Previously expressed glycoproteins, have been used to probe HIV-infected sera for unique 
antibodies, eventually leading to the discovery of VRC01 (Walker et al., 2011), a CD4 binding 
site antibody, and 3BCN117- also a CD4 binding site antibody (Figure 5), which was isolated 
from a viraemic controller (Scheid et al., 2011). Interestingly, the recent discovery of N6, a 
potent CD4bs NAb capable of neutralizing 98% of HIV-1 isolates, was discovered and is 
currently undergoing further investigation for use in future clinical trials (Huang et al., 2016). 
Passive immunization studies using broadly neutralizing antibodies have shown potential in 
preventing HIV infection (Armbruster et al., 2004, Mascola et al., 2000, Mascola et al., 1999, 
Shingai et al., 2014). Furthermore, studies conducted pre-ART era, investigated the potential 
of passive immunity through, inactivated hyper-immune plasma containing anti-HIV 
immunoglobulins that likely included both neutralizing and non-neutralizing activities. These 
studies provided early evidence of passive immunity in ameliorating HIV disease progression 
and suppressing viral replication [as reviewed in (Stephenson and Barouch, 2016)]. Initial 
findings showed viral clearance through declining p24 antigen detection (Jackson et al., 
1988, Karpas et al., 1990, Karpas et al., 1988). However, other passive immunity studies in 
contrast showed no impact on the morbidity or mortality of HIV-infected subjects through 
viral clearance or increased CD4+ T cell counts (Jacobson et al., 1993). Further conflicting 
data showed improved clinical parameters like increases in CD4 T cell counts (Levy et al., 
1994), and no delay to the progression to AIDS-defining criteria (Vittecoq et al., 1992). 
Despite the mixed results, passive immunization with bNAbs have shown promise. 
 
Passive immunity studies in the 1990’s and early 2000’s mainly tested first generation 
bNAbs like 2G12, 2F5 and 4E10 (Armbruster et al., 2004, Armbruster et al., 2002, Stiegler et 
al., 2002, Trkola et al., 2005, Joos et al., 2006, Morris et al., 2014, Günthard et al., 1994). 
These bNAbs at high doses were safe, and well tolerated, and conferred transient viral 
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suppression in HIV-infected individuals.  Proof of concept clinical trials in humans, using 
passive immunity with the newer, more potent second generation of bNAbs, are currently 
underway and include bNAbs such as VRC01, VRC07, PGT121 and CAP256 26.25LS. These 
antibodies have been previously tested in preclinical studies and in-vivo, in small animals 
and in-vitro and VRC07  and PGT121 and CAP256 26.25 LS (Rudicell et al., 2014, Dosenovic 
et al., 2015, Julg et al., 2017, Lynch et al., 2015). 
 
Although bNAbs show promise, eliciting these types of antibodies through vaccination 
remains a formidable challenge, and while the proof-of-concept studies involving passively 
infused bNAbs to prevent infection are highly successful and confer complete protection in 
animal models, the practicality, cost and wide-scale use in humans is a substantial hurdle 
(Shingai et al., 2014, Mascola et al., 1999). 
 
2.5 Vaccines and Vaccine Trials 
 
The development of an efficacious HIV vaccine remains a challenge and is a public health 
priority. After three decades of HIV vaccine research focussed on studying the relationship 
between the virus pathogenicity and the host immunogenicity, the majority of researchers 
believe that engaging both arms of the adaptive immune system may be the best approach 
(Chhatbar et al. 2011).  Retroviruses such as HIV, have developed mechanisms of evading 
the immune system like glycosylation and frequent mutation of dominant epitopes, 
therefore underscoring the need for innovative approaches to vaccine strategies (Gulick et 
al., 2008, Yang et al., 2005a). 
Vaccine immunogen design usually involves the administration of an attenuated or whole 
inactivated virus, to induce an immune response, known as active immunization [as 
reviewed in (Law and Hangartner, 2008)]. However, this strategy in the context of HIV, is 
potentially dangerous as the virus could revert to the wild type, integrating its viral genome 
into the host DNA,  eventually resulting in HIV infection [as reviewed in (Koff, 2012)].   
In 1998, researchers genetically engineered a canarypox vaccine as a prime and a protein 
boost that included Gag and Env proteins from the HIV virus (Belshe et al., 1998, Rubens et 
al., 2015). NAbs and CD8 T cells directed towards Gag and Env-proteins were detected 
amongst 64% of volunteers, however, these results were not replicated in a larger clinical 
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trial (Belshe et al., 1998, Russell et al., 2007). This initial study in 1998, established the 
concept for the prime-boost strategy, which was used in the RV144 trial (Rubens et al., 
2015). However studies that preceded and proceeded the RV144 trial in 2009, such as  
HVTN P5, HVTN 505, VAX004, and VAX003, HVTN 503 (STEP and Phambili) some of which 
were recombinant DNA vector virus trials, showed no protection- (Table 2), (Rubens et al., 
2015). Trials such as the STEP and PHAMBILI trials had no efficacy (Table 2), with the STEP 
trial exhibiting an increased risk for HIV infection (Gray et al., 2010, Buchbinder et al., 2008). 
Specifically, within the STEP trial the increased risk of HIV infection was found following the 
analysis of a specific population of individuals. 
The RV144 trial in 2009, included 16,402 healthy individuals and is the only vaccine trial to 
achieve a modest efficacy of 31.2% (95% CI, 1.1 to 52.1) (Rerks-Ngarm et al., 2009). The 
vaccine expressed HIV-1 Gag and Pol (subtype B LAI strain) and CRF01_AE (subtype E) HIV-1 
gp120 (92TH023) (Rerks-Ngarm et al., 2009). The protein boost was  AIDSVAX B/E, a bivalent 
subtype B/E HIV-1 gp120 glycoprotein (Rerks-Ngarm et al., 2009). Ensuing responses from 
those vaccinated, mediated protection from infection by non-neutralizing, binding antibody 
responses to the V1V2 regions of the gp120, and Env and Gag CD4+ T cell responses, have 
also been reported (Tomaras et al., 2012).  While the V1V2 binding antibodies were not 
broadly neutralizing, they did mediate non-neutralizing Fc mediated antibody functions, 
namely antibody dependent cellular cytotoxicity (ADCC) and elicited NAbs not capable of 
achieving great breadth (Tomaras et al., 2012). Moreover, the correlates of risk of HIV 
infection were identified as an enhanced IgA or a reduced gp70 IgG antibody response 
(Zolla-Pazner, 2014, Haynes et al., 2012a, Bonsignori M, 2012, Chung et al., 2014, Bomsel et 
al., 2011).   
Following the original RV144 Trial, South Africa and South America are currently testing the 
ALVAC vaccine with a subtype C envelope gp120 (Table 2) (Rubens et al., 2015).
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TABLE 2: Efficacies of past and ongoing HIV vaccine trials [adapted from (Rubens et al., 2015)]. 
Study Site Active/ Passive Vaccine Volunteers Vaccine to Placebo 
randomization 
Results 
Vax004 USA and Netherlands AIDSVAX B/B’Env gp120 with alum 5100 MSM and 300 
women 
2:1 No vaccine efficacy 
Vax003 Thailand AIDSVAX B/E Env gp120 with alum 2500 men and women 
IDUs 
1:1 No vaccine efficacy 
HVTN 502 
Step trial 
North and South America, the 
Caribbean, and Australia 
Merck (MRK) Ad5 HIV-1 Gag/Pol/Nef trivalent 
vaccine based on adenovirus type 5 
3000 MSM and 
heterosexual women and 
men 
1:1 No vaccine efficacy 
RV144 Thailand Recombinant canarypox vector vaccine 
(ALVAC-HIV[vCP1521]) and recombinant 
gp120 subunit vaccine (AIDSVAX B/E) 
16 402 community-risk 
men and women 
1:1 31.2% vaccine 
efficacy at 42 
months 
HVTN503 
Phambili 
trial 
South Africa Merck (MRK) Ad5 HIV-1 Gag/Pol/Nef trivalent 
vaccine based on adenovirus type 5 
801 heterosexual men 
and women 
1:1 No vaccine efficacy 
HVTN 505 USA 6-plasmid DNA vaccine and rAd5 vector boost 2504 men or transgender 
women who have sex 
with men 
1:1 No vaccine efficacy 
HIV-V-
A004 
USA, Rwanda, South Africa, 
Thailand and Uganda 
Homologous Ad26 mosaic vector regiments or 
Ad26 mosaic and MVA mosaic heterologous 
vector regimen, with high-dose, low-dose or 
no clade C gp140 protein plus adjuvant 
400 men and women - Ongoing 
HVTN 100 South Africa Clade C Canarypox-HIV (vCP2438) and bivalent 
subtype C gp120/MF59 
252 men and women 5:1 Ongoing 
HVTN 702 South Africa Canarypox-HIV and bivalent subtype C gp120 
MF59 
5400 men and women 1:1 Ongoing 
HVTN 
703/ 
HPTN 081 
South America and Sub-Saharan 
Africa 
VRC01 bNAb passive immunity 2400 MSM and 
transgender and 1500 
women 
2:1 Ongoing 
Note: MSM: men who have sex with men; IDUs: Injection drug users 
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Other immunization strategies such as active immunization, may also elicit antibodies 
capable of partial protection in the absence of neutralization. Evidence of active 
immunization in Rhesus macaques vaccinated with a mosaic HIV-1 vaccine showed partial 
protection after intrarectal SHIV-SF162P3 challenge (Barouch et al., 2013a, Barouch et al., 
2012). This mosaic vaccine consisted of an adenovirus/adenovirus vector or an 
adenovirus/poxvirus vector, with HIV-1 Env/Gag/Pol proteins, elicited Env-specific immune 
responses (Barouch et al., 2013a). Non-neutralizing antibody functions such as ADCP and 
NAbs against tier 1 and tier 2 were elicited by the vaccine, as well as Env-specific CD4+ T cell 
responses and were associated with protection (Barouch et al., 2013a). These results 
substantiate a coordinated synergy of multiple and diverse immune responses in preventing 
HIV infection (Barouch et al., 2013a, Barouch et al., 2012).  
 
Eliciting a sustained B-cell response, CD8+ and CD4+ T cell response that can eliminate 
viruses and contain infection at the site of transmission, remains a substantial hurdle to 
vaccine development (Rubens et al., 2015). Vaccine strategies have therefore been directed 
towards stimulating humoral immunity to elicit effective antibody responses capable of 
neutralization across multiple subtypes, administering passively infused bNAbs or inducing 
CD8+ cytotoxic T cell responses or harnessing nNAb effector function (Chhatbar et al., 2011).  
 
2.6 Fc-Mediated Antibody Functions – Non-neutralizing antibodies 
 
Historically, potential vaccine immunogens were chosen based on their ability to elicit 
neutralizing antibodies and high antibody titres [as reviewed in (Pulendran and Ahmed, 
2011)]. The challenge in HIV vaccine trials is the waning of antibody responses, the low 
potency and breadth of elicited antibodies that failed to prevent HIV-infection or control 
disease progression (Corey et al., 2015). Although the RV144 vaccine did not elicit cytotoxic 
T cells, antibody titres and neutralizing antibodies, this vaccine did confer moderate 
protection from HIV infection (Rerks-Ngarm et al., 2009, Chung et al., 2015). Protective 
immune responses have been associated with non-neutralizing antibody mediated 
functions, such as ADCC functions (Chung et al., 2015, Barouch et al., 2015, Hessell et al., 
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2007, Bournazos et al., 2014, Dilillo et al., 2016, Kohl and Loo, 1982). Chung et al., (2015), 
reported that a protective response was associated with “antibody features” including 
polyfunctional responses and not antibody titres (Hessell et al., 2009a). Besides the Fab 
region of the antibody that recognizes antigen, the Fc portion (Figure 6), engages specific 
effector cells of the innate immune system to induce a polyfunctional responses such as 
complement activation, viral inhibition or phagocytosis (Sips et al., 2016).  
 
 
 
FIGURE 6: Crystal representation of the structure of an antibody. The Fc portion of IgG interacts 
with FcR on effector cells. The Fab region recognizes the antigen/epitope resulting in either 
phagocytosis, viral inhibition or cytotoxicity [adapted from (Jefferis, 2009)]. 
 
The Fc portion of the antibody is versatile and can engage with various Fc receptors (FcR) on 
various effector cells, thus linking the innate and humoral immune system (Sips et al. 2016).  
ADCC is commonly induced by NAbs, but can be triggered by nNAb, activating effector cells 
of the innate immune system such as natural killer (NK) cells, neutrophils, and monocytes 
(Chung et al. 2009; Hessell et al. 2007). ADCC activation includes the granzyme B pathway, 
which causes lysis of infected cells as well as the release of immunomodulatory cytokines 
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[as reviewed in (Russell and Ley, 2002, Berke, 1995), (Kagi et al., 1994)]. Fc receptor-
mediated function through nNAbs has been shown to be a correlate of protection in 
vaccinated animals (Barouch et al., 2013a). These findings were further supported by animal 
and human studies of HIV-1 controllers, showing that nNAb-mediated responses were 
associated with viral control and reduced risk of infection (Moog et al., 2014, Barouch et al., 
2013a). Furthermore, Hessel et al., (2007) showed that Fc-mediated activity but not 
complement binding, sufficiently conferred protection. The Fc portion is crucial for antiviral 
activity, for example when b12 was genetically altered to exclude the Fc portion, antiviral 
activity was completely ablated (Hessell et al., 2009b).  
A study by Stromberg and Nussenzweig et al., (2014) investigated combination therapy of a 
triple cocktail of bNAbs and post-exposure prophylaxis in humanized mice and rhesus 
macaques following HIV infection. Their study drew attention to the role of Fc-mediated 
antiviral activity in delaying viral rebound, from the latent reservoir (Halper-Stromberg et 
al., 2014). Additionally, data from Nussenzweig et al., (2014) and Hessel et al., (2007), 
underscored the importance of engaging  effector cells as a means of ameliorating disease, 
during HIV infection (Halper-Stromberg et al., 2014, Hessell et al., 2007). However, the 
dynamics of the Fc-FcR interaction and their ability to elicit effector functions may not be as 
efficient in the genital tract mucosae, compared to the systemic compartment and requires 
further investigation. 
 
2.6.1 Fc-FcR interaction and the potential role of non-neutralizing antibodies in HIV-1 
infection  
 
Where neutralization fails to prevent infection of HIV target cells, various studies have 
reported the role of non-neutralizing antibody activity, mediated by Fcγ-receptor binding, in 
the control of HIV-1 infection (Mabuka et al., 2012, Barouch et al., 2013a). In animal 
infection established models, macaques passively infused with SIV-specific non-neutralizing 
IgG facilitating ADCC activity, was associated with the reduction of SIV infected cells (Banks 
et al., 2002, Ferrantelli et al., 2003). These data, along with other studies, [reviewed by 
(Forthal and Moog, 2009)], indicate the role of ADCC activity in altering HIV disease 
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progression, with increased ADCC activity associated with better disease outcome (Figure 6 
and Figure 7C) (Hessell et al., 2007, Milligan et al., 2015).  
More interestingly, the observed protection in the RV144 trial showed that binding 
antibodies, directed to the V1V2 region of gp120, in particular the IgG1 (Forthal et al., 2013) 
and IgG3 subclass, mediated ADCC (Figure 4) (Yates et al., 2014). Levels of V1V2 specific-
IgG3 were considered correlates of protection, however plasma Env-specific IgA antibodies 
were correlated with reduced vaccine efficacy (Yates et al., 2014, Vasan et al., 2015). Thus, 
these findings initiated further scrutiny into factors that may contribute to better protection 
from HIV, two of which will be discussed in the sections below, namely antibodies and 
effector cell characteristics.  
Effector cell population relative abundance, tissue location, FcR expression and frequency, 
are key factors that influence nNAb activity (Cheeseman et al., 2016). Innate immune 
effector cells such as NK cells and macrophages are able to induce cytotoxicity (Ackerman et 
al., 2013a) and phagocytosis (Ackerman et al., 2013b), respectively. Therefore, the presence 
of both effector cells and antibodies at mucosal portals of entry (Figure 7 and 8), such as the 
genital mucosae should be considered in vaccine design as  both need to be present, in 
order to provide protection from infection (Cheeseman et al., 2016). 
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FIGURE 7: Mechanisms of broadly neutralizing and non-neutralizing antibodies in immune 
defences at mucosal portals of entry, from HIV infection. nNAb elicit humoral immune responses, 
other than neutralization. NNAbs are capable of mediating viral inhibition, trogocytosis, cytotoxicity 
or phagocytosis of infected cells, via Fc-FcR interactions with innate immune effector cells. These 
activities suggest a role for nNAbs in mucosal protection from HIV challenge [adapted from (Hope, 
2011)].  
 
Effector cells are commonly found in the sub-epithelial and basal layers of the mucosal 
tissue as well as in the blood (Cheeseman et al., 2016). Neutrophils, are one of the most 
abundant white blood cells in the body and are essential in pathogen clearance associated 
with innate immunity (Amulic et al., 2012). Furthermore these predominant innate cells are 
capable of eliciting phagocytic activity and are reportedly found in consistent populations in 
the cervix, in both HIV infected and uninfected women (Nkwanyana et al., 2009). These 
characteristics of the genital tract should be considered in vaccine design where 
immunoglobulin subtypes may be harnessed as it has been shown that IgG3 has greater 
virion uptake capacity than IgG1 (Tay et al., 2016). These neutrophils bind IgG3 more 
effectively and should these antibodies exist at frequently challenged site, they might 
provide greater mucosal protection from HIV infection (Sips et al., 2016).  
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Considering the competitive and inhibitory binding Env-specific IgA had in reducing the 
efficacy observed in the RV144 trial, vaccine design would need to account for influencing 
factors, such as antibody isotype and subclass (Haynes et al., 2012a). As seen with the 
RV144 vaccine, IgG3 exhibited a higher affinity to effector cells than IgG1, which would 
resulting in a stronger antiviral response, due to the more rapid release of perforin 
granzymes and other antiviral cytokines a (Smalls-Mantey et al., 2012, Kramski et al., 2013). 
These differences may dictate the efficacy of the immune-induced responses, which are 
influenced by immunogen design, active or passive immunization strategies and as well as 
whether the vaccine is administered intravenously or subcutaneously (Cheeseman et al., 
2016).  
Furthermore, IgG3 had the highest internalization of HIV-1 antigen compared to IgG1 and 
IgA1, which corroborated with the correlates of protection analyses from the RV144 trial 
(Tay et al., 2016, Tomaras et al., 2012). Thus, these findings support recent studies and 
building momentum regarding the importance that Fc-mediated antiviral activity may have 
to further protect from HIV-1 infection (Barouch et al., 2013a, Hessell et al., 2007). 
 
2.6.2 Antibody Dependent Cellular Phagocytosis (ADCP) mediated by Polymorphonuclear 
Neutrophils and Macrophages 
 
Phagocytosis is the complete internalization of a pathogen or infected cell by  phagocytic 
cells such as neutrophils, macrophages, plasmacytoid dendritic cells (pDC) or eosinophils 
and result in antigen presentation and the release of cytokines that modulate inflammation 
(Kramski et al., 2013, Sips et al., 2016). Antibody mediated functions such as phagocytosis 
have not been explored in detail as studies have focussed on alternate antibody mediated 
effector functions like direct neutralization or cytotoxicity (Kramski et al., 2013). IgG1 and 
IgG2 engage with innate cells such as monocytes, neutrophils and macrophages expressing 
FcRγII on their surfaces and mediate phagocytosis (Figure 8) (French et al., 2013, Sips et al., 
2016). Phagocytic activity during acute HIV infection may play a key role in pathogen 
clearance, through early recognition of immune complexes and warrants further research as 
a mechanism of effective viral control and clearance (Tomaras et al., 2008). However, during 
HIV infection, phagocytic activity is reduced as a result of the dysregulation of actin 
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polymerization and the loss of FcγR intracellular signalling molecules of monocytes and 
macrophages (Kedzierska et al., 2003). Interestingly, in HIV controllers and untreated 
progressors, ADCP activity is increased and may be attributed to the glycosylation of the Fc 
portion, which results in increased interaction with phagocytic cells expressing FcγRIIb and 
FcγRIIa (Ackerman et al., 2013b). Thus, these Fc expressing macrophages, may be one of the 
“most important functions” required for clearance of HIV infection (Kramski et al. 2013; 
Kedzierska et al. 2003). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 8: Diagrammatic representation of three various antiviral activities, mediated by 
antibodies. (A) Neutralization of cell free viruses.  Antibodies bind to specific parts of the virus 
envelope inhibiting the attachment of the virus to the target cell co-receptors, i.e. CCR5 and CD4. (B) 
Antibody dependent cellular cytotoxicity. Usually mediated by NK cells, by binding of the Fab region 
with the antigen resulting in the formation of an immune complex. The Fc portion of the bound 
antibody i.e. IgG engages with the FcR of the effector cell (NK cell) to destroy the infected cell. (C) 
Antibody dependent cellular viral inhibition (ADCVI). A measure of the secondary effects of ADCC 
activity and the resulting release of anti-viral products such as cytokines that lead to phagocytosis or 
viral inhibition  [adapted from (Overbaugh and Morris, 2012)]. 
32 
 
ADCP activity in the mucosal tissue may elicit a stronger protective response than ADCC 
mediated functions,  due to the relative abundance of phagocytic effector cells, such as 
neutrophils, in the colorectal, penile glans and cervical tissue (Cheeseman et al., 2016).  
Neutrophils may be key in protecting the female genital tract from HIV infection, due to 
their stable population abundance during menstrual cycles and inflammation Interestingly, 
these effector cells have been associated with the control of HPV viral loads, in the female 
reproductive tract (FRT), suggesting a potential role for ADCP activity against HIV in the FRT 
(Sips et al., 2016, Day et al., 2010).  
 
Antibody dependent cellular viral inhibition (ADCVI), another diverse Fc-mediated activity, 
inhibits viral yield from infected cells and is a measure of antiviral activity mediated by ADCC  
and ensuing secondary antiviral activity such as phagocytosis and viral inhibition [as 
reviewed in (Overbaugh and Morris, 2012), (Forthal et al., 2006)]. nNAbs mediate 
ADCC/ADCVI antiviral activity (Figure 8B and C), via crosslinking of the IgG Fc to NK cell 
FcRγIII which results in NK cell activation [as reviewed in (Daëron, 1997)]. NK cell activation 
releases cytokines: IFN-y, TNF-α, MIP1-β and results in degranulation of infected cells [as 
reviewed in (Scully and Alter, 2016), (Chung et al., 2009, Kramski et al., 2013)]. ADCVI 
contributes to viral reduction and decrease in viral transmission, acting against both cell free 
and cell associated virus [as reviewed in (Scully and Alter, 2016)]. Post-challenge animal 
studies have reported partial protection from SHIV infection as well as viral load reduction 
and viral clearance due to ADCVI/ADCC activity (Hidajat et al., 2009, Xiao et al., 2010, 
Florese et al., 2009, Banks et al., 2002, Gómez-Román et al., 2005). Furthermore, in another 
animal study, ADCVI activity has shown potential in protecting neonates from infection 
(Forthal et al., 2006). According to a review by Overbaugh and Morris (2012), in the Vaxgen 
Phase III vaccine study, despite the absence of protection, levels of binding antibody, 
incidence of infection and ADCVI activity were correlated to lower disease pathogenesis, 
further supporting the role of non-neutralizing antibody mediated protection in HIV 
infection [as reviewed in (Overbaugh and Morris, 2012),(Gilbert et al., 2005, Forthal et al., 
2010)]. Together these findings highlight the importance of Fc mediated antiviral activity in 
reducing viral load and providing a level of protection from HIV infection, mediated by 
either phagocytic or cytotoxic activity.  
33 
 
 
 
 
 
 
FIGURE 9: Phagocytic activity mediated by innate cells like macrophages or neutrophils. The 
interactions between the Fc portions of nNAbs and surface-bourne Fc receptors innate immune 
cells, results in phagocytic activity and triggering of the downstream activation of other immune 
responses subsequent to the secretion of cytokines and leading to the destruction of the pathogen 
(Kramski et al., 2013). 
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2.6.3 The role of NK cell mediated Antibody Dependent Cellular Cytotoxicity in HIV 
infection 
 
NK cells play a crucial role in innate immunity because they recognize and destroy infected 
cells. This activity shapes the adaptive immune response. Harnessing these characteristics 
may be central in preventing or controlling HIV infection. Antibodies capable of mediating 
ADCC activities usually develop in the early stages of HIV infection and were shown to be 
associated with better disease outcome (Milligan et al., 2015, Mabuka et al., 2012). Mabuka 
et al., (2012) reported that ADCC activity in the breastmilk of HIV infected mothers was 
associated with reduced vertical HIV transmission. Furthermore in a related study, pre-
existing and passively transferred ADCC antibodies through the breastmilk, showed that for 
every 10% increase in ADCC activity a correlated  49% decrease in childhood mortality 
occurred (Milligan et al., 2015, Mabuka et al., 2012). This was attributed to pre-existing 
ADCC activity, present at the oral mucosal surface. Similarly, ADCC activity correlated to 
reduced HIV RNA levels at the mucosae (Battle-Miller et al., 2002).  
Additionally, ADCC activity was correlated to low systemic levels of viremia, in patients 
initiated on ART treatment and who stopped ART after three years, indicating a sustained 
nNAb responses [as reviewed in (Scott-Algara, 2015, Scully and Alter, 2016)]. Early ART may 
preserve ADCC function and may mimic ADCC in HIV elite controllers who display superior 
ADCC function (Scott-Algara, 2015). In addition, a macaque study, showed that application 
of topical NAb, nNAb gel or both, before SHIV challenge, resulted in reduced viral loads 
through ADCC (Moog et al., 2014). Taken together, these data suggest that the presence of 
nNAb at frequently challenged sites of transmission, such as the genital mucosae, may 
provide a level of protection against HIV infection.  
NK cell populations in the mucosae of penile, cervical and colorectal tissue, may contribute 
to protection by binding IgG antibodies (Cheeseman et al., 2016). At the subclass level, IgG3 
antibodies mediate ADCC activity more effectively (see Figure 8 and Figure 9) (Chung et al., 
2014). Highly effective NK cells release CD107 and cytokines IFN-γ and TNF-α, which in turn 
recruit more effector cells bolstering antiviral activity (Alter et al., 2004). Methods 
investigating ADCC function have varied in sensitivity and ease of conduct.  To date the rapid 
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fluorescent antibody dependent cellular cytotoxicity (RFADCC) has been described as a 
quantitative (Gómez-Román et al., 2006) and more efficient method to analyse ADCC 
activity in comparison to the chromium release assay (Chung et al., 2009, Ahmad et al., 
2001) . However, the intracellular based staining (ICS) ADCC assay which measures NK cell 
activation, allows for the measurement of various NK cell mediated antiviral activities such 
as IFN-γ, CD107a and MIP-1β expression (Chung et al., 2009, Stratov et al., 2008). This assay 
utilises HIV antigens, enabling individual peptide responses to be analysed as potential 
targets for future HIV vaccines eliciting this function (Chung et al., 2009). In addition, the 
ICS- NK cell activation assay is easier and less laborious, allowing for the use of fresh whole 
blood for assays, irrespective of whether the blood are from the autologous or healthy 
donors (Chung et al., 2009).  However HIV downregulates HLA through Nef and Vpu 
proteins, inhibiting NK cell activation and therefore undermines ADCC activity (Cohen et al., 
1999). The prior use of PrEP or ongoing ART may be able to rescue NK cell activity through 
viral loads suppression (Brunetta et al., 2010, Mavilio et al., 2005).  
 
2.7 Preliminary data 
 
Following the recommendation of PrEP to high risk populations which include women 
between the ages of 15-24 years by the World Health Organization, understanding the 
kinetics of the immune response in the genital mucosal tract requries further investigation, 
in order to better inform on future prevention strategies. Recently published data by  
Archary et al., (2016) demonstrated that seroconverter women from the CAPRISA 004 1% 
tenofovir microbicide gel trial had significantly higher responses and higher frequencies and 
titres of HIV-1 specific gp70 V1V2 IgG and Env gp120 respectively. In addition, in the genital 
tract and in the plasma, these women displayed higher titres of p66 and p24 IgGs and IgA’s, 
compared to women in the placebo group.This discriminant pattern of HIV-specific binding 
antibodies between the tenofovir and placebo gel users was seen predominantly in the first 
12 months post-infection. The close concordance between the plasma and the genital tract 
was seen for 9 of the 10 HIV-IgG specificities where plasma antibody titres predicted GT 
levels in the first six months post-HIV infection. However whether the IgG functionality was 
mirrored between the plasma and genital compartments is an aspect we proposed to 
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investigate. These published data suggest that in the presence of tenofovir, women who 
acquired HIV infection had elevated humoral immune responses in the blood and genital 
tracts of individuals. These data reveal strong associations between the prior use of 
tenofovir gel, the profile of binding antibodies that prevail and further distinguish the 
women that used 1% tenofovir gel compared to those who did not, as well as identifyingthe 
strong cross compartment association of HIV specific IgG antibodies. 
  
Therefore, the aim of the study was to elucidate the effects of PrEP as an HIV prevention 
method, on humoral immune responses in the plasma and genital tracts of women who 
acquired HIV infection, but who had prior exposure to 1 % tenofovir microbicide gel.  We 
investigated effector functions such as ADCC and ADCP activity of non-neutralizing HIV-1 
specific IgGs, following the discovery of unique antibody signatures, in the plasma and 
genital tracts of the women who participated in the CAPRISA 004 trial. These data will be 
crucial for informing the development of future HIV prevention strategies, in an era where 
vaccines and PrEP will likely be used in combination, to prevent HIV. 
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CHAPTER 3  
 
3.1 Aim 
 
1. To determine the Fc-mediated ADCP and ADCC activities of HIV-1 specific IgG binding 
antibodies in the blood of women from the CAPRISA 004 1 % Tenofovir gel trial, who 
acquired HIV during the first 12 months post-infection, in both the tenofovir and 
placebo arms. 
2. To determine the Fc-mediated ADCP and ADCC activities of HIV-1 specific binding 
antibodies in the genital tracts of women from the CAPRISA 004 1 % Tenofovir gel 
trial, who acquired HIV during the first 12 months post-infection, in both the 
tenofovir and placebo arms. 
 
3. To determine if the functional profiles of HIV-specific IgGs mediating ADCP and ADCC 
were similar between the blood and genital tracts, of women in the tenofovir and 
placebo arms. 
3.2 Objectives 
 
1. To investigate Fc-mediated ADCP and ADCC assays using IgGs isolated from the 
plasma of women who participated in the trial in both the tenofovir and placebo 
arm. 
2. To investigate Fc-mediated ADCP and ADCC activities in the genital tracts of women 
in both study arms, using CVL samples. 
3. To determine the correlation between ADCP and ADCC activity in the plasma and 
genital tracts of women, at 3 months, 6 months and 12 months post-infection. 
 
3.3 Hypothesis 
 
Antibodies isolated from the plasma and genital tracts of women in the CAPRISA 004 trial, 
elicited functional Fc-mediated ADCP and ADCC activities and were associated with prior 
tenofovir gel use.  
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CHAPTER 4 
 
4.1 Study population and study design 
 
This was a retrospective study of 48 HIV-infected women, who seroconverted during the 
CAPRISA 004 1% tenofovir microbicide gel trial (Abdool Karim et al., 2010). The CAPRISA 004 
microbicide gel trial (Clinical Trials Number #00441298) participants had given written 
informed consent, to use their stored samples for future research. Approval for the CAPRISA 
004 trial was obtained from the University of Kwa-Zulu Natal Biomedical Research Ethics 
Committee (BREC) (E111/06), Family Health International’s protection of Human Subjects 
Committee (#9946) and the South African Medicines Control Council (#20060835). BREC at 
the University of KwaZulu-Natal approved this sub-study for post-graduate degree purposes 
(BE241/16) (appendix A and B).  
Twenty-four women from the tenofovir arm and 24 women from the placebo arm were case 
matched according to their viral loads and CD4+ T-cell counts at six-months post-infection. 
Women who were HIV-infected were followed for a median of 36 months after enrolment 
(range 11.5-53.5 months) however; the samples from 3; 6 and 12 months post-infection 
were included in this sub-study (Figure 10).   
4.2 Biological Specimen and Sampling collection  
 
Cervical lavages (CVL) and plasma samples from the women who had experienced 
breakthrough HIV-1 infection during the CAPRISA 004 1% tenofovir microbicide gel trial 
were used to achieve the objectives of this sub-study. All women were antiretroviral (ARV) 
treatment naïve. CVL samples were collected from women at each visit according to the 
method described (Bebell et al., 2008). CVL were collected by bathing the cervix with 10mL 
of sterile saline, which was allowed to pool in the posterior fornix before aspirating using a 
bulb pipette. Upon aspiration, the fluid from the cervicovaginal tract was dispensed into a 
sterile container and centrifuged at 2700 rpm for 10 minutes. Following this process, 
aliquots of the CVL supernatant were prepared and stored at - 80°C until required. These 
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CVL specimens were used undiluted in subsequent assays, unless otherwise stipulated. 
However, if the participant was menstruating at the proposed time of CVL collection, the 
collection was postponed until the end of the menses (Bebell et al., 2008). Plasma samples 
collected by venepuncture into acetate citrate dextran (ACD) vacutainers were spun down 
to separate the plasma from the packed cells.  The plasma was stored at - 80°C until 
required HIV statuses of the women were determined by two HIV-1 rapid antibody tests and 
polymerase chain reaction (PCR) (Roche amplicon v1.5) and confirmed by enzyme 
immunoassay. Viral loads were determined using a Cobas Amplicor HIV-1 Monitor Test, v 
1.5 (Roche diagnostics) and CD4+ T cell counts were assessed using a FACS Calibur flow 
cytometer (Becton Dickinson, where from San Jose, CA) (Abdool Karim et al., 2010). 
4.3 Statistical analysis 
 
Comparisons of IgG phagoscores between the study arms at 3 months, 6 months and 12 
months, in the plasma and CVL were analysed using the Wilcoxon Rank Sum tests. Wilcoxon-
Signed Rank test were used to compare plasma IgG phagocytic scores and CVL IgG 
phagocytic scores across 3 to 6 months, 6 to 12 months and from 3 to 12 months, using 
GraphPad Prism version 7, software. This analysis was further stratified by randomization 
arm. Spearman Rank Correlation analysis was done to determine inter-compartmental 
relationships between the tenofovir and placebo at each time point, in both arms. In order 
to identify correlations between phagocytic activity and CD4+ T cell count and viral load, 
correlation analysis was done at 6 months post-infection for plasma and genital tract, HIV-
specific mediated antibody activity.   
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FIGURE 10: Methodology used to investigate the nNAb functions of plasma IgG and CVL from 
women in both the tenofovir (n = 24) and placebo arms (n = 24). Plasma and CVL samples from the 
genital tract were collected at 3, 6 and 12 months, for women in both study arms, and were used in 
ADCP and ADCC assays.   
  
48 HIV+ women
Placebo (n=24) and
Tenofovir (n=24) arm
IgG was isolated from both 
arms using the Thermofisher 
Scientific Melon Gel kit
ADCP assays were conducted 
using the optimised 
concentration of sample IgG
ADCC assays were conducted 
using the optimised 
concentration of sample IgG
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 4.4 Methods 
 
4.4.1 Isolation of IgG from CVL and Plasma samples  
 
In order to determine the Fc-mediated functional capabilities of IgG’s isolated from the 
plasma and CVL samples of women in both the tenofovir and placebo arms were isolated 
using an IgG isolation kit, in the following manner. 50µl of the plasma/CVL sample, was 
diluted in 450µl of Purification buffer (Thermofisher Scientific, Waltham, MA). The CVL IgG 
isolation procedure was discontinued due to the low total immunoglobulins present in the 
lavage specimens, therefore undiluted CVL specimens were used in the future experiments.  
 Purification buffer was previously diluted in deionised water from a 10X stock provided in 
the kit to a 1x working solution. Pierce spin columns-screw caps, with 20-50µl filters, were 
removed and replaced with the 100-400µl filter (Thermofisher Scientific, Waltham, MA). 
Melon Gel IgG Purification Support matrix (Thermofisher Scientific, Massachusettes, USA) 
was reconstituted by repeated swirling to ensure an even suspension before 500µl of Melon 
Gel (Thermofisher Scientific, Waltham, MA) was dispensed into the pierce columns. The 2ml 
Eppendorf with the spin column and melon gel, was then spun at 14,000 rpm for 1 minute in 
a microcentrifuge (Beckman Coulter, Germany). The supernatant was removed and 300µl of 
Melon Gel Purification buffer (Thermofisher Scientific, Waltham, MA) was added and 
centrifuged at 14,000 rpm for 1 minute. This process was repeated three times to ensure 
that the gel was purified and any remnants that may interfere with downstream assays 
were removed. In order to seal the column, column plugs were inserted onto the bottom 
ends of the columns and 500µl of each of the diluted samples were added to the remaining 
melon gel support.  The Pierce columns containing the sample and melon gel support was 
re-suspended by inverting it several times before being mixed using a Hula Mixer 
(Invitrogen, Oslo, Norway) for 15 min in order to homogenize the suspension with the 
sample and ensure maximum binding of the gel matrix and the IgG. The pierce columns 
were then placed in new 2ml Eppendorf tubes and centrifuged for 1 min at 14,000 rpm. The 
flow through was collected and the concentration of the purified IgG calculated by using a 
Nanodrop Lite Spectrophotometer (Thermofisher Scientific, Waltham, MA). The isolated IgG 
was stored at 4 °C until required.  The spin column with the remaining Melon Gel Support 
was reconstituted and used again, by adding 500µl of regeneration buffer from the 
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Thermofisher Scientific kit and mixed on the Hula Mixer (Invitrogen, Oslo, Norway) for 5 
minutes.  The column plug was removed and the tubes were centrifuged for 1 minute at 
14,000 rpm using the microcentrifuge, to remove the regeneration buffer. The Melon Gel 
support was then washed 3 times with 300µl of regeneration buffer and centrifuged for 1 
minute at 14,000 rpm. 500µl of purification buffer was added and the column plug inserted 
and the cap screwed on, were stored at 4°C until further use.  
4.4.2 R10 Media preparation for cell culture 
 
The neutrophils were temporarily stored in R10 media. R10 was made in the following 
manner, RPMI without L-glutamine (Whitehead Scientific, USA), was supplemented with 55 
ml of heat-inactivated fetal calf serum (FCS) (Sigma-Aldrich, USA). FCS was heat inactivated 
by placing it in a water bath that was set at 56°C for one hour. 5ml of 2mM L-glutamine 
(Whitehead Scientific, USA), 5ml of Pen/Strep, 5ml of 1mM HEPES (Whitehead Scientific, 
USA) and was thoroughly mixed to ensure and even suspension.  
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4.4.3 Proteins used in both ADCP and NK cell activation Assay 
 
In order to gauge the functionality of the IgGs four HIV-1 antigens were used. These 
included envelope and gag proteins like Con6 gp120 and gp41, Gag p24 and p66 (RT). The 
antigens used in the assays included Con6 gp120/B (Consensus Group M gp120), gp70_B 
CaseA_ V1_V2 (gp70 V1V2) (Immune Technology, California, USA) only for the ADCP plasma, 
commercially available antigens included p24 (HIV-1/Clade B/C CN54) (Immune Technology, 
California, USA) and gp41 (Ectodomain) (HIV-1) (Immune Technology, California, USA) and 
p66 RT (ImmunoDX, Massachusetts, USA). All experiments were conducted with compliance 
to good clinical laboratory practice. 
 
4.4.4 Isolation of white blood cells to assay neutrophil mediated phagocytosis 
 
 Neutrophils undergo rapid respiratory burst therefore this cell isolation process was done 
immediately before the assay. The white blood cells were prepared by pipetting 1mL of 
EDTA-treated whole blood in a tube containing 9mL of ACK lysis buffer (Life technologies, 
Grand Island, NY) and incubated for 3-5 minutes at room temperature. White blood cells 
were collected by centrifugation (Beckman Coulter Allegra, California, USA) at 1500 rpm for 
5 minutes at room temperature. The supernatant was aspirated, leaving approximately 50µl 
to avoid disturbing the pellet. The cells were washed with 5mL of cold phosphate buffered 
saline (Lonza, Walkersville, MD) to detach the cells from the bottom of the falcon tube. The 
re-suspended cells were inverted before being pooled and then collected by centrifugation 
at 1500 rpm for 5 minutes at 4°C. The supernatant was aspirated and re-suspended in 
approximately 5mL of R10. A haemocytometer was used to count live cells, which were then 
re-suspended to approximately 50,000 cells/mL in the volume of R10 required for each 
assay. 
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4.4.5 Antibody Dependent Cellular Phagocytosis Assay (ADCP) – Neutrophil Assay 
 
The plate layout for a 96 well round bottom tissue culture plate (Sigma-Aldrich) was 
prepared and designed to include positive, negative and no antibody controls. Assays were 
run in duplicate with controls run in triplicates. Each plate layout included positive and 
negative controls, in order to establish a true positive and negative result in comparison to 
the sample results (Figure 11). For the positive control, HIV immunoglobulin (HIVIG) was 
diluted to a concentration of 0.5mg/ml in a volume of 100µl of R10. For the ‘negative 
control,’100 µl of PBS was used. 5µl of biotinylated antigen was added to each well in a 96 
well round-bottom tissue culture plate and then 100 µl of sample/control were added to 
each well. The plate was incubated at 37°C for 2 hours in an incubator at 5% CO2. 50,000 
neutrophils in a total volume of 100 µl of R10 were added to each sample and then 
incubated at 37°C for 1 hour. The plate was spun at 500 g for 5 min at 4°C. The supernatant 
was flicked off and the pellet re-suspended in the remaining fluid, by gently running the 
plate over a rack. Each well was stained with the 1µL of CD3 Alexa Flour 700 (A700) to stain 
for CD3 negative cells (BD Biosciences New Jersey, USA), 1µL of CD14 Phycoerythrin and 
cyanine 7 (PE-Cy 7) (BD Biosciences, New Jersey, USA) to stain for monocytes, 1 µL of CD66b 
Violet 450 (VP450) (BD Biosciences, New Jersey, USA) to stain for neutrophils and 17µl of 
PBS, approximately 20µL of stain was added per well (Table 3). Following staining, the plate 
was incubated at room temperature for 15 minutes, in the dark before 200 µL of PBS was 
added to each well. The cells were pelleted by centrifugation at 500 g for 5min and then 
removed by flicking off the supernatant. 50µL of 4% paraformaldehyde (PFA) was added and 
incubated at room temperature for 15 minutes in the dark. The cells were pelleted by 
centrifugation at 500 g for 5 minutes before the supernatant was flicked off. 100 µL of PBS 
was added to each well and then stored overnight at 4°C until run on the LSR Fortessa (BD 
Biosciences, California, USA). The total number of events that were acquired for each well 
was set as 20 000 events. 
 
4.4.6 Biotinylation Protocol 
 
The biotinylation process was conducted according to a previously published method 
(Ackerman et al., 2011). The neutravidin (FlouroSphere ®Neutravidin® Labelled from LTC 
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Technologies, USA) bead solution was biotinylated (EZ-Link Sulfo-NHS-LC-Biotin, No-Weigh 
Format) (Thermofisher Scientific, Rockford, IL) to one of the five HIV antigens. The 
neutravidin beads required for 5µl per plate was calculated. The amount of biotinylated 
antigen is equal to the volume of neutravidin beads multiplied by 4 due to the 1:4 ratio of µl 
beads to µg of antigen. The antigen-bead solution was prepared by vortexing the beads 
before transferring neutravidin beads with a pipette into 1.7ml microcentrifuge tube. The 
required volume of biotinylated antigen was added using a pipette and mixed by repeat 
pipetting. The tubes were labelled with the date, antigen and operator initials. The beads 
with the antigen were incubated together in an incubator at 37°C at 5% CO2 for 2 hours. 
After the incubation period, the tube was washed with 1ml of 0.1 % phosphate buffered 
saline (PBS) - bovine serum albumin (BSA) - PBS-BSA solution (KPL, USA) twice before re-
suspending it in 0.1% PBS-BSA at a ratio of 1:100 beads: PBS-BSA. The coupled beads and 
antigen were then stored at 4°C until use- with a maximum storage period of two weeks.  
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4.4.7 ADCP Antibody Panel 
 
 
4.4.8 Plate design 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 11: Plate design used for both the ADCP and ADCC assays  
TABLE 3: Antibody panel for the ADCP assay 
Antibody Cell type Volume (µl) 
CD3 AF700 CD3 negative cell 1 
CD66 VP450 Neutrophil marker 1 
CD14 Pe-Cy7 Macrophages and monocytes 1 
 1 2 3 4 5 6 7 8 9 10 11 12 
A             
B             
C             
D             
E             
F             
G             
H             
  Cells only 
 antigen 
 sample 
 Negative control 
 Positive control 
 R10 
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4.4.9 Gating Strategy for ADCP 
 
To accurately gate for the monocyte populations, the cell size and granularity were used to 
place the population of interest within the grid, by altering the voltages. Unstained cells 
were used and the forward and side scatter voltages adjusted accordingly to identify live 
cells and distinguish them from cellular debris. Positive controls using HIVIG are shown in 
Figure 12 and negative controls using PBS are shown in supplementary Figure 2, to 
accurately gate for ADCP activity. The parameters on the x and y –axis was then altered to 
SSC-Area and SSC-Height in order to identify single cell populations. Once the single cells 
were confirmed, the axis was changed again for the x-axis to represent CD3 AF700 and the 
y-axis to SSC-Height in order to identify the CD3 negative population, in this case the 
population of interest.  Once identified, the x-axis to CD14 PE-Cy 7 and the y-axis to CD66B 
V450 in order to identify the neutrophils population expressing the CD66B, which is a 
neutrophil marker.  The X-axis was changed to the FITC marker and the Y-axis to CD66B 
V450 (Figure 12), which will aid in calculating the percentage of neutrophils that 
phagocytosed the neutravidin beads that were conjugated onto the selected antigen, i.e.: 
gp120. Phagocytic scores were determined by analysing the data using FlowJo V10.0.1 
(TreeStar) [(percentage of neutrophils taking up beads x mean fluorescent 
intensity)/10,000], which represents the integrated MFI (iMFI). This was proportional to the 
number of cells and relative to the bead uptake, adapted from (Ackerman et al., 2011). 
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FIGURE 12: Gating strategy for the ADCP assay, investigating the phagocytic activity of neutrophils. 
Live cells were gated on using FSC-A and SSC-A. Sequential gating from live cells, included singlets, 
followed by CD3- cell, neutrophils and then neutrophils that phagocytosed antigen coated 
neutravidin beads.  
 
4.4.10 Intracellular Cytokine Staining of NK cell activated Antibody Dependent Cellular 
Cytotoxicity (ADCC) Assay  
 
The ADCC assay required isolation of natural killer cells from fresh whole blood collected in 
citrate tubes, by venepuncture. The assay was conducted according to the protocol outlined 
by the Ragon Institute, Boston, USA. R10 media composed of 10% heat inactivated FCS, 
RPMI 1640 (Lonza, Maryland, USA), HEPES (Lonza, Maryland, MD), Penicillin-streptomycin 
(Whitehead Scientific, Cape Town, SA) and L-Glutamine (Gibco, New York, USA) was 
prepared. The R10 and ficoll (Histopaque) (Sigma-Aldrich, Dramstadt, Germany) was 
warmed to room temperature before proceeding with the experiment. A 96 flat bottom 
A B C 
D E 
FITC+ neutrophils 
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high-binding ELISA plate (Sigma-Aldrich, Dramstradt, Germany) was used to incubate 1.5-
3µg/ml of HIV positive proteins per well and an SF PBS-BSA as the background control, in a 
total volume of 100 µl (made up in 1 x sterile PBS). Assays were run in duplicate with 
controls run in triplicates. The plate was centrifuged at 1000RPM for 2 minutes. The plate 
was sealed and incubated for 2 hours at 37˚C before it was washed, 3 times with 200 µl of 
PBS per well, using a multichannel pipette, with blotting in between each wash.  Following 
the removal of excess antigen, 200µl of 5% BSA (10% BSA, KPL, Massachusettes, USA) in PBS 
was added to prevent non-specific binding. The plate was then incubated overnight at 4˚C, 
or for 1hr at room temperature. During incubation, the samples were prepared at the 
optimal concentration in PBS as determined by optimisation experiments, which included 
serial dilutions of purified IgG from 1mg/ml>0.5mg/ml>0.25mg/ml for the plasma. 
Regarding genital tract CVL samples, neat CVL was used at the same volume used for ADCP 
assays, which was 50µl of neat CVL, in order to standardise the volume used. Following 
incubation, the plate was washed 3x with 200µl of PBS and incubated with 50 µl of purified 
IgG at 0.25mg/ml at 37°C for 2 hours.  
During the incubation period, the natural killer (NK) cells were isolated from whole blood on 
the day of the experiment or the day before, using a RosetteSep (Separations Scientific, 
Vancouver, ca) as per manufacturing instructions. Briefly, 25µl of RosetteSep per 1 ml of 
fresh whole blood was added and then incubated at room temperature for 20 minutes. 15 
ml of Ficoll (Histopaque) (Sigma Aldrich, Dramstradt, Germany), was added to a 50 ml falcon 
tube. After the incubation period the 15ml falcon tube containing the blood and Rosettesep 
beads was topped up with an equal volume of PBS. The blood with the RosetteSep beads, 
were layered onto the ficoll with care taken to avoid mixing the blood and ficoll. After 
layering, the ficoll and blood was spun down for 20 minutes at 1200 x g at 25°C, with breaks 
off, to isolate the NK cells. The NK cells were washed twice with R10, after being centrifuged 
at 1700 rpm for 5min at 25°C. The NK cells were re-suspended to 2.5 x 105 cells/ml in R10. If 
the cells were incubated overnight, 0.2 µl per ml of IL-15 at a concentration of 1ng.ml (Life 
Technologies, USA), was added to the culture flask and incubated overnight at 37˚C, 5% CO2. 
A full plate requires 5 x 106 NK cells in 20 ml of media. An inhibitor cocktail consisting of the 
following antibodies, 2.5 µl of CD107a-PE-Cy5, 0.4µl of brefeldin and 10µl of Golgi stop (BD 
Biosciences, San Jose, CA). The Golgi stop was made up in the following manner, 13.6µl of 
stock Golgi stop +1ml of R10 Notably, the inhibitor cocktail was added to the NK cells in the 
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culture flask, before they were added in at a volume of 200µl per well. After incubating the 
antigen coated ELISA plate with the sample, the plate was flicked to remove excess IgG and 
blotted before it was washed 3 times with 200µl of PBS from Lonza. The plate was covered 
with a lid from the V-bottom ELISA plate (Sigma-Aldrich, USA) and then incubated for 5 
hours at 37°C at 5% CO2. The surface stain was prepared to consist of the following 
antibodies – 0.25µl of CD3 A700, 1µl of CD56 PE-Cy-7, 1 µl of CD16 Allophycocyanin and 
Cyanine 7(APC-CY 7) (BD Biosciences, San Jose CA) and 7.75µl of PBS. 10µl of the surface 
stain was added to a new V bottom plate and after the cells-antibody complex incubated, 
the complex was transferred to the ELISA plate, containing the surface stain. If the NK cells 
were isolated the day before the experiment and stimulated with IL-15 overnight, the 3µl of 
the Live/dead aqua stain (Life Technologies, USA), was included in the surface stain, per 
well. The V-bottom plate was then incubated at room temperature in the dark for 15 
minutes. The plate was then spun at 500g for 5 minutes with breaks off and flicked, to 
remove excess antibodies and 200µl of PBS added, before being spun and flicked again. 
Following washing, 50µl of Perm A (Thermofisher Scientific, Gerichtsberg) was added to the 
V-bottom plate and incubated for 15 minutes. After incubation, 100µl of PBS was added and 
the plate washed, by centrifuging the plate at 500g for 5 minutes. The plate was washed a 
further 2 times with 200µl of PBS and flicked between each wash.  The intracellular stain 
was prepared in the following format, 1 µl of IFN-γ APC, 1 µl of MIP1-β Phycoerythrin (PE) 
(BD Biosciences, California, USA) and 48 µl of Invitrogen Perm B (Life Technologies, USA). 
Following the plate wash, 50 µl of the intracellular stain was added to each well, mixed and 
incubated at room temperature, for 15 minutes, in the dark. Following incubation, the plate 
was washed with 200µl of PBS, by centrifuging the plate each time at 500g, for 5 minutes at 
25°C and flicked after each wash. 150 µl of BD Cell fix at a 1x concentration, was added to 
each well and then acquired on FACS Fortessa from BD Biosciences USA, using the high 
throughput system (BD Biosciences, California, USA). The total number of events that were 
acquired for each well was set as 20 000 events. 
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4.4.11 Antibody Panel for NK cell activated ADCC Assay 
 
The same plate design as the ADCP assay was used in the ADCC assays. The NK cells were 
isolated and used on the same day, therefore forward and side scatter was used to identify 
the live population (Table 4).  
 
TABLE 4: Antibody panel for the ADCC assay the ADCC assay 
Antibody Inhibitor cocktail Cell type Volume (µl) 
CD107a –PE-Cy5 Marker for degranulation 2.5 
Brefeldin (BFA) Inhibits protein transport from 
Endoplasmic Reticulum to golgi 
0.4 
Golgi Stop Accumulates cytokine production 
in the cell 
10 
Surface Stain 
CD3 A700 CD3 negative population 0.25 
CD56 PE-Cy7 NK cell marker of activation 1 
CD16 APC Fc receptor marker on NK cells 1 
Intracellular Stain 
IFN- γ APC Cytokine marker 1 
MIP- 1β PE Chemokine marker produced to 
signal other NK cells 
1 
 
4.4.12 Gating Strategy for ADCC assay 
 
Compensation for each experiment was run and set to ensure that the peaks for each 
fluorescent label were within range. This was done to ensure reproducibility and accuracy of 
each experiment according to those set by the rainbow beads, of a previously optimized 
ADCC experiment.  To accurately gate for the NK cell population the voltages that are 
determined by the cell size and granularity were altered to place the population of interest 
within the grid. Unstained cells were used and the forward and side scatter voltages 
adjusted accordingly. The gating strategy was determined by both positive controls using 
HIVIG (Figure 13) and negative controls using PBS (supplementary Figure 3) in order to 
accurately identify NK cell mediated ADCC activity. The x-axis parameter was change to SSC-
H and the y-axis to SSC-A to gate for singlet populations. To gate for CD3 negative NK cells 
only and to exclude NKT cells, CD3 AF700 was selected for the x-axis ad the y-axis to SSC-A 
to identify the CD3 negative population. CD16 receptor expression define the NK cell 
population, therefore the y-axis was changed to CD16- APC-Cy7 and the x-axis to CD56 PE-
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Cy7. Upon activation CD16 MFI significantly decreases relating to ADCC activity (Stratov et 
al., 2008). Following this gating, the x-axis is changed to CD107 PE-Cy5 and the y-axis to 
CD16 APC-Cy7 to gate on the expression of the degranulation marker which indicates NK cell 
activity. Further gating to identify NK cell activity was done by changing the x-axis to IFN-γ 
AF647 and then to MIP-1β PE, while maintaining the y-axis on CD16-APC Cy7 (Figure 13). 
“The percentage of NK cell CD107a, IFN-γ and MIP-1β expressions were used to calculate 
the cytotoxic activities using FlowJo V10.0.1 (Treestar).” 
 
 
 
FIGURE 13: Gating strategy for the ICS NK cell activated ADCC assay. (A) Live cells were gated on 
using FSC-A and SSC-A. Following identification of live cells in this bio-assay, (B) singlets were gated 
on, (C) followed by CD3- cells, (D) CD56+CD16dim NK cells and the subsequent cytokine productions 
to identify NK cell activity (E) CD107a, (F) IFN-γ and (G) MIP-1β. 
  
F  
A
  
B  C  D
  
E  G
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CHAPTER 5 
 
Results 
 
5.1 Demographics of study participants in the CAPRISA 004 1 % Tenofovir gel trial  
 
This sub-study included 48 women who acquired HIV infection while participating in the 
CAPRISA 004 1% tenofovir gel trial (Abdool Karim et al., 2010). In order to account for CD4+ 
T helper cells and the viral loads that could confound analysis, the women from both arms 
were matched on CD4+ T cell counts and viral loads at 6 months post-infection. Therefore, 
there were no significant differences in either the CD4+ T cell counts or HIV viral loads 
between the arms. Twenty-four women from the tenofovir gel (cases) arm and 24 women 
from the placebo (controls) arm were included in this sub-study. Over half of the women 
came from rural KwaZulu-Natal area (58.3%, Table 5). Overall, the median age of women in 
this study was (23; IQR = 22 - 28 years) with no significant differences noted between the 
ages of the women in the tenofovir (24; IQR = 22 - 28 years) and placebo arms (22; IQR = 22 
- 23 years). Delay in time to infection was significantly longer among women who used the 
tenofovir gel (12.8 months; IQR = 6.6-16.6) compared to those who used the placebo gel 
(7.4 months; IQR = 3.3 - 10.6) (P = 0.02), with an average difference of 5.4 months between 
the arms. There were no significant differences for education level or hormonal 
contraceptive use between the women in both arms (Table 5). With regard to condom use, 
33 (68.8%) women reported using condoms at the last sex act and 45 (93.8%) women 
reported 0 - 1 sexual partners in the past 3 months, however there was no statistically 
significant differences observed between women who used condoms in the tenofovir or 
placebo arm. Overall, the women in this study were similar across each demographic 
category except for the time to HIV infection (Table 5). 
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Table 5: Demographics and clinical characteristics of the sub-set of women who acquire HIV infections 
during the CAPRISA 004 trials (n = 48) 
Characteristics All (n = 48) Tenofovir (n = 24) Placebo (n = 24) P - value 
Rural % (n) 58.3% (28) 58.3% (14) 58.3% (14) ns 
Median age in years (IQR) 23 (22 - 25) 24 (22 - 28) 22 (22 - 23) ns 
Median days PI at 
enrolment (IQR) 
38 (24 - 65) 35 (27 - 63) 45 (23 - 65) ns 
Median CD4 count 
(cells/µl) (IQR) 
498 (434 to 655) 468(444 - 569) 515 (433 - 685) ns 
Median viral load 
(copies/ml) (IQR) 
59,0505 (17,300 -  
135,500) 
80,600 (22,000 - 
130,000) 
54.800 (13,600 - 
148,000) 
ns 
Time to HIV infection from 
enrolment in months (IQR) 
9.2 (4.9 - 14.1) 12.8 (6.6 - 16.6) 7.4 (3.3 - 10.6) 0.02** 
Completed high school % 
(n) 
54.2% (26) 41.7% (10) 66.7% (16) ns 
Hormonal contraceptive 
useb 
97.9% (47) 100% (24) 95.8% (23) ns 
Marital Status % (n)     
Stable/married partner 79.2% (38) 87.5% (21) 70.8 (17) ns 
Single  18.7% (9) 12.5% (3) 25.0% (6) ns 
>2 partners 2.1% (1) 0.0% (0) 4.2% (1) ns 
Numbers of reported 
sexual partners in the last 
3 months % (n) 
    
0 to 1 93.8% (45) 95.8% (23) 91.7% (22)a ns 
2 to 5 6.2% (3) 4.2% (1) 8.3% (2) ns 
Reported condom used at 
last sex act % (n) 
68.8% (33) 75.0% (18) 62.5% (15) ns 
IQR = interquartile range, PI = post-infection. 
Significant values were defined as **(P ≤ 0.05) and those that trended as *(P < 0.1) 
a Two non-rapid progressing women had missing sexual partner data (in previous 3 months) as they refused to answer the 
question.  
b Hormonal contraception use included the injectable norethisterone and depot medoxyprogesterone acetate, and oral 
contraception. One woman in the placebo arm of the study was using an intrauterine device. 
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5.2 Antibody dependent cellular phagocytosis mediated by IgG’s isolated 
from the plasma and genital tracts of study participants  
 
5.2.1 Plasma IgG was more detectable and had higher concentrations than that of the 
genital tract 
 
Plasma IgG concentrations in the tenofovir and placebo arm were similar at 3 months 
(2.8mg/ml for both arms), 6 months (2.5mg/ml for both arms) and at 12 months (tenofovir 
arm = 2.9mg/ml; placebo = 2.9mg/ml). IgG concentrations were determined after purifying 
IgG from 50µl volume of the plasma samples from the HIV infected women were diluted 
with 450 µl of IgG purification buffer, representing a 10-fold dilution of the plasma IgG 
concentrations, which roughly translates to between 25-28mg/ml. In the CVL, the 
concentrations of IgG were similar between both arms and across time points. However, the 
CVL concentrations irrespective of arm and time points were much lower than the IgG 
quantified in the plasma (Table 6). Furthermore, there were significant differences between 
IgG levels in the plasma compared to those in the genital tract, across time points and 
irrespective of arm assignment (P < 0.0001). For these analyses, the concentrations were 
adjusted to similar units of measurement i.e. mg/ml for the concentration of IgG quantified 
in each compartment. Notably, in the tenofovir arm, the plasma IgG concentrations were 
96.6-fold higher at 3 months, 125.0-fold higher at 6 months and 193.3-fold higher at 12 
months, than that in the genital tract. A similar trend followed for the placebo arm with the 
plasma IgG concentrations being 140.0-fold higher at 3 months, 138.9-fold higher at 6 
months and 117.4-fold higher at 12 months, then those in the genital tract. Plasma and CVL 
IgG unit concentrations were represented differently, in order to best portray the data i.e. 
plasma IgG concentrations in mg/ml and CVL IgG concentrations in µg/ml. The IgG isolated 
from the plasma and genital tracts of women in the study, had similar concentrations 
regardless of study arm, at each time point (Table 6). 
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TABLE 6: Plasma and Genital tract IgG concentrations for women in the Tenofovir and Placebo arms 
Months 
Post-
infection 
Plasma median IgG (mg/ml) 
(IQR) 
CVL median IgG 
(IQR) (µg/ml) 
Plasma vs CVL 
IgG concentration 
P - value 
Fold differences between 
Plasma IgG and CVL IgG *** 
Tenofovir 
vs Placebo 
P-value 
Arm Tenofovir Placebo Tenofovir Placebo Tenofovir Placebo Tenofovir Placebo Plasma CVL 
3 
2.8 
(2.3 - 3.2) 
2.8 
(2.5 - 3.2) 
29.0 
(18.0 - 36.5) 
20.0  
(11.0 - 28.0) 
0.0001** < 0.0001** 96.6 140.0 0.807 0.104 
6 
2.5 
(2.3 - 2.6) 
2.5  
(2.2 - 2.8) 
20.0 
 (13.5 to 30.5) 
18.0  
(15.0 - 35.0) 
< 0.0001** < 0.0001** 125.0 138.9 0.715 0.857 
12 
2.9 
(2.3 - 3.0) 
2.7  
(2.5 - 3.5) 
15.0 
(6.0 - 28.0) 
23.0  
(18.0 - 27.0) 
< 0.0001** < 0.0001** 193.3 117.4 0.948 0.503 
**indicates significant values defined as P ≤ 0.05 
***fold difference was calculated by dividing the plasma median IgG concentrations (mg/ml) in each arm and time point by the corresponding median IgG concentration in the genital 
specimens (CVL) (µg/ml). The mg/ml concentrations in the plasma were converted to (µg/ml) in order to calculate differences between the plasma and genital tract 
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5.2.2 Tenofovir gel use did not diminish the detectability of the phagocytic function in the 
genital tracts of women who used the gel 
 
To determine whether antibody functions were different in women who had prior tenofovir 
gel use compared to the placebo gel users, the neutrophil phagocytic activity mediated 
through the antibodies isolated from the genital tract and the plasma, were performed. 
Phagocytic responses above detectability were defined as scores greater than the 
background as indicated by the negative control [negative control HIV-1 gp120 > 11.24; 
gp41 >11.22; p66 > 9.32; p24 >29.5]. In the plasma, based on the phagocytic scores above 
the background, most women in the tenofovir and placebo arms had detectable phagocytic 
function, which did not diminish over time (Table 7). Notably at 12 months, there was an 
increased detection for phagocytic function, in the plasma to all the HIV-1 proteins in both 
arms (Table 7). In particular, in the tenofovir arm, there was a 100% detection to both p66 
and gp41 from 3 months and 6 months, up until 12 months, where the phagocytic response 
declined to 82.4% and 88.2% for p66 and gp41 respectively.  
Phagocytic activities in both compartments and arms were highly detectable at 3 months, 
after which responses seemed to increase or decrease sporadically in both arms, over the 6 
months and 12-month period for which these analyses were done (Table 7 and Table 8). 
To assess the impact of IgG titres on ADCP activities, titrations of IgG isolated from the 
plasma of women in both arms were performed. No differences in ADCP specific activities 
were found between 1mg/ml and 0.5mg/ml (P > 0.1) (supplementary Figure 1A). Therefore, 
the sample concentrations were diluted to a concentration of 0.5mg/ml to be used in the 
ADCP assays.  
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TABLE 7: Detection of HIV-specific phagocytic activity in the tenofovir and placebo arms in the plasma 
HIV Proteins 
Tenofovir Arm Placebo Arm 
3 months 6 months 12 months 3 months 6 months 12 months 
n/N 
= 15 (%) 
n/N 
= 23 (%) 
n/N 
= 17 (%) 
n/N 
= 16 (%) 
n/N 
= 25 (%) 
n/N 
= 22 (%) 
gp120 12 (80) 18 (78.3) 14 (82.4) 13 (81.3) 23 (92.0) 22 (100.0) 
gp41 15 (100.0) 23 (100.0) 15 (88.2) 15 (93.8) 24 (96.0) 22 (100.0) 
p66 15 (100.0) 23 (100.0) 14 (82.4) 16 (100.0) 25 (100.0) 22 (100.0) 
p24 11 (73.3) 18 (78.3) 16 (94.1) 14 (87.5) 22 (88.0) 21 (95.5) 
 TABLE 8: Detection of HIV-specific phagocytic activities in the genital tracts (CVL) of women in both the 
tenofovir and placebo arms 
HIV Proteins 
Tenofovir Arm Placebo Arm 
3 months 6 months 12 months 3 months 6 months 12 months 
n/N 
= 15 (%) 
n/N 
= 23 (%) 
n/N 
= 17 (%) 
n/N 
= 16 (%) 
n/N 
= 25 (%) 
n/N 
= 22(%) 
gp120 12 (80) 16 (69.6) 14 (82.4) 15 (93.8) 23 (92.0) 19(86.4) 
gp41 14 (93.3) 20 (86.9) 15 (88.2) 14 (87.5) 19 (76.0) 16(72.7) 
p66 14 (93.3) 20 (86.9) 14 (82.4) 15 (93.8) 24 (96.0) 21(95.5) 
p24 15 (100) 22 (95.7) 16 (94.1) 15 (93.8) 22 (88.0) 22(100.0) 
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5.2.3 Phagocytic activities to HIV-1 gp120 and p66, increased from 3-12 months post-
infection in the plasma 
 
To determine if there were differences between arms for the phagocytic functions mediated 
by the HIV-specific antibodies, the phagocytic activities between arms were compared at 
the three different time points. There were no significant differences between the tenofovir 
and placebo phagocytic responses to gp120 in the plasma, at 3 months (P = 0.295), 6 
months (P = 0.760) or 12 months (P = 0.664). Phagocytic responses to gp41 remained similar 
at 3 months (P = 0.446), 6 months (P = 0.759) and 12 months (P = 0.644) when the placebo 
and the tenofovir arms were compared (Figure 14B). However, phagocytic activities to gp70 
was higher in the tenofovir compared to the placebo arm at 6 months (tenofovir 35.70; IQR 
= 23.31 - 87.37, placebo 23.68; IQR = 14.74 - 48.52) (P = 0.067). Plasma phagocytic activities 
to p66 between arms at 3 months (P = 0.338), 6 months (P = 0.210) and 12 months (P = 
0.664) was not statistically significant. Furthermore, there were no statistically significant 
differences between arms for p24 at 3 months (P = 0.512), 6 months (P = 0.609) and at 12 
months (P = 0.457) (Figure 14E, supplementary Table 1). 
 
5.2.4 Increasing phagocytic activity to HIV-Env and p66 over time, in both arms 
 
Longitudinal analyses of HIV- gp120 phagocytic activities in the tenofovir arm in the plasma, 
were significantly lower at 3 months (27.12; IQR = 18.49 - 39.85), compared to 12 months 
(41.99; IQR = 25.17 - 66.51) (P = 0.007) (Figure 15A). This significantly increasing response 
was observed from 6 months (27.12; IQR = 18.14 - 39.65), to 12 months (P = 0.029). 
However, when only the detectable responses for the gp120 specific phagoscores were 
included for the tenofovir arm, (that is all phagoscores below the negative control were 
removed from analyses), a difference from 3 months to 6 months was observed (P = 0.067) 
and an increase from 3 months to 12 months was observed (P = 0.001) (supplementary 
Figure 5A). Phagocytic activities to gp120 in the placebo arm significantly increased from 3 
months (26.52; IQR = 10.08 - 29.56) to 12 months (37.52; IQR = 28.00 - 49.11) (P = 0.007, 
Figure 15A). Additionally, the increase in phagocytic activities were maintained from 6 
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months (27.12; IQR = 18.14 - 39.65) to 12 months (37.52; IQR = 28 - 49.11), in the placebo 
arm to gp120, although this increase trended to significance (P = 0.082, Figure 15A) and this 
difference was more obvious when only detectable gp120 responses were analysed 
(supplementary Figure 5A). Responses to gp41 revealed no significant increase from 3 
months to 6 months in the tenofovir (P = 0.535) or placebo arms (P = 0.721) (Figure 15B). 
However, in the tenofovir arm a significant increase was observed from 6 months (51.52; 
IQR= 37.26 - 71.69) to 12 months (64.1; IQR = 41.91 - 71.59) (P = 0.051, Figure 15B) 
(supplementary Figure 5B). No further significant differences were observed to gp41 in the 
placebo arm from 6 months to 12 months (P = 0.519) or from 3 months to 12 months in the 
tenofovir (P = 0.114) or placebo arms (P = 0.988) (Figure 15B). Interestingly, gp70 specific 
ADCP activity in the tenofovir arm only, increased from 3 months (30.56; IQR = 19.1 – 45.58) 
to 6 months (35.7; IQR = 23.31 – 87.37) (P = 0.079) (Figure 15C), but this difference was lost 
when looking at detectable gp70 ADCP only (supplementary Figure 5C). In the tenofovir 
arm, phagocytic activity to p66 increased (Figure 15D), that trended to significance, from 3 
months (43.25; IQR = 27.40 - 62.37) to 6 months (62.76; IQR = 50.15 - 84.58), (P = 0.091). 
This profile also significantly increased in the same arm from 3 months (42.35; IQR = 27.4 - 
62.37) to 12 months (79.01; IQR = 60.21 - 107.5) (P = 0.002) (Figure 15D). Analysis in the 
placebo arm to HIV-p66, in the plasma, exhibited significant differences from 6 months 
(42.41; IQR = 24.87 - 80.24) to 12 months (80.89; IQR = 56.81 - 101.90) post-infection (P = 
0.008). Further differences for HIV-specific p66 responses were observed at 3 months 
(47.16; IQR = 32.4 - 77.85) to 12 months (80.89; IQR = 56.81 - 101.9) (P = 0.022) post-
infection (Figure 15D) (supplementary Figure 5D). This HIV-p66 specific pattern was also 
seen in the tenofovir arm with increasing activity from 3 months to 6 months (P = 0.091), 
and from 3 months to 12 months (P = 0.002, Figure 15D). P24-specific phagocytic activities 
in the plasma of women in both the tenofovir and placebo arms showed no significant 
trends, when longitudinal analyses were performed (Figure 15E).  Phagocytic activities were 
similar at 3 to 6 months in the tenofovir (P > 0.999) and placebo arms (P = 0.670), as well as 
from 6 months to 12 months in the tenofovir (P = 0.274) and placebo arms (P = 0.622) and 
from 3 months to 12 months in the tenofovir (P = 0.365) and placebo arms (P = 0.188) 
(Figure 15E). In contrast, in the detectable only analyses, a significant increase in p24 
phagocytic activities in the placebo arm were observed, from 3 months to 12 months (P = 
0.048) (supplementary Figure 5E).  
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FIGURE 14: Comparisons of plasma IgG HIV-specific phagocytic activities between the tenofovir 
and placebo arms at 3 months, 6 months and 12 months. Phagocytic activities (Log10 phagoscores) 
to HIV A) gp120, B) gp41, C) gp70, D) p66 and E) p24. Solid lines in either the tenofovir or the 
placebo arm indicate the minimum and maximum values of box and whisker plots, with black solid 
lines across the dots indicating the median of each time point and arm, accordingly. Horizontal lines 
across bars, indicate statistical differences between arms at respective time points and values that 
trended to significance as *(P < 0.1). Statistical differences were determined by Wilcoxon Sum Rank 
tests. 
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FIGURE 15: Longitudinal analyses of plasma IgG HIV-specific phagocytic activities in both the 
tenofovir and the placebo arms across 3 months, 6 months and 12 months. Phagocytic activities 
(Log10 phagoscores) to HIV A) gp120, B) gp41, C) gp70, D) p66 and E) p24. Solid lines indicate the 
minimum and maximum values of box and whisker plots, with black solid lines across the dots 
indicating the median of each time point and study arm, accordingly. Horizontal lines across dot 
plots indicate statistical differences between the tenofovir and placebo arm, at respective time 
points. *(P < 0.1) indicate values that trended to significance. Those that were statistical differences 
were defined as ** (P ≤ 0.05) and were determined by Wilcoxon Signed Rank test. 
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5.2.5 CVL phagocytic activity to p66 and p24 significantly increased only at 12 months in 
the tenofovir arm compared to the placebo arm 
 
Phagocytic responses to gp120 were not significantly different at 3 months (P = 0.572), 6 
months (P = 0.235) or 12 months (P = 0.721) between placebo and tenofovir arms. However, 
phagocytic activity to gp41 was significantly increased in the tenofovir arm (37.92; IQR =19.4 
- 65.60) compared to the placebo arm (19.4; IQR = 9.43 - 28.93) at 6 months (P = 0.014) 
(Figure 16B). Following this analysis, no significant differences were observed at any other 
time point between the two study arms for gp41 at 3 months (P = 0.579) and 12 months (P = 
0.642) (Figure 16B). Cross-sectional analysis of phagocytic responses to p66 revealed that 
responses were significantly elevated in the tenofovir arm (63.58; IQR = 33.48 - 83.09) 
compared to the placebo arm (24.03; IQR = 17.44 - 54.16) (P = 0.063) (Figure 16C) at 12 
months post-infection. No significant differences were observed at 3 months (P = 0.892) and 
6 months (P = 0.570). Similarly, phagocytic activity to p24 was significantly increased only in 
the tenofovir arm at 12 months (26.15; IQR = 16.61 - 30.62) compared to the placebo arm 
(13.42; IQR = 4.16 - 18.11) (P = 0.01) (Figure 16D). No other significant differences were 
observed between arms at 3 months (P = 0.358) and 6 months (P = 0.461) for p24 
(supplementary Table 2). Similar responses were observed in the detectable cross-sectional 
analyses for the HIV-specific phagocytic activities in the genital tract (supplementary Figure 
6A-D). 
 
5.2.6 HIV-p66 specific phagocytic activity in the genital tract evolved significantly, in those 
women who used tenofovir, prior to HIV infection 
 
To identify trends in each arm over time, longitudinal analyses were performed. Analysis of 
phagocytic responses revealed varying differences and increasing (in some cases) responses 
to different HIV proteins over time. Interestingly, the only observable difference in 
phagocytic activities occurred in the tenofovir arm to p66, with responses increasing from 6 
months (32.33; IQR = 14.68 - 67.99) to 12 months (63.58; IQR = 33.48 - 83.09) (P = 0.039) 
(Figure 17C). In contrast, the p66 specific responses in the placebo arm remained similar 
from 3 months to 12 months (P > 0.1). Phagocytic activity in the genital tract to gp120 
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(Figure 17A), gp41 (Figure 17B) and p24 (Figure 17D) were similar across all time points, 
irrespective of study arm (P > 0.1). Similar responses were observed in the detectable 
analyses (supplementary Figure 7A-D). 
 
FIGURE 16: Cross-sectional comparisons of ADCP responses in the genital tracts (CVL) of women in 
the tenofovir and placebo arms, for all HIV proteins, at 3, 6 and 12 months. Phagocytic activities 
(Log10 phagoscores) to A) gp120, B) gp41, C) p66 and D) p24 illustrated by box and whisker plots. 
Horizontal solid lines within each arm at respective time points indicate the maximum and minimum 
percentiles, as well as the median phagoscores. Data collected did not display a Gaussian 
distribution therefore the Wilcoxon Sum Rank test tests were used. Differences that trended to 
significance were defined as *(P < 0.1) and those that were significant, as ** (P ≤ 0.05). 
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FIGURE 17: Longitudinal analyses of HIV-specific phagocytic activities in the genital tracts (CVL) of 
women in the tenofovir and placebo arms across 3 months, 6 months and 12 months. Phagocytic 
activities (Log10 phagoscores) to HIV A) gp120, B) gp41, C) p66 and D) p24. Solid lines indicate the 
minimum and maximum values of box and whisker plots, with black solid lines across the dots 
indicating the median of each time point and study arm, accordingly. Horizontal lines across dot 
plots indicate statistical differences between the tenofovir and placebo arm, at respective time 
points. *(P < 0.1) Indicate values that trended to significance. Those that were statistically different 
were defined as ** (P ≤ 0.05) and were determined by Wilcoxon Signed rank test. 
 
5.2.7 Tenofovir gel enhanced functional phagocytic activities in the genital tract, which 
were mediated by non-neutralizing antibodies 
 
In order to compare ADCP activities between the systemic and genital tract, the CVL and 
plasma ADCP responses to HIV-1 proteins (gp120, gp41, p66 and p24) in both arms were 
analysed at 3 months, 6 months and at 12 months. In the tenofovir arm phagocytic activities 
to gp120 were greater at 3 months in the plasma (27.12; IQR = 18.49 - 39.85) compared to 
the CVL (9.95; IQR = 3.83 - 14.72) (P = 0.0002, Figure 18A). These significantly increased 
responses were consistently observed at 6 months [plasma 27.12 (IQR = 21-32 - 49.47); CVL 
11.82 (IQR = 6.10 - 21.10)] (P < 0.001) and at 12 months [plasma 41.99 (IQR = 25.17 - 65.51); 
CVL 9.51 (IQR = 4.12 - 19.44)] (P < 0.0001, Figure 18A).  In the placebo arm, gp120 responses 
were higher at 3 months in the plasma (10.08; IQR = 3.23 - 29.56), compared to the CVL 
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(9.54; IQR = 7.30 - 20.35) (P = 0.073, Figure 18B) but this difference only trended to 
significance. However, when only detectable phagoscores were compared in the placebo 
arm, similar responses at 3 months between the plasma and genital tract were found (P > 
0.1, supplementary 8B). Furthermore, in the same arm, the observed disparity in 
compartment responses increased significantly, and became greater at 6 months in the 
plasma, (27.12; IQR = 18.14 - 39.65) compared to the CVL (9.73; IQR = 3.43 - 14.23) (P < 
0.0001), as well as at 12 months (plasma 37.52; IQR = 28.00 - 49.11; CVL 11.21; IQR = 6.71 - 
18.45) (P = 0.002) (Figure 18B).   
HIV-gp41 specific phagocytic activity in the tenofovir arm, in the plasma, showed close 
concordance with those responses observed in the genital tract at 3 months and 6 months 
(P > 0.1). However, at 12 months plasma phagocytic activity (64.1; IQR = 41.91 - 71.59) was 
significantly greater than the CVL (19.4; IQR = 7.69 - 53.40) (P = 0.017) (Figure 18C). Placebo 
arm responses to gp41 at 3 months in the plasma (47.26; IQR = 44.08 - 71.82) were greater 
compared to those observed in the genital tract (23.04; IQR = 5.94 - 41.09) (P = 0.001) 
(Figure 18D). Furthermore, in the placebo arm, gp41 responses in the plasma at 6 months 
(49.00; IQR = 39.12 - 62.56) were greater than those in the genital tract (19.4; IQR = 9.43 - 
28.93) (P = 0.0002). This pattern was observed at 12 months in the same arm, with greater 
responses observed in the plasma (54.74; IQR = 38.35 to 71.13) compared to the genital 
tract (19.40; IQR = 16.39 - 23.75) (P < 0.0001) (Figure 18D), and these differences were still 
preserved when only the detectable responses were included (supplementary Figure 8D).  
Interestingly ADCP activity to p66 was similar between compartments at 3 months in the 
tenofovir arm (P = 0.525). However, at 6 months phagocytic activity was higher in the 
plasma (62.76; IQR = 50.15 - 84.58) compared to the genital tract (32.33; IQR = 14.68 - 
67.99) (P = 0.020), a difference that was not seen at 12 months (P = 0.284) (Figure 18E). In 
the placebo arm, phagocytic activity to p66 at 3 months (P = 0.433) was similar between 
compartments, but a trend was observed at 6 months in placebo arm, with phagocytic 
activity being greater in the plasma (42.42; IQR = 24.87 - 80.24) compared to the CVL (22.98; 
IQR = 13.37 - 62.46) (P = 0.095). The increasing difference between systemic and genital 
tract phagocytic activity, became more pronounced at 12 months with the plasma exhibiting 
greater responses (80.89; IQR = 56.81 - 101.9) than in the CVL (24.03; IQR = 17.44 - 54.16) (P 
= 0.019) (Figure 18F).  HIV-p24 specific responses in the tenofovir arm were similar between 
the plasma and CVL at the 3 months (P = 0.978). However, at 6 months plasma were higher, 
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(plasma 41.51; IQR = 8.02 - 71.99, CVL 25.4; IQR = 14.2 - 36.81), and by 12 months was 
significantly different (plasma 53.48; IQR = 16.24 - 76.11, CVL 13.41; IQR = 4.16 - 18.11) (P = 
0.009) (Figure 18G). P24 specific responses in the placebo arm at 3 months were 
significantly different, with greater phagocytic activity observed in the plasma (59.78; IQR = 
10.59 - 93.42) compared to the CVL (18.71; IQR = 10.32 - 33.13) (P = 0.008) (Figure 18H). 
Similar differences were observed at 6 months with greater plasma median phagocytic 
activity (52.79; IQR = 18.71 - 79.68) compared to the CVL (19.81; IQR = 9.99 - 35.65) (P = 
0.004). At 12 months post-infection in the placebo arm, this difference was more evident, 
with greater p24 specific phagocytic activity in plasma, (53.48; IQR = 16.24 - 76.11) 
compared to the CVL (13.41; IQR = 4.16 - 18.11) (P =0.0003) (Figure 18H). 
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FIGURE 18: Compartmental comparisons between plasma and genital tracts (CVL) of all women (n 
= 48), across 3 months, 6 months and 12 months, for all HIV-proteins, in the tenofovir and placebo 
arms. Inter-compartmental analysis, for phagocytic activities (Log10 phagoscores) in the tenofovir 
arm on the left and the placebo arm on the right to gp120 (A and B), gp41 (C and D), p66 (E and F) 
and p24 (G and H). Wilcoxon Sum rank tests were done to determine statistical differences between 
phagocytic activities within each arm of the study and between compartments, for each protein. 
Statistically significant values were defined as **P ≤ 0.05, values that trended as *P < 0.1 and P = NS 
for differences that were not significant. Cervicovaginal lavages (CVL) were collected from the 
genital tract.  
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5.2.8 Genital tract and plasma phagocytic activity to p66 is inversely correlated  
 
In order to establish whether the the phagocyic activity in the plasma correlated with the 
phagocytic activity in the genital tract  cross-compartmental Spearman R correlation 
analyses for both the tenofovir and placebo arms were performed for all women. Gp120 
specific ADCP at 6 months in the tenofovir arm exhibited a weak, positive correlation 
between the systemic and genital tract phagocytic activity (R = 0.352; P = 0.099) (Table 9). 
At 12 months in the placebo arm, gp120 responses showed a weak negative correlation 
between the systemic and genital tract (R = -0.368; P = 0.092). Additionally, regarding HIV 
envelope responses, systemic and genital tract phagocytic activity to gp41 exhibited a 
positive correlation in both the tenofovir and placebo arms, however this association was 
not significant (tenofovir: R = 0.454; P = 0.092; placebo:  R = 0.432; P = 0.096). Interestingly, 
at 12 months post-infection in the placebo arm, phagocytic activity to p66, showed a 
significantly inverse correlation between the systemic and genital tract compartments (R = -
0.481; P = 0.024). HIV-p24 phagocytic responses did not exhibit any significant cross-
compartmental associations for either arm, at any of the time points (Table 9). 
Furthermore, when only detectable phagoscores were correlated between compartments, 
gp120 activity negative correlated only at 12 months in the placebo arm (R = - 0.603; P = 
0.012). Additional negative correlations were found only in the placebo arm to gp41 (R = 
0.511; P = 0.054) and p66 (R = -0.442; P = 0.051) (supplementary Table 3). 
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5.2.9 Plasma phagocytic responses to HIV-gp70 was positively correlated with CD4+ T cell 
counts  
 
CD4+ T cells can influence B cell activity, as well as antibody titres. Therefore, in order to 
determine if CD4+ T-cell count at 6 months post-infection impacted on the HIV-antibody 
specific phagocytic activities, correlation analyses were performed (Table 10). In the 
tenofovir arm, there were no observable correlations between the systemic CD4+ T cell 
counts and any of the HIV-antibody specific phagocytic activities. However, in the placebo 
arm a positive correlation between the CD4+ T cell count and gp70 antibody specific 
phagocytic activity was found (R = 0.465; P = 0.025). In the genital tract, overall, there were 
no significant associations observed between the systemic levels of CD4+ T cells, and the 
HIV-antibody specific phagocytic activities (Table 10).  
 
 
 
 
 
 
 
TABLE 9: Compartmental correlations of phagocytic activities between the plasma and the genital tracts 
(CVL) of women, in the Tenofovir and Placebo arms, for all HIV-proteins 
Protein Arm 3 months 6 months 12 months 
  R-value P-value R-value P-value R-value P-value 
gp120 Tenofovir -0.034 0.905 0.352 0.099* 0.012 0.966 
 
Placebo -0.268 0.313 0.047 0.8223 -0.368 0.092* 
gp41 Tenofovir 0.454 0.092* -0.195 0.372 -0.004 0.991 
 Placebo 0.432 0.096* -0.062 0.769 0.259 0.245 
p66 Tenofovir 0.046 0.873 0.260 0.231 -0.297 0.246 
 
Placebo -0.147 0.586 -0.257 0.215 -0.481 0.024** 
p24 Tenofovir 0.088 0.753 -0.340 0.113 -0.172 0.509 
 
Placebo -0.167 0.536 0.030 0.887 -0.053 0.817 
*indicates values that trended to significance, defined as P < 0.1 
**indicates significant values defined as P ≤ 0.05 
71 
 
 
 
 
 
 
 5.2.10 HIV-gp120 specific phagocytic activities negatively correlated with viral loads, in 
the genital tracts of women in the placebo arm  
 
Viral load in infected individuals is a marker of disease progression. Therefore, in order to 
elucidate the impact of phagocytic activities in the plasma and genital tracts on viral load, 
Spearman R correlation analyses were performed (Table 11). In the placebo arm only, HIV-
gp120 specific activity, in the genital tract negatively correlated with plasma viral load (R = -
0.418; P = 0.047). There were no further significant correlations observed between viral 
loads and any HIV-specific phagocytic activities, in either arm of the plasma or genital tract 
(P > 0.1).  
 
 
 
 
 
 
TABLE 10: Correlations between CD4+ T cells and phagocytic activities for HIV-specific antibodies at 6 months, in 
the plasma and genital tract (CVL) 
HIV 
antigens 
CD4+ T cells vs Plasma 
phagocytic scores 
(Tenofovir) n = 24 
CD4+ T cells 
vs Plasma phagocytic 
scores (Placebo) n = 24 
CD4+ T cells vs CVL 
phagocytic scores 
(Tenofovir) n = 24 
CD4+ T cells vs CVL 
phagocytic scores 
(Placebo) n = 24 
 R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 0.080 0.724 -0.236 0.278 -0.026 0.908 0.147 0.503 
gp41 0.105 0.644 0.229 0.294 0.003 0.988 -0.072 0.746 
gp70 0.248 0.266 0.465 0.025** - - - - 
p66 0.266 0.233 -0.020 0.929 -0.005 0.982 0.110 0.617 
p24 -0.174 0.440 -0.041 0.854 0.116 0.608 0.310 0.149 
**indicates significant values defined as P ≤ 0.05 
-no data for gp70 HIV-IgG specific activity due to limited sample availability 
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5.2.11 Gp41 IgG titres in the tenofovir arm and p66 IgG titres in the placebo arm, exhibited 
inverse correlations to IgG mediated phagocytic activities at 6 months post-infection, in 
the plasma  
 
In order to identify an association between antibody titres measured in a previously 
published study (Archary et al., 2016)and antibody activities obtained in this sub-study, the 
analyses were done using the Spearman R correlations. Interestingly, a strong correlation 
was detected to HIV-gp41 in the tenofovir arm, which indicated that as systemic IgG 
mediated phagocytic activity increased, antibody gp41-specific titres decreased (R = -0.499; 
P = 0.015). Furthermore, a moderate correlation was observed for p66 in the placebo arm 
and although this trended (R = -0.404; P = 0.062), it suggests that as systemic IgG mediated 
phagocytic activity increased, antibody p66-specific titres decreased. No further correlations 
were observed to any of the other HIV-proteins in either the plasma or the genital tract, in 
either study arm (P > 0.01) (Table 12).  
 
 
 
 
 
TABLE 11: Correlations between viral loads and phagocytic activity for HIV-specific antibodies at 6 months 
post-infection, in the plasma and genital tract (CVL) 
HIV 
antigens 
Viral load vs Plasma 
phagocytic scores 
(Tenofovir) n = 23 
Viral load vs Plasma 
phagocytic scores 
(Placebo) n = 24 
Viral load vs CVL 
phagocytic scores 
(Tenofovir) n = 23 
Viral load vs CVL 
phagocytic scores 
(Placebo) n = 24 
 R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 -0.298 0.168 0.126 0.567 -0.169 0.440 -0.418 0.047** 
gp41 -0.213 0.329 -0.254 0.242 0.278 0.199 0.202 0.356 
gp70 -0.243 0.264 -0.13 0.555 - - - - 
p66 -0.305 0.157 -0.227 0.298 -0.063 0.774 -0.097 0.659 
p24 0.317 0.140 -0.089 0.684 -0.267 0.218 -0.101 0.647 
**indicates values that were significant, defined as P ≤ 0.05 
-no data for gp70 HIV-specific activities due to limited sample availability 
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5.3 Functional NK cell activated Antibody Dependent Cellular Cytotoxicity using an 
Intracellular Cytokine Staining based assay to investigate plasma nNAb IgG functionality  
 
To assess the impact of IgG titres on NK cell activated ADCC activities, titrations of IgG isolated 
from the plasma of women in both arms were performed. No differences in NK cell activated 
ADCC specific activity were found between 1 - 0.5mg/ml, 0.5 – 0.25mg/ml and 1- 0.25mg/ml 
(P > 0.1) (supplementary Figure 1B).  
 
5.3.1 Cross-sectional and longitudinal analysis of plasma nNAb activities, identified an 
increase in IgG mediated NK cell activated ADCC at 6 and 12 months to HIV-gp41, p66 
and from 3-12 months to HIV-gp120 
 
To determine functional nNAb differences between women who used either tenofovir or 
the placebo gel, cross-sectional analyses of NK cell activated ADCC activity to the four HIV-
proteins at various time points were done. Cytotoxic activities were identified as CD107a 
expression and IFN-γ and MIP-1β production as NK cell ADCC antiviral activity. Gp120 
specific cytotoxic activity at 3 months in the tenofovir arm (449.5; IQR = 76.5 - 640.5) was 
TABLE 12: Correlations between HIV-specific IgG titres and phagocytic activities for HIV-specific antibodies at 
6 months post-infection, in the plasma and the genital tract (CVL) 
HIV 
antigens 
IgG titres (Log10) 
vs plasma ADCP 
(Tenofovir) n = 23 
IgG titres (Log10) 
vs plasma ADCP 
(Placebo) n = 23 
IgG titres (Log10) 
vs CVL ADCP 
(Tenofovir) n = 23 
IgG titres (Log10) 
vs CVL ADCP 
(Placebo) n = 24 
 R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 -0.026 0.907 0.097 0.659 0.105 0.635 0.070 0.750 
gp41 -0.499 0.015** 0.016 0.942 -0.083 0.705 0.484 0.181 
Gp70 -0.033 0.883 -0.114 0.606 - - - - 
p66 0.262 0.227 -0.404 0.062* 0.050 0.824 -0.181 0.407 
p24 0.234 0.283 0.320 0.147 -0.226 0.325 -0.239 0.272 
*indicates values that trended to significance defined as P < 0.1 
**indicates values that were significant defined as P ≤ 0.05 
-no data for gp70 HIV-IgG titres due to limited sample availability 
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significantly lower than the placebo arm (644.8; IQR = 272.5 - 918.3) (Figure 19A). NK cell 
activated ADCC gp120 specific activity at 6 and 12 months and antiviral cytokine production 
at 3, 6 and 12 months were similar between the tenofovir and placebo arms (P > 0.1) (Figure 
19C). Cytotoxic activity to p66 was similar at 3, 6 and 12 months (P > 0.1). However, at 6 
months only, post-infection IFN-γ was greater in the placebo arm (548.3; IQR = 365.8 - 
764.3) compared to the tenofovir arm (246; IQR = 112.5 - 478.5) (P = 0.086) (Figure 19H). 
P66 specific MIP-1β chemokine responses were greater in the placebo arm, compared to 
the tenofovir arm at 3 months (tenofovir 317.5; IQR = 149 – 500, placebo 535; IQR = 323.4 - 
740.8) (P = 0.049) (Figure 19G). This p66 specific response was maintained at 6 months 
(tenofovir 246; IQR = 112.5-478.5, placebo 548.3; 365.8-764.3) (P = 0.003) and at 12 months 
(tenofovir 391; IQR = 95.25 - 549.5, placebo 473.3; IQR = 391.8 - 776.3) (P = 0.049) (Figure 
19I). Gp41 and p24 specific ADCC and antiviral cytokine production were similar between 
both study arms across the time points assessed (P > 0.1) (supplementary Table 4) (Figure 
19D-F and 19J-l, supplementary Table 4).  
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FIGURE 19: Cross-sectional comparisons of plasma IgG activities mediated by NK cells isolated from fresh whole blood, between the 
tenofovir and placebo arms, across 3 months, 6 months and 12 months. ADCC activities (Log10 ADCC) measured by CD107a, IFN-γ and MIP-
1β production in both the tenofovir and placebo arm to HIV gp120- (A-C), gp41 (D-F), p66 (G-I) and p24 (J-L). Graphs read from top to bottom, 
to observe differences in ADCC responses over time, from 3-12 months post-infection. Solid lines in either the tenofovir or the placebo arm 
above the column indicate the maximum geometric mean of each cytokine detected in the ICS assay. Horizontal lines across bars, indicate 
statistical differences between arms at respective time points and statistical differences were defined as **(P ≤ 0.05) and values trending to 
significance were defined as *(P < 0.1) (Wilcoxon Sum Rank test)
76 
 
5.3.2 Longitudinal plasma IFN-γ and MIP-1β production increased over time to HIV gp120, 
p66 and p24 mainly in the Tenofovir arm 
 
Furthermore, in order to elucidate the potential evolution of cytotoxic and antiviral cytokine 
production over time in either study arm, longitudinal analyses were performed. There was 
no significant difference in NK cell activated ADCC activity in both study arms to gp120 
across all time points (P > 0.1) (Figure 20A). IFN-γ responses to gp120 in the placebo arm 
only, increased from 6 months (441.5; IQR = 393.5 - 1158) to 12 months (553.8; IQR = 430.9 
- 1158) (P = 0.084) (Figure 20B). Furthermore, MIP-1β production only increased in the 
tenofovir arm from 3 months (494; IQR = 380.5 - 1158) to 6 months (644; IQR = 245 - 895) (P 
= 0.020) (Figure 20C). Additional differences were observed in the tenofovir arm from 3 
months to 12 months (733.5; IQR = 144 - 1256) (P = 0.007) (Figure 20C), exhibiting a 
significant increase in MIP-1β production. Similarly, MIP-1β production increased in the 
placebo arm, only from 3 months (719.3; IQR = 89.25 - 849.4) compared to 12 months 
(777.8; IQR = 186.6 - 907.4) (P = 0.030) (Figure 20C). 
Furthermore, only MIP-1β antiviral production to p66 in the tenofovir arm, demonstrated a 
significant increase from 6 months (246; IQR = 122.5 - 478.5) to 12 months (391; IQR = 95.25 
- 549.5) (P = 0.044) (Figure 20I). No further differences were observed for p66 and p24 
CD107a expression and IFN-γ production. However, only p24 specific MIP-1β production in 
the tenofovir arm, exhibited a significant increase from 3 months (129; IQR = 111 - 580.5) to 
6 months (415.5; IQR = 206 - 855) (P = 0.002) (Figure 20L). NK cell activated ADCC activity 
and antiviral cytokines to gp41 in the plasma were similar in both study arms across all time 
points (P > 0.1, supplementary Table 4). 
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FIGURE 20: Longitudinal analysis of plasma IgG mediated NK cell activated-ADCC activities, in the tenofovir and the placebo arms, across 3 
months, 6 months and 12 months. ADCC activities (Log10 ADCC) measured by CD107a, IFN-γ and MIP-1β production in both the tenofovir and placebo 
arm to HIV gp120 (A-C), gp41 (D-F), p66 (G-I) and p24 (J-L). Solid lines in either the tenofovir or the placebo arm within the dot plots indicate the maximum 
geometric mean of each cytokine detected in the ICS assay. Horizontal lines across bars indicate statistical values between arms at over time. Wilcoxon-
Signed Rank test was used to analyse the data and statistical differences were defined as ** (P ≤ 0.05). 
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5.3.3 HIV-gp41, p66 and p24 NK cell activated ADCC and antiviral activities varied between 
study arms in the genital tract  
 
To elucidate the impact of tenofovir on genital tract nNAb NK cell activated ADCC activity, 
cross- sectional analyses were done. Gp41 specific MIP-1β responses were higher in the 
tenofovir arm compared to the placebo arm, at 3 months (tenofovir 2905; IQR = 2555 - 
2990, placebo 1539; IQR = 1056 - 2905) (P = 0.065) (Figure 21D) and at 12 months (tenofovir 
2905; IQR = 2055 - 2905; placebo 2155; IQR = 389 - 2905) (P = 0.081) (Figure 21F).  P66 
specific cytotoxic activity at 12 months, was higher in the tenofovir arm (903.3; IQR = 774.6 - 
1061) compared to the placebo arm (691.5; IQR = 575.5 - 801.5) (P = 0.034) (Figure 21G). In 
contrast, IFN-γ production in the tenofovir arm was lower (954.8; IQR = 687.9 - 11.35) 
compared to that of the placebo arm (1198; IQR = 948.8 - 1525) (P = 0.082) (Figure 21I) at 
12 months. Furthermore, chemokine p66 specific MIP-1β responses at 3 months in the 
tenofovir arm was greater than that of the placebo arm (tenofovir 9654; IQR = 8361 - 11372, 
placebo 8568; IQR = 8108 - 9041) (P = 0.034) (Figure 21G). P24 specific IFN-γ antiviral 
responses were only discernibly greater in the tenofovir arm (538; IQR = 502 - 857.5) 
compared to the placebo arm (478.5; IQR = 448.3 - 559) (P = 0.026) (Figure 21K) at 6 
months. Cytotoxic activity mediated by CVL antibodies to gp120 at 3, 6 and 12 months were 
similar between tenofovir and placebo arms for CD107a, IFN-γ and MIP-1β (P > 0.1) (Figure 
21A-C, supplementary Table 5). 
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FIGURE 21: Cross- sectional comparisons of CVL IgG ADCC activities mediated by NK cells isolated from fresh whole blood, between the tenofovir and the 
placebo arms across 3 months, 6 months and 12 months. ADCC activities (Log10 ADCC) measured by CD107a, IFN-γ and MIP-1β production in both the 
tenofovir and placebo arm to HIV gp120 (A-C), gp41 (D-F), p66 (G-I) and p24 (J-L). Graphs read from top to bottom in order to observe differences in ADCC 
responses over time, from 3-12 months post-infection. Solid lines in either the tenofovir or the placebo arm above the column indicate the maximum 
geometric mean of each cytokine detected in the ICS assay. Horizontal lines across bars, indicate statistical differences determined by Wilcoxon Sum rank 
tests, between arms at respective time points and statistical differences were defined as **(P ≤ 0.05) and values that trended toward significance were 
defined as *(P < 0.1).
80 
 
5.3.4 Increased HIV-gp41 and p66 cytotoxic and antiviral activities in the genital tracts of 
women who used tenofovir 
 
In order to ascertain the evolution in nNAb mediated NK cell activated ADCC activity over 
time, longitudinal analyses from 3 months to 12 months were done. Placebo arm responses 
to gp41, decreased from 3 months (1096; IQR = 614.4 - 1663) to 6 months (666; IQR = 421 - 
842.8) (P = 0.008) and from 3 months to 12 months (697; IQR = 355.8 - 1019) (P = 0.016) 
(Figure 22D-F). In contrast, cytotoxic responses to gp41 in the genital tract were similar over 
time in the tenofovir arm (P > 0.1). However, in the tenofovir arm, gp41 specific antiviral 
IFN-γ production increased from 3 months (1288; IQR = 1048 - 1768) to 6 months (1797; IQR 
= 1430 - 2103) (P=0.084) and decreased from 6 to 12 months (1410; IQR = 1238 - 2020) (P = 
0.092) (Figure 22E). P66 specific NK cell activated ADCC activity in the tenofovir arm only, 
was lower at 3 months (84; IQR = 626.5 - 1106) compared to 6 months (754.5; IQR = 615.3 - 
931.3) (P = 0.078) (Figure 22G). However, p66 specific cytotoxic activity increased in the 
tenofovir arm from 6 months to 12 months (903.3; IQR = 774.6 - 1061) (P = 0.065) (Figure 
22G) but this was not significantly different. Longitudinal analysis of p24 specific cytotoxic 
activity in the genital tract of women who used tenofovir only, significantly decreased from 
3 months (356.5; IQR = 140.5 - 34.5) to 12 months (70; IQR = 37.5 - 354.5) (P = 0.094) 
(Figure 22J). Responses to gp120 in the genital tract were similar in both arms over time for 
CD107a, IFN-γ and MIP-1β (P > 0.1) (Figure 22A –C, supplementary Table 5). 
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FIGURE 22: Longitudinal analyses of CVL IgG mediated NK cell activated ADCC activities, in both the tenofovir and placebo arms across 3 
months, 6 months and 12 months. ADCC activities (Log10 ADCC) measured by CD107a, IFN-γ and MIP-1β production in both the tenofovir and placebo 
arm to HIV gp120 (A-C), gp41 (D-F), p66 (G-I) and p24 (J-L). Solid lines in either the tenofovir or the placebo arm within the dot plots indicate the maximum 
geometric mean of each cytokine detected in the ICS assay. Horizontal lines across bars indicate statistical values between arms at over time. Wilcoxon 
Signed Rank tests were performed to elucidate statistical differences, which were defined as ** (P ≤ 0.05) and values trending towards significance, were 
defined as *(P < 0.1). 
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5.3.5 NK cell activated ADCC activities in the genital tract were significantly higher than 
those of the plasma for gp41 and p66 at 3 months, 6 months and 12 months, irrespective 
of study arm 
 
To determine if there was concordance between NK cell activated ADCC activities in the 
plasma and genital mucosae, responses in both arms were compared at 3 months, 6 months 
and 12 months for HIV-gp120, gp41, p66 and p24. Cytotoxic activity (CD107a production) to 
gp120 in the tenofovir arm, was greater in the plasma at 3 months (449.5; IQR = 76.5 - 
640.5) compared to the CVL (24.8; IQR = 14.95 - 31.25) (P = 0.004). This pattern was 
consistent at 6 months [plasma 644; (IQR = 245 - 895); CVL 17.6; (IQR = 5.05 - 27.95)] (P = 
0.001) and at 12 months [plasma 559.5 (IQR = 294.5 - 805.8); CVL 15.95; (IQR =  7.5 - 37.73)] 
(P = 0.002, Figure 23A). Similarly, in the placebo arm, responses to gp120 were significantly 
higher in the plasma at 3 months [plasma 644.8; (IQR = 272.5 - 918.3); CVL 16.35; (IQR = 
5.475 - 49.28)] (P = 0.008), at 6 months [plasma 604; (IQR = 242.3 - 9703.5); CVL 29.6; (IQR = 
10.7 - 64.8)] (P = 0.004) and at 12 months [plasma 609; (IQR = 453 - 694.1); CVL 23.9; IQR = 
2.4 - 33.4)] (P = 0.016, Figure 23B). In contrast, the genital tract shows a different pattern of 
gp41 specific NK cell activated ADCC activities in both arms. In the tenofovir arm, responses 
were greater in the CVL at 3 months compared to those observed in the plasma at 3 months 
[plasma 379.5; (IQR = 58 - 596.5); CVL 808; (IQR = 667 - 1113)] (P = 0.002). This greater CVL 
response was maintained at 6 months [plasma 337.5; (IQR = 34 - 562); CVL 718; (IQR = 591 - 
853.5)] (P = 0.001) and at 12 months [plasma 398; (IQR = 323.3 - 579.3); CVL 753.3; (IQR = 
415.5 - 1317)] (P = 0.009, Figure 23C). Similarly, in the placebo arm, responses to gp41 were 
greater in the CVL at 3 months [plasma 362; (IQR = 25 - 587.9); CVL 1096 (IQR = 614.4 - 
1663)] and 6 months [plasma 268.5; (IQR = 47.5 - 562)]. Only at 12 months responses to 
gp41 in the placebo arm, between the plasma and genital tract (CVL) were similar (P = 
0.194, Figure 23D).  
 
NK cell activated ADCC activity to p66 in the tenofovir arm were greater in the CVL at 3 
months [plasma 422.5; IQR = 338 - 461); CVL 846; (IQR = 626.5 - 1106)] (P = 0.004). These 
responses were maintained at 6 months [plasma 417; (IQR = 351 - 437); CVL 754.5; IQR = 
612.3 - 931.3)] (P = 0.0002) and at 12 months [plasma 428.5; IQR = 390.5 - 479.8); CVL 
903.3; IQR = 774.6 - 1061)] (P = 0.001, Figure 23E). Similarly, in the placebo arm responses 
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to p66 were greater in the genital tract compared to the plasma at 3 months [plasma 398.5; 
(IQR = 356.9 - 512.9); CVL 842.3; (IQR = 720.1 - 1029)] (P = 0.039) and at 6 months [plasma 
420; (IQR = 363.8 - 473.8); CVL 824; (IQR = 729.7 - 957.5)] (P = 0.001). This p66 specific 
response was maintained at 12 months [plasma 433.8; (IQR = 359.6 - 505.6); CVL 691.5; (IQR 
= 575.5 - 801.5)] (P = 0.055, Figure 23F). Interestingly, NK cell activated ADCC activity to p24 
in both the tenofovir and placebo arms (Figure 23G and H), were similar between the 
plasma and genital tract (P > 0.1).  
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FIGURE 23:Compartmental comparisons of NK cell activated ADCC activities between the 
plasma and genital tracts (CVL) of women at 3 months, 6 months and 12 months, between 
the tenofovir and placebo arms, for each HIV-protein. Inter-compartmental analysis for 
cytotoxic activities (Log10 ADCC) in the tenofovir arm on the left and the placebo arm on the right to 
gp120 (A and B), gp41 (C and D), p66 (E and F) and p24 (G and H). Wilcoxon Sum Rank paired tests, 
were done to determine statistical differences between phagocytic activities within each arm of the 
study and between compartments, for each protein. Statistically significant values were defined as 
**P ≤ 0.05 and those that trended as *P < 0.1. 
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5.3.6 NK cell activated ADCC gp41 and p66 specific responses, exhibit strong correlations 
between the plasma and genital tract 
 
To determine whether transudation of nNAb mediating HIV-specific NK cell activated ADCC 
occurred in either arm, Spearman R correlation analyses were done. Interestingly, ADCC 
activity in the plasma positively correlated with ADCC activity in the genital tracts of women 
in the tenofovir arm (R = 0.819; P = 0.002) (Table 13). In the placebo arm for NK cell 
activated ADCC p66-specific responses at 3 months, in the plasma negatively correlated with 
those observed in the genital tract (R = -0.643; P = 0.096). However, in contrast, at 6 
months, in the plasma, p66 specific NK cell activated ADCC activity strongly correlated with 
those in the genital mucosa (R = 0.809; P = 0.004) (Table 13). No further significant 
correlations were observed for gp120 and p24. 
 
 
 
 
  
TABLE 13: Compartmental correlations of cytotoxic activity between the plasma and the genital tract (CVL), 
for the tenofovir and placebo arms, for all HIV-proteins 
Protein Arm 3 months 6 months 12 months 
  R-value P-value R-value P-value R-value P-value 
gp120 Tenofovir -0.300 0.437 -0.236 0.437 -0.358 0.313 
 
Placebo -0.084 0.849 0.35 0.359 -0.631 0.143 
gp41 Tenofovir 0.043 0.918 0.281 0.307 0.819 0.002** 
 Placebo 0.464 0255 0.057 0.862 0.068 0.856 
p66 Tenofovir -0.333 0.349 -0.148 0.630 0.175 0.588 
 
Placebo -0.643 0.096* 0.809 0.004** 0.267 0.493 
p24 Tenofovir -0.300 0.683 0.036 0.964 -0.100 0.950 
 
Placebo 0.5 > 0.999 -0.257 0.658 0.8 0.333 
**indicates significant values defined as P ≤ 0.05 
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5.3.7 CD4+ T cell count correlates negatively with HIV-gp41 and positively with HIV-p66 
specific NK cell activated ADCC activity in the tenofovir arm at 6 months post-infection 
 
In order to determine if NK cell activated ADCC activity in the plasma correlated with CD4+ T 
cell counts in the plasma and genital tract correlation analyses were performed. Analysis 
revealed a significant negative correlation in the plasma, between CD4+ T cell count and 
gp41 specific NK cell activated ADCC activity in the tenofovir arm (R = -0.501; P = 0.018) 
(Table 14). Interestingly a positive but weak correlation trended for HIV-p24 NK cell 
activated ADCC, in the plasma tenofovir arm (R = 0.397; P = 0.067). No further differences or 
similarities were observed when CD4+T cells were compared to HIV-specific gp120, p66 in 
the plasma tenofovir or placebo arm. In the genital tract, no significant correlations were 
observed for HIV protein specific NK cell activated ADCC activity and blood CD4+ T cell 
counts for either arm (Table 14).  
 
 
 
 
 
 
  
TABLE 14:  Correlations between CD4+ T cells and NK cell activated ADCC activities for all HIV-specific antibodies at 6 
months post-infection, in the plasma and the genital tract (CVL) 
HIV 
antigens 
CD4+ T cell count vs 
Plasma ADCC by 
CD107a 
(Tenofovir) n = 22 
CD4+ T cell count vs 
Plasma ADCC by 
CD107a 
(Placebo) n = 23 
CD4+ T cell count vs 
CVL ADCC by CD107a 
(Tenofovir) ^ n = 12 
CD4+ T cell count vs 
CVL ADCC by CD107a 
(Placebo) ^ n = 10 
  R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 0.081 0.719 -0.031 0.889 0.245 0.443 -0.383 0.313 
gp41 -0.501 0.018** 0.243 0.264 -0.021 0.952 0035 0.921 
p66 -0.051 0.821 -0.330 0.124 -0.231 0.471 -0.5 0.122 
p24 0.397 0.067* -0.274 0.207 0.233 0.552 0.204 0.629 
*indicates values that trended to significance, defined as P < 0.1 
**indicates significant p-values which were classified as P ≤ 0.05 
^CVL was not available for 10 participants in the tenofovir arm and 12 participants in the placebo arm. Therefore, the 
values represented were from the available CVL samples to test for each protein.  
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5.3.8 HIV-gp41 specific NK cell activated ADCC activity in the plasma placebo arm, 
negatively correlated with viral load at 6 months post-infection in the plasma 
 
To identify the impact of NK cell activated ADCC activity in the plasma on viral loads at 6 
months post-infection, in the tenofovir and placebo arm, correlation analyses were 
performed. The analyses showed a significant weak negative correlation between HIV-gp41 
specific nNAb mediating cytotoxic activity in the plasma of the placebo arm and viral load (R 
= -0.433; P = 0.039). Thus, as HIV-gp41 NK cell activated ADCC activity increased, viral load 
decreased, possibly due to cytotoxic activity. No further correlations were observed 
between any other HIV-protein specific NK cell activated ADCC activities analysed and 
plasma viral loads (Table 15). Many samples were unavailable for certain time points, 
therefore many CD4+ T cell correlations with genital tract HIV specific NK cell activated ADCC 
activities had to be excluded, which precluded a more complete analysis of the data.  
 
 
 
  
TABLE 15:Correlations between the viral loads and NK cell activated cytotoxic activities mediated by HIV-
specific antibodies, at 6 months post-infection, in the plasma and the genital tract (CVL) 
HIV 
antigens 
Viral load (Log10) 
vs plasma ADCC 
- CD107a 
(Tenofovir) 
n = 23 
Viral load (Log10) 
vs plasma ADCC 
- CD107a 
(Placebo) 
n = 23 
Viral load (Log10) 
vs CVL ADCC 
- CD107a 
(Tenofovir) 
^ n = 12 
Viral load (Log10) 
vs CVL ADCC 
- CD107a 
(Placebo) 
^ n = 10 
 R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 0.205 0.348 0.268 0.216 0.313 0.298 0.05 0.912 
gp41 -0.056 0.800 -0.433 0.039** -0.361 0.185 -0.109 0.737 
p66 0.048 0.826 -0.043 0.844 -0.028 0.931 0 >0.999 
p24 0.205 0.348 -0.032 0.886 -0.35 0.359 -0.108 0.806 
**indicates significant p-values which were classified as P ≤ 0.05 
^ CVL was not available for 11 participants in the tenofovir arm and 13 participants in the placebo arm. Therefore, the 
values represented were from the available CVL samples to test for each protein. 
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5.3.9 HIV-p24 IgG titres negatively correlated with HIV-p24 specific NK cell activated ADCC 
activity in the tenofovir arm at 6 months post-infection 
 
Correlation analyses were performed in order to ascertain the association between 
previously reported antibody titres (Archary et al., 2016) and HIV specific NK cell activated 
ADCC activities. At 6 months post-infection and only in the tenofovir arm, HIV-p24 IgG titres 
correlated with ADCC activity in the plasma (R = -0.430; P = 0.041) and in the genital tract (R 
= -0.174; P = 0.058) (Table 16). Neither the tenofovir nor the placebo arms demonstrated 
significant correlations between IgG titres and NK cell activated ADCC activity to gp120, 
gp41 and p66. 
 
 
 
 
 
  
TABLE 16: Correlations between HIV-specific IgG titres and HIV-specific antibody mediated cytotoxic 
activities at 6 months post-infection, in the plasma and the genital tract (CVL) 
HIV 
antigens 
IgG titres (Log10) 
vs plasma ADCC 
- CD107a 
(Tenofovir) n = 23 
IgG titres (Log10) 
vs plasma ADCC 
- CD107a 
(Placebo) n = 23 
IgG titres (Log10) 
vs CVL ADCC- 
CD107a 
(Tenofovir) ^ n = 12 
IgG titres (Log10) 
vs CVL ADCC- CD107a 
(Placebo) ^ n = 10 
 R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 -0.021 0.925 0.034 0.879 -0.160 0.600 0.274 0.476 
gp41 -0.069 0.755 -0.188 0.390 -0.162 0.560 -0.081 0.894 
p66 -0.270 0.212 0.121 0.584 0.416 0.181 0.523 0.103 
p24 -0.430 0.041** 0.087 0.692 -0.174 0.058* 0.120 0.779 
*indicates values that trended to significance defined as P < 0.1 
**indicates significant p-values which were classified as P ≤ 0.05 
^ CVL was not available for 11 participants in the tenofovir arm and 13 participants in the placebo arm. Therefore, the 
values represented were from the available CVL samples to test for each protein. 
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5.3.10 Moderate to strong correlations between ADCP and NK cell activated ADCC activity 
in the plasma, to HIV-gp120, gp41 and p66 
 
In order to elucidate any correlations between the two different nNAb functions assessed in 
this study and to address the final objective, correlation analyses of HIV-specific IgG-
mediated ADCP and NK cell activated ADCC activities in the systemic compartment and in 
the genital tract were performed. In the plasma HIV-gp120 specific ADCP activity directly 
correlated with NK cell activated ADCC activity at 6 months in the tenofovir arm (R = 0.422; 
P = 0.035) (Figure 24A) and at 3 months in the placebo arm (R = 0.442; P = 0.087) (Figure 
24B, supplementary Table 9). Interestingly, HIV-gp41 nNAb ADCP activity in the tenofovir 
arm at 6 months, positively correlated with NK cell activated ADCC at the same time point (R 
= 0.523; P = 0.011) (Figure 24C). Similarly, at 12 months in the placebo arm, ADCP and NK 
cell activated ADCC activity to HIV-gp41, exhibited a strong, significant, positive correlation 
(R = 0.566; P = 0.006) (Figure 24D). Furthermore, nNAb functions to p66 at 12 months post-
infection in the tenofovir arm also showed strong, direct and significant correlations (R = 
0.708; P = 0.002) (Figure 24E), indicating that in the plasma, both nNAb functions may occur 
simultaneously with similar magnitudes of activities, no correlations were observed for p24 
specific activity (supplementary Table 8).  
 
Interestingly, when ADCP in the genital tract were correlated to NK cell activated ADCC 
activities in the genital tract, no significant associations were observed (supplementary 
Table 9) for any of the HIV-specificities.  
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FIGURE 24: Correlations comparing ADCP and NK cell activated ADCC activities in the 
plasma and genital tracts (CVL) of women in both the tenofovir and the placebo arms. HIV-
specific activities (both Log10) A) gp120 responses at 6 months in the tenofovir arm, B) gp120 
responses at 3 months in the placebo arm, C) gp41 responses at 3 months in the tenofovir arm, D) 
gp41 responses at 12 months in the placebo arm, E) p66 responses in the tenofovir arm in the 
plasma. Spearman R correlation analyses were performed and patient nNAb HIV-specific functions 
were matched in the plasma and in the genital tracts of women. Significant values were identified as 
** P ≤ 0.05 and those that trended as * P < 0.1. 
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CHAPTER 6  
 
Discussion  
 
In recent years, there has been emerging evidence strongly supporting the role of non-
neutralizing antibodies in preventing, controlling and altering HIV disease progression 
(Haynes et al., 2012a, Halper-Stromberg et al., 2014). However, in the era of PrEP as a new 
HIV prevention strategy in combination with HIV vaccines, the subsequent effect of PrEP on 
immunity, in particular antibody functionality has yet to be determined. In this novel study, 
we investigated the effect of prior PrEP on ensuing nNAb functions in both the blood and 
genital tracts of women from the CAPRISA 004 1 % tenofovir gel trial. NNAb assessed 
included Fc-mediated ADCP using a neutrophil-based assay, as well as a NK cell activated 
ADCC, using a novel intracellular cytokine staining based assay. IgG isolated from the plasma 
samples and matching genital tract CVL supernatants were investigated for nNAb 
functionality to HIV-1 proteins, from 24 women who had used either 1 % tenofovir gel or 
the placebo gel respectively, prior to seroconversion (Abdool Karim et al., 2010). We report 
that prior use of the topical 1% tenofovir microbicide gel impacted antibody functionality in 
women who used the gel prior to HIV-1 infection compared to the placebo gel users. 
Furthermore, this study showed that prior use of the gel did not diminish antibody 
detectability or functionality both systemically or at the genital tract  
In this study, plasma IgG concentrations were much higher compared to those in the genital 
tract, irrespective of arm assignment of women, corroborating with previously reported 
data by Archary et al., (2016). The quantity of IgG’s in the genital tract depends on whether 
IgG is locally produced (Bélec et al., 1995) or is transudated across the epithelial barrier (Li 
et al., 2011). Various factors influence transudation dynamics such as FcRn expression on 
epithelial cells, the glycosylation properties of the IgG Fc portion (Ackerman et al., 2013a), 
the affinity interaction between antibody Fc-FcRn on epithelial cells (Gupta et al., 2013, Li et 
al., 2011) and the pH of the genital tract [as reviewed by (Cocklin and Schmitz, 2014)]. 
Furthermore, IgG compared to IgA is well known to be the most dominant antibody isotype 
in the female genital tract (Bomsel et al., 2011, Bélec et al., 1995, Archary et al., 2016, 
Johansson and Lycke, 2003). Indeed, this Ig isotype in particular, may have functional 
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relevance, given that Env-specific IgG1 and IgG3 mediate enhanced ADCP (Tay et al., 2016, 
Liu et al., 2016). In this study, HIV-specific IgG phagocytic function was highly detected in 
both the plasma and the genital tract in women irrespective of study arm. Notably, ARV 
treatment has been associated with reduced antibody titres (Hare et al., 2006, Payne et al., 
2015, O'sullivan et al., 2002) and reduced antibody avidity (Laeyendecker et al., 2015) and 
to date the effect on antibody functionality is not known. In this study, we observed inverse 
correlations in both arms of the study, between HIV-specific IgG titres and nNAb functions. 
The inverse correlations between gp41 and p24 IgG titres and the HIV-specific phagocytic 
activities, in the tenofovir and placebo arm respectively in the plasma, indicate that even in 
the presence of low titre HIV-specific antibodies, nNAbs may still be able to elicit potent 
antiviral ADCP functions. Our findings corroborate other studies, which report that it is the 
quality of the elicited antibodies and not necessarily the magnitude, that is key to conferring 
protection (Hessell et al., 2009a, Mascola et al., 2000, Hessell et al., 2009b). 
Due to nNAb engagement with innate immune cells, effector cell populations at sites of 
infection influence Fc –mediated antiviral activity (Cheeseman et al., 2016, Sips et al., 2016). 
Furthermore, neutrophils and monocytes/ macrophages may confer superior protection due 
to their relative abundance compared to other immune cells in the female genital tract (Sips 
et al., 2016, Tay et al., 2016). In this study, we report phagocytic activities in the genital tract 
to levels comparable to the plasma in women who used tenofovir gel. During HIV-infection, 
in the presence of the tenofovir or placebo gel, neutrophil-mediated gp120 specific ADCP 
increased over time in the blood. Furthermore, gp41 and gp120 specific ADCP activity in the 
genital tract were directly associated with those systemically, in both arms. In the genital 
tracts of women in the placebo arm, gp120 specific phagocytic activities negatively 
correlated with viral loads, at 6 months post-infection. This data may indicate that Env-
specific phagocytosis may be undermined in the genital tract with increasing plasma viral 
loads, possibly due to circulating gp120-mediated specific ADCP, resulting in less gp120-
specific antibodies transudating into the genital tract or that gp120 antibodies showed 
delayed kinetics in the genital tract. Our data indicates that gp120 ADCP and NK cell 
activated ADCC remained higher in the plasma than the genital tract compared to other HIV-
specific antibodies mediating either functions. Therefore, the detectability or increases in 
HIV-specific antiviral activities suggest that prior tenofovir gel use did not dampen these 
responses. Interestingly, women from the tenofovir arm had distinct functional differences 
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from those in the placebo arm with enhanced gp70 V1V2, gp41 and p66 ADCP systemically, 
over time. This enhanced HIV-specific IgG mediated phagocytic activity in the tenofovir arm 
may suggest immune priming due to continuous antigen exposure over a long period of 
time prior to infection (Archary et al., 2016, Haynes et al., 2012a, Cranage et al., 2008). 
Notably, in this study phagocytic responses to gp70 correlated with an increase in CD4+ T cell 
counts and not viral loads, which may impact humoral immune nNAb responses due to 
preserved CD4+ T cells and resulting B cell interaction. Other studies, have suggested that 
antibodies that bind to variable regions of the HIV envelope, may impede infection (Pinter 
et al., 1998, Gorny et al., 1993, Corti et al., 2010, Mouquet et al., 2011, Rerks-Ngarm et al., 
2009). Additionally, gp70 directed antibodies have also exhibited cross-clade reactivity with 
other HIV subtypes as well as to HIV-subtype C, the most prevalent subtype in South Africa 
(Zolla-Pazner, 2014), further underscoring the importance of the inclusion of Env as a 
vaccine immunogen (Haynes et al., 2012a). Interestingly, gp70  antibody specific profiles 
have also been linked to enhanced phagocytic activity associated with IgG3 (Zolla-Pazner, 
2014, Chung et al., 2015), which corroborates our gp70 specific ADCP activity. However, 
whether this can be attributed to a IgG specific subclass was not investigated in this study. 
Notably, ADCP activity has also been identified as a correlate of protection in the RV144 trial 
(Chung et al., 2014), therefore the increased phagocytic activities observed in this study, 
suggest the potential benefits of PrEP in enhancing nNAb associated protection from HIV 
infection, in the absence of neutralization. These findings further underscore the 
importance of the inclusion of Env targets (Haynes et al., 2012a), not only as a bNAb vaccine 
immunogen but also to elicit nNAb functions, as correlates of protection and post-infection 
viral control mechanisms (Barouch et al., 2015, Bournazos et al., 2014, Hessell et al., 2007, 
Chung et al., 2015).  
In addition to ADCP, NK cell mediated ADCC has been recognized as a correlate of 
protection, effecting viral control in elite controllers (Lambotte et al., 2009) and delaying 
disease progression (Baum et al., 1996a, Gómez-Román et al., 2005, Aasa-Chapman et al., 
2005, Ljunggren et al., 1990, Ahmad et al., 1994). More importantly, ADCC activity was 
identified as a correlate of protection in the only vaccine trial to exhibit a 31.2 % efficacy 
(Haynes et al., 2012a, Rerks-Ngarm et al., 2009). The main effector cells mediating ADCC 
antibodies, are NK cells which engage and destroy infected cells by recognition of stress 
ligands [as reviewed by (Moretta et al., 2001)]. ADCC gp120 and p66 specific IFN-γ and MIP-
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1β production, for both arms, exhibited increased antiviral production over time. 
Subsequent to acute infection, cellular and humoral responses to HIV regulatory proteins in 
a NHP study, reportedly contributed to HIV control (Florese et al., 2009). In addition to p66 
responses, p24 specific CD107a NK cell activated ADCC was directly associated with CD4+ T 
cell counts and in the tenofovir arm, we observed an increase in MIP-1β production. We 
report that NK cell activated ADCC activity, in the plasma to p66 was positively associated 
with CD4+ T cells in women who used tenofovir prior to infection, these data provide 
additional evidence for the role of nNAbs in altering disease progression. Additionally, p24 
specific CD107a NK cell activated ADCC was directly associated with CD4+ T cell counts in the 
tenofovir arm. These data corroborate findings that preserved Gag-specific CD4+ T cells in 
the context of topical PrEP (Mureithi et al., 2012), can confer help to B cells, a hypothesis 
that was tested by Archary et al., (2016). In the context of topical PrEP, Gag specific CD4+ T 
cells in women who used tenofovir gel were reportedly preserved 3 months post-infection 
in the plasma (Mureithi et al., 2012) and our data suggest that these Gag specific NK cell 
activated ADCC responses continued until 6 months post-infection. CD4+ antigen specific T 
cells significantly influence antibody development, allowing for antigen presentation and 
contributing significantly to antigen specific B cells and antibody development (Moir et al., 
2003). It is well known that HIV infection, results in dysfunctional B cell responses (Moir et 
al., 2003, Bussmann et al., 2010, Nicholas et al., 2013) and various immune responses, which 
in the presence of PrEP, may have been rescued and preserved (Mureithi et al., 2012, 
Abdool Karim et al., 2010, Archary et al., 2016). The resulting cellular and humoral 
interactions possibly allowed for affinity maturation, due to preserved antigen specific CD4+ 
T cell populations, leading to increased ADCC activity 6 months post-infection (Nicholas et 
al., 2013, Mureithi et al., 2012, Archary et al., 2016). Furthermore, gp41 and p24 antibody 
responses have been correlated with delayed disease progression (Schmidt et al., 1989, 
Fernández-Cruz et al., 1990, Mertens et al., 1990, Allain et al., 1991, Sheppard et al., 1991, 
Cheingsong-Popov et al., 1991, Chargelegue et al., 1993a, Zwart et al., 1994, Chargelegue et 
al., 1993b, Chargelegue et al., 1995, Morand‐Joubert et al., 1995, Garland et al., 1996, 
Thomas et al., 1996, Farzadegan et al., 1992). The increase and decrease of gp41 responses 
from 3 months to 12 months, may be attributed to antibody responses stimulated due to 
the presence of antigen, and the subsequent decline due to the decrease in viral protein 
production, as suggested in a previous study (Mcrae et al., 1991). Specifically, data from a 
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study by McRae et al., 1991 indicated that fluctuations in p24 antigen may be due to to the 
decrease in viral protein production often associated in HIV-disease, and therefore it is 
plausible that any fluctuations in HIV viral loads, could impact other HIV antigens [like gp41, 
or p66] and therefore related humoral or other immune functions. These gp41 and p24 
responses suggest that stimulating the production of certain antibodies through antigen 
specific T cell help may aid in nNAb activity. The elevated mucosal HIV-gp41 NK cell 
activated ADCC activity in the genital tract of women in the tenofovir arm further infer that 
gp41 specific Ab responses may have been a result of cumulative immune priming (Cranage 
et al., 2008) and pre-existing cross reactivity with commensal bacteria (Trama et al., 2014, 
Williams et al., 2015), even in the presence of tenofovir gel. In the placebo arm, a negative 
correlation between gp41 specific NK cell activated ADCC and viral loads at 6 months post-
infection were observed in the plasma. Therefore, in the absence of prior topical PrEP, 
circulating nNAbs are capable of antiviral activity, which in macaque studies have been 
associated with correlates of protection (Bomsel et al., 2011, Hessell et al., 2010).  
NK cells in the gut and genital tract during HIV infection have been reported to be 
phenotypically similar [as reviewed by (Roy, 2000)]. Furthermore, following HIV infection, 
NK cells were reported to expand in the intraepithelial lining and lamina propria at the 
mucosae and was directly shown to be associated with CD4+ T cell loss (Sips et al., 2012). In 
the presence of ARVs where CD4+ T cell counts were still not completely recapitulated, 
corresponding NK cell expansions were observed (Sips et al., 2012). NK cells in the gut 
expand in the intraepithelial lining and lamina propria at the mucosae, due to extensive 
CD4+ T cell loss and incomplete CD4+ T cell restoration associated with ARV treatment (Sips 
et al., 2012). Therefore, it is plausible that perhaps NK cells in the lamina propria in the 
genital tract expand during infection to target infected cells. This suggests that the observed 
NK cell mediated ADCC activity observed in the genital tracts of women in this study, 
irrespective of arm, might have increased in responses to NK cell expansion at the site of 
transmission. However, this requires further investigation into NK cell-mediated activities in 
response to infection, specifically in the female genital tract. Moreover, NK cell-mediated 
ADCC activities were shown to control viral loads in elite controllers and were a correlate of 
protection in highly exposed seronegative women (HESN) (Baum et al., 1996b, Lambotte et 
al., 2009). These ADCC-mediating nNAbs were also found at early stages of HIV infection 
(Connick et al., 1996, Forthal et al., 2001). Furthermore, in the context of menstrual cycles, 
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NK cells are reportedly stable (Martin et al., 2002, Alter et al., 2007a), underscoring the 
importance of harnessing NK mediated anti-HIV activity at the most vulnerable surface - the 
female genital tract (Martin et al., 2002, Alter et al., 2007b).      
However, NK cells are present at low frequencies in vaginal tissue (Sips et al., 2016) and 
should there be lower titres of HIV-specific IgG’s mediating NK ADCC in the genital 
secretions, NK cell mediated activity alone, may likely be inadequate in reducing genital 
tract viral loads or preventing HIV infection (Cheeseman et al., 2017). In addition to NK cell 
activity, the IFN-γ production observed in response to gp120, gp41 and p66 in both arms, at 
varying time points and in both compartments, suggests that this antiviral cytokine may 
have played a role in augmenting NK cell activity. The stimulatory function of IFN-γ (Welsh, 
1984, Boehm et al., 1997) may likely be involved in post-infection control of viremia and 
furthermore influences Ig class switching and thus antibody production (Mills et al., 1990). 
NK cells produce MIP-1β, a chemotactic cytokine which may magnify the immune responses 
through NK cell recruitment (Taub et al., 1995, Pincetic et al., 2014). In the genital tract, 
while the MIP-1β production was secondary to gp41 specific NK cell activated ADCC, and 
CD107a NK cell activated ADCC for p66 was elevated in the tenofovir arm, the CD107a gp41 
NK cell activated ADCC diminished significantly in the placebo arm over time. Indeed, innate 
immune functions involving effector cells and synergized innate antibody recruitment have 
been associated with elite controllers (Ackerman et al., 2016). NHP studies have shown a 
strong and direct association between the Env IgG titres and ADCC activity (in Env prime 
boost strategies) which conferred protection to SHIV infection (Xiao et al., 2010, Florese et 
al., 2009). In this study however, a negative association was found between p24 CD107a NK 
cell activated ADCC activity and p24 specific IgG titres both in the blood and genital 
compartments, and this may suggest that even in the presence of low IgG-specific titres, 
antibody function is not compromised. Previously Archary et al., (2016) did show that p24 
specific IgG binding titres were assciated with the placebo rather than the tenofovir arm. 
These data may further suggest that despite low p24 specific titres in the genital tract or 
blood of tenofovir gel exposed women, the p24-specific NK cell activated ADCC function is 
preserved. Therefore, there is rationale to harness nNAb targets that effect ADCC function 
for example, even if available in low titres, which likely may exert functional activity on 
contemporaneous virus and may circumvent the need to focus solely on only developing 
epitope based neutralizing recognition [as reviewed by (Overbaugh and Morris, 2012)]. 
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Whether both HIV-specific ADCC and ADCP functions need to be equally exerted in the 
genital tract and systemically remains a point of interest.  
The magnitudes of ADCP and ADCC functions directly correlated to those in the plasma for 
gp120, gp41 and p66-specific activities. These data highlight the plausibility of inducing an 
immune response capable of targeting multiple epitopes, which may contribute to reducing 
viral loads (Moog et al., 2014). Our data showed that ADCP and NK cell activated ADCC 
activities for any of the HIV-antibody specificities were not correlated in the genital tract, 
indicating that certain HIV-specific antibodies that may elicit redundant nNAb functions may 
occur simultaneously, although they may not occur at the same magnitude, or in the same 
compartment but may act in a coordinated manner (Ackerman et al., 2016). ADCC and ADCP 
functions may be differentially regulated possibly to avoid redundancies of nNAb functions, 
and supports the notion that various immunological mechanisms of protection occupy 
specific compartmental spaces in pathogenic control (Tay et al., 2016, Liu et al., 2013). 
Whether this profile of a coordinated functional relationship is restricted to, certain other 
HIV-IgG specificities not covered in this study and to the genital tract remains to be 
determined. IgG predominates the genital tract and is associated with ADCC activity 
(Mestecky et al., 2011, Jackson et al., 1999, Stratov et al., 2008) and reduced genital tract 
viral loads (Nag et al., 2004) and may likely play a role in ameliorating disease progression 
(Pincetic et al., 2014). The data from our study showed that plasma gp41 specific NK cell 
activated ADCC activity was negatively associated with plasma viral loads. Additionally, 
other studies have shown strong associations between ADCC activity in mucosal fluids such 
as breastmilk of infected mothers, and decreased infant mortality and HIV transmission 
(Milligan et al., 2015, Mabuka et al., 2012), further supporting the role of mucosal 
associated ADCC activity in reducing HIV disease progression. Furthermore, localization of 
effector cells (Cheeseman et al., 2016) and immune cell trafficking, may influence the 
predominant Fc-mediated activity prevailing, depending on the expression of antibody 
subclass specific FcR expressed on effector cells (Cheeseman et al., 2016, Dugast et al., 
2011). Interestingly, viral suppression has been associated with a more enhanced effector 
cell activity suspected to influence antibody glycosylation and thus nNAb functionality, 
which may in part be due to B cell education (Ackerman et al., 2013a). Therefore, 
vaccination with immunogens that elicit nNAbs may provide increased antiviral control in 
concert with NAbs  (Moog et al., 2014). Several studies have suggested that Fc-associated 
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functions enhance bNAb responses (Bournazos et al., 2014, Hessell et al., 2007, Halper-
Stromberg et al., 2014). Therefore, elucidating the non-neutralizing functions that augment 
bNAb functions may be central to mucosal protection and also in limiting systemic spread of 
the virus, an important consideration for HIV reservoir and cure studies.  
Although this study investigated the functional activity of IgG using peripheral neutrophils 
and NK cells, the study’s findings support the role of tissue resident neutrophils in mediating 
phagocytosis (Sips et al., 2016). Furthermore, the fairly consistent populations of 
neutrophils and NK cells in tissue during inflammation (Sips et al., 2016), may be harnessed 
by nNAbs to elicit antiviral activity. Additionally, a polyfunctional antibody response 
mediated by IgG1 and IgG3 has been shown to recruit and engage other effector functions 
to induce a synergistic nNAb response that maintains viremia at levels below detectability 
(Ackerman et al., 2016). However, this study did not exploit the relative contributions of 
subclass HIV-specific IgG1 versus IgG3 ADCC or ADCP activities and remains undefined. The 
panel of HIV-specific antibodies used to test for NK cell activated ADCC and ADCP activities 
were premised on the previous publication that showed distinct antibody profiles associated 
with prior topical PrEP (Archary et al., 2016), therefore the panel of HIV-IgG specificities 
tested for, was not exhaustive. In this study, women with prior topical PrEP compared to 
placebo gel users, had increased HIV-gp41 and p66 cytotoxic and antiviral activity in the 
genital tracts indicating preservation of nNAb functions despite HIV infection. In addition, 
NK cell activated ADCC activities in the genital tract were significantly higher, compared to 
circulating plasma NK cell activated ADCC activities for gp41 and p66 over time, indicating 
compartmental differences for these HIV-specific IgG functions. In the context of PrEP, long 
term ARV treatment has been shown to partially reconstitute the immune system (Connick 
et al., 2000), and improve antiviral responses to HIV infection (Ackerman et al., 2016) 
despite the delays in antibody binding avidity (Laeyendecker et al., 2015). Improving nNAb 
function can be engineered through altering the Fc portion of various bNAbs which has 
shown to synergistically enhance Fc-mediated antiviral activity [as reviewed in (Jefferis et 
al., 1998),(Lazar et al., 2006, Sips et al., 2016, Hessell et al., 2007)], suggesting that for 
vaccine development there is rationale for perhaps inducing bNAbs capable of augmented 
Fc-mediated activities.  
Our study focussed on IgG mediated nNAb activities particularly because IgG is more 
common in vaginal secretions than IgA (Bomsel et al., 2011) and was a correlate of 
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protection in the RV144 trial (Haynes et al., 2012a, Yates et al., 2014). One of the limitations 
of this study was that due to the low yield of IgGs in the genital compartment and the 
limited sample volumes available to do the assays the standardization of the concentrations 
of CVL IgGs could not be performed. We therefore used the undiluted CVLs (a sample more 
closely representing in vivo Fc-mediated activities), previously shown to mediate ADCC 
activity as an unpurified IgG mucosal sample (Nag et al., 2004). Therefore, using this method 
allowed us to assess both the ADCP and NK cell activated ADCC activities of genital tract 
specimens. We did however, standardize for the volume of undiluted CVL used in these 
assays.  To address this limitation, we suggest that the soft-cup method of genital specimen 
collection which has been proven to display superior and concentrated amounts of total 
immunoglobulins (Ig) compared to CVL should be used (Archary et al., 2015, Mkhize et al., 
2016). Therefore, future studies should be done using a less diluted genital tract specimen 
like that obtained in the soft-cup sample in order to make an accurate and direct 
comparison between the genital tract and the blood. We acknowledge that this is a 
limitation of our current method which depended on a diluted CVL specimen, which was 
collected routinely as part of the genital tract specimens in the CAPRISA 004 clinical trial 
study. A further limitation of this study was the lack of comparison for the NK cell activation 
ADCC assays with the RFADCC assay, mostly due to the lack of sample availability. Another 
limitation is that we did not evaluate the impact of PrEP on IgA nNAb activities in the blood 
or genital tracts of women. Various studies have shown that gp41 specific IgA’s prevent viral 
transcytosis of HIV across mucosal tissue (Bomsel et al., 2011, Alfsen et al., 2001, Tudor et 
al., 2009, Yates et al., 2013, Devito et al., 2000). However, due to the lack of availability of 
genital specimens for further experiments, such experimental analyses cannot be 
undertaken and should perhaps be interrogated in other PrEP studies. In chronic HIV 
infection NK cells are dysfunctional [as reviewed by (Fauci et al., 2005)], in the absence of 
contemporaneous, autologous NK cells or neutrophils from the study’s participants, we 
cannot confirm any cellular dysfunction. However, the strengths of the study include the 
longitudinal analysis of the matching plasma and genital tract specimens that allowed us to 
cross-examine both mechanistic functions of the IgG’s over time and in both compartments 
and relate these findings to HIV-specific binding antibody titres from previously published 
data. This study was designed to be a case-matched control study based on plasma viral 
loads and CD4+ T cell counts at 6 months post-infection. NNAb differences observed 
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between the tenofovir and placebo arms were not confounded by differences between the 
groups, for markers of disease progression. However, the effect of NK cell activated ADCC 
activities on viral loads in the genital tract were not assessed and warrants further 
investigation to determine the contribution of local nNAb activity on genital tract viral load 
control. In addition, in this study effector cells from healthy individuals were used, which 
has previously been shown to augment nNAb cell mediated antiviral activity (Chung et al., 
2011). Therefore, we suggest that if PrEP preserves NK cell function, it may lead to better 
protection from HIV infection at sites of transmission. However, the effects of PrEP on 
autologous NK cells and other effector cells associated with innate immunity, remains a gap 
in our knowledge. In light of several limitations, we were able to show that there are 
compartment specific differences for NK cell activated ADCC and ADCP functions, where 
higher NK cell activated ADCC activity in the genital tract may translate to lower ADCP for 
the same HIV specificity mediating nNAb functions. Therefore, these data will have to be 
more thoroughly investigated in larger studies.  
Conclusions 
Our findings suggest that prior topical PrEP usage did not dampen but rather primed and 
augmented certain humoral nNAb activities in the plasma and genital tracts of women who 
used 1 % tenofovir gel and underscores the potential role of nNAbs that target a variety of 
HIV epitopes in vaccine design. These data indicate that certain HIV-specific nNAb immune 
activities, which may contribute to HIV protection, also show differences in magnitudes for 
these activities and may be compartment specific possibly to avoid immunological 
redundancies and avert extra inflammation associated with nNAb functions. Moreover, the 
simultaneous assessment of these two nNAb functions as well as other functions such as 
ADCVI requires further investigation for the contribution of polyfunctional immune 
mechanisms to better protection. Taken together, these data provide more evidence for the 
role of nNAbs as quintessential to a functional and protective immune profile, especially in 
the area of vulnerability, the female genital tract. Further studies should be undertaken to 
assess the impact of oral PrEP on humoral and cellular immunity for correlates of risk and 
protection in the genital tract, especially if combination PrEP and vaccines are to be used as 
HIV prevention strategies.   
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SUPPLEMENTARY FIGURE 1: Titrations of IgG isolated from the plasma of women in the CAPRISA 
004 trial assessing how different IgG titres affect ADCP and ADCC nNAb functional assays. 
Wilcoxon Sum Rank tests were performed in order to determine differences between IgG 
concentrations and their relative functional responses. HIVIG was used to determine optimal IgG 
concentrations to be used in the assays. (A) ADCP phagocytic activities were similar between 
dilutions (P > 0.999). (B) ADCC Cytotoxic activities (CD107a) between 1mg/ml to 0.5mg/ml (P = 
0.721), 0.5mg/ml to 0.025mg/ml (P = 0.169) and 1mg/ml to 0.025mg/ml (P = 0.235), were similar. P = 
NS defined values that were P > 0.1. 
 
 
SUPPLEMENTARY FIGURE 2: Gating strategy for the ADCP assay, investigating the phagocytic 
activity of neutrophils using PBS as a negative control, to indicate the level of background ADCP 
A B C 
D E 
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activity. Live cells were gated on using FSC-A and SSC-A. Sequential gating from live cells, included 
singlets, followed by CD3- cell, neutrophils and then neutrophils that phagocytosed antigen coated 
neutravidin beads.  
 
 
SUPPLEMENTARY FIGURE 3: Gating strategy for the ICS NK cell activated ADCC assay using PBS as a 
negative control, to indicate the level of NK cell activated ADCC background activity. (A) Live cells 
were gated on using FSC-A and SSC-A. Following identification of live cells in this bio-assay, (B) 
singlets were gated on, (C) followed by CD3- cells, (D) CD56+CD16dim NK cells and the subsequent 
cytokine productions to identify NK cell activity (E) CD107a, (F) IFN-γ and (G) MIP-1β. 
 
 
A C D 
E F G 
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SUPPLEMENTARY FIGURE 4: Comparisons of detectable phagocytic activities in the plasma to HIV-
proteins at 3, 6 and 12 months. Phagocytic activity below background phagocytic activity were 
removed, in order to adjust for outliers, for each of the HIV proteins A) gp120, B) gp41, C) gp70 and 
D) p66 and E) p24. Horizontal solid lines within each arm and time point indicate maximum and 
minimum values with the central solid line indicating the median. Horizontal lines across boxes, 
between arms and time points, if any, identify differences between tenofovir and placebo arm 
medians using the Wilcoxon Sum Rank test.  
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SUPPLEMENTARY FIGURE 5: Longitudinal analyses of detectable phagocytic activities in the plasma 
to HIV-proteins from 3 months to 12 months, post-infection, in both study arms. Phagocytic 
activities below background phagocytic activity were removed, in order to adjust for outliers, for 
each of the HIV proteins A) gp120, B) gp41, C) gp70 and D) p66 and E) p24. Horizontal solid lines 
within each arm and time point indicate maximum and minimum values with the central solid line 
indicating the median. Horizontal lines across boxes, between arms and time points, if any, identify 
differences between tenofovir and placebo arm medians using the Wilcoxon Signed Rank test. 
Statistically significant values were defined as **P ≤ 0.05, and those that trended as *P < 0.1. 
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SUPPLEMENTARY FIGURE 6: Comparisons of detectable phagocytic activities in the genital tracts 
(CVL) of women in the tenofovir and placebo arms at 3, 6 and 12 months, post-infection, for all 
HIV-proteins. Phagocytic activities below the background score were removed. Phagocytic scores to 
A) gp120, B) gp41, C) p66 and D) p24 shown in box and whisker plots, with horizontal lines indicating 
the median, maximum and minimum values. Solid black horizontal lines indicate statistical analysis 
using Wilcoxon Sum Rank tests. Significant values were defined as **P ≤ 0.05 and those that trended 
as *P < 0.1.  
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SUPPLEMENTARY FIGURE 7: Longitudinal analyses of detectable phagocytic activities in the genital 
tracts (CVL) of women in the tenofovir and placebo arms, 3 months to 12 months post-infection, 
for all HIV-proteins. Phagocytic activities below the background score were removed. Phagocytic 
scores to A) gp120, B) gp41, C) p66 and D) p24 shown in box and whisker plots, with horizontal lines 
indicating the median, maximum and minimum values. Solid black horizontal lines indicate statistical 
analysis using Wilcoxon-Signed Rank test.   
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SUPPLEMENTARY FIGURE 8: Inter-compartmental analyses of detectable phagocytic activities 
between the tenofovir and placebo arms. Phagocytic activity between the plasma and genital 
mucosae were analysed using a Wilcoxon Rank-Signed test, in order to determine any significant 
differences. HIV-specific phagocytic activities were separated into tenofovir (left) and placebo (right) 
arms according to the respective HIV proteins with A) gp120 tenofovir, B) gp120 placebo, C) gp41 
tenofovir, D) gp41 placebo E) p66 tenofovir, F) p66 placebo, G) p24 tenofovir and H) p24 placebo. 
**P ≤ 0.05 were defined as significant, and those that trended as *P < 0.1 with pink dots indicating 
plasma phagocytic activity and turquoise indicating genital mucosal (CVL) phagocytic activity. 
Maximum and minimum values are shown by solid lines in the box and whisker plots as well as 
median phagocytic activity for each compartment, at different time points. Horizontal solid lines 
above the box and whisker plots identifying significant values.  
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SUPPLEMENTARY TABLE 1: Cross-sectional analyses of plasma tenofovir and placebo phagocytic activities to HIV-gp120, gp41, p66 and p24, at 3, 6 and 12 months, post-infection 
 3 months 6 months  12 months 
 Tenofovir Placebo P - value Tenofovir Placebo P - value Tenofovir Placebo P value 
HIV protein Median (IQR)  Median (IQR  Median (IQR  
Gp120 27.12  
(18.49-39.85) 
26.52  
(1008 – 29.56) 
0.295 27.12 
(21.32 – 49.47) 
27.12  
(18.14 – 39.65) 
0.759 41.99 
(25.17 – 65.51) 
37.52 
(28-49.11) 
0.664 
Gp41 43.85  
(29.48 – 66.04) 
47.26 
 (44.08 – 71.82) 
0.446 51.52  
(37.26 – 71.69) 
49 (39.18 – 62.56) 0.759 64.1  
(41.91 – 71.59) 
54.74  
(38.35 – 71.13) 
0.644 
P66 42.35  
(27.4 – 62.37) 
47.12  
(32.4 – 77.85) 
0.338 62.76  
(50.15 – 84.58) 
41.41  
(24.87 – 80.24) 
0.210 79.01  
(60.21 – 107.5) 
80.89  
(56.81 – 101.9) 
0.664 
P24 27.01  
(6.26 – 80.82) 
59.78  
(10.59 – 93.42) 
0.512 41.51  
(8.018 – 71.99) 
52.79  
(18.71 – 79.68) 
0.609 69.16  
(15.63 – 96.35) 
53.48  
(16.24 – 76.11) 
0.457 
*indicates values that trended towards significance, defined as P < 0.1 
**indicates significant values defined as P ≤ 0.05 
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SUPPLEMENTARY TABLE 2: Cross-sectional analyses of phagocytic activities in the genital tracts of women in the tenofovir and placebo arms at 3, 6 and 12 months, post-infection. 
 3 months 6 months 12 months 
 Tenofovir Placebo P - value Tenofovir Placebo P - value Tenofovir Placebo P value 
HIV protein Median (IQR)  Median (IQR  Median (IQR  
Gp120 9.95  
(3.831 – 14.72) 
9.54  
(7.298 – 20.35) 
0.572 11.81 
(6.07 – 21.1) 
9.735  
(3.431 – 14.23) 
0.235 9.50 
 (4.123- 19.44) 
11.21  
(6.712 – 18.450) 
0.721 
Gp41 19.4  
(5.243 – 65.6) 
23.04  
(5.942 – 41.09) 
0.579 37.92  
(19.4 – 65.6) 
19.4  
(9.43 – 28.93) 
0.014** 19.4  
(7.691 – 53.4) 
19.4  
(16.39 – 23.75) 
0.642 
P66 62.56  
(12.24 – 78.28) 
34.01 
 (22.82 – 65.93) 
0.173 32.33  
(14.68 – 67.99) 
22.98  
(13.37 – 62.46) 
0.039** 63.58  
(33.48 – 83.09) 
24.03  
(17.44 – 54.16) 
0.622 
P24 25.67  
(10.54 – 40.76) 
18.71  
(10.32 – 33.13) 
0.326 25.4  
(14.2 – 36.81) 
19.81 
 (9.989 – 35.65) 
0.860 20.15  
(16.61 – 30.61) 
13.41  
(4.16 – 18.11) 
0.569 
*P < 0.1 indicate values that trend to significance 
** P ≤ 0.05 values that are significant  
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SUPPLEMENTARY TABLE 3: Correlations between detectable phagocytic activities in the plasma and genital tracts for all HIV-proteins, in the tenofovir and placebo arms.  
Protein Arm 3 months 6 months 12 months 
  
R-value P-value R-value P-value R-value P-value 
gp120 Tenofovir 0.283 0.463 -0.027 0.935 0.324 0.280 
 
Placebo -0.218 0.521 0.107 0.642 -0.603 *0.012 
gp41 Tenofovir 0.454 0.092 -0.207 0.355 -0.004 0.989 
 Placebo 0.511 0.054** -0.062 0.769 0.259 0.245 
p66 Tenofovir 0.046 0.873 0.36 0.105 -0.268 0.334 
 
Placebo -0.093 0.744 -0.208 0.342 -0.442 0.051** 
p24 Tenofovir 0.118 0.735 -0.287 0.264 -0.132 0.639 
 
Placebo -0.071 0.821 -0.044 0.859 -0.074 0.750 
*indicates values that trended towards significance, defined as P < 0.1 
**indicates significant values defined as P ≤ 0.05 
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SUPPLEMENTARY TABLE 4: Cross-sectional analyses of plasma ADCC activities mediated by IgG from women in the tenofovir and placebo arms, at 3, 6 and 12 months, post-infection 
3 months 
median (IQR) TFV n = 15 median (IQR) placebo n = 16 P-value 
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 449.5 
 (76.5-640.5) 
494  
(380.5-1158) 
713.5 (106.5-
814)) 
644.8  
(272.5-918.3) 
430.3  
(389.5-995.1) 
719.3  
(89.25-849.4) 
0.041 0.686 0.778 
gp41 379.50  
(58-596.5) 
190.5  
(72-411) 
370.5 (108.5-
2792) 
362  
(25-587.9) 
315.3  
(90.38-406.4) 
403  
(133.6-2792) 
0.616 0.429 0.961 
p66 422.5 
 (338-461) 
1706  
(691.5-1880) 
317.5 (149-
500) 
398.5  
(356.9-512.9) 
1692  
(815.5-1818) 
535  
(323.4-740.8) 
0.741 0.626 0.049** 
p24 109.5  
(65-388.5) 
595  
(527.5-1147) 
129  
(111-580.5) 
100.4  
(36.5-575.3) 
569.5 
 (424.1-1074) 
257.5 
 (159.6-699.4) 
0.792 0.423 0.120 
6 months 
median (IQR) TFV (n=23) median (IQR) Placebo (n=25)  P - value  
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 644 
(245-895) 
497 
(409-1158 
837 (179.5-
1154) 
604 
(242.3-703.5) 
441.5 
(393.5-1158) 
730.5 
(134-865.5) 
0.315 0.847 0.384 
gp41 337.5 
(34-562) 
157.5 
(51.5-304.5) 
368.5 (256-
2792) 
268.5 
(47.5-562) 
233.5 
(98.25-395.5) 
345.5 
(104.8-2792) 
0.786 0.317 0.930 
p66 417 
(351-437) 
1639 
(660-1745) 
246 (112.5-
478.5) 
420 
(363.8-473.8) 
1711 
(1101-1966) 
548.3 
(365.8-764.3) 
0.613 0.086* 0.003* 
p24 310 
(110-566) 
606 
(374-1147) 
415.5 (206-
855) 
149.0 
(111.6-449) 
549 
(451.8-763) 
236.5 
(129.8-591.5) 
0.556 0.744 0.144 
12 months 
median (IQR) TFV (n=17)  median (IQR)Placebo (n=22) P - value 
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 559.5 
(294.5-805.8) 
461 
(392.8-1158) 
733.5 
(144-1256) 
609 
(453-694.1) 
553.8 
(430.9-1158) 
777.8 
(186.6-907.4) 
0.778 0.119 0.763 
gp41 398 
(323.3-579.3) 
155.5 
(50.25-461.2) 
340 
(122-1623) 
380.8 
(52-596.5) 
218.8 
(141.6-379) 
442.3 
(90.13-2792) 
0.749 0.276 0.558 
p66 428.5 
(390.5-479.8) 
1654 
(679.8-1731) 
391 
(95.25-549.5) 
433.8 
(359.6-505.6) 
1741 
(923.6-1864) 
473.3 
(391.8-776.3) 
0.856 0.172 0.049** 
p24 220 
(57.5-634.5) 
536 
(444.8-1161) 
354.5 
(206-734.5) 
128.8 
(70.75-300.1) 
582.3 
(466-1147) 
221 
(136.5-595.8) 
0.295 0.922 0.333 
indicates values that trended towards significance, defined as P < 0.1 
**indicates significant values defined as P ≤ 0.05 
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SUPPLEMENTARY TABLE 5: Cross-sectional analyses of ADCC activities mediated by IgG from the genital tracts of women in the tenofovir and placebo arms, at 3, 6 and 12 months, post-infection 
3 months 
median (IQR) TFV n=15 median (IQR) placebo n=16 P-value 
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 24.8 
(14.95 – 31.25) 
1.32 
(1.32 – 1.43) 
398.4 
(318.6 – 708.4) 
16.35 
(5.475 – 49.28) 
1.32 
(1.32 – 1.32) 
577.4  
(318.6 – 1663) 
0.835 0.559 0.536 
gp41 808 
(667 – 1113) 
1288 
(1048 – 1768) 
2905 
(2555-2990) 
1096 
(614.4 – 1663) 
1665 
(1368 -3210) 
1539  
(1056 – 2905) 
0.573 0.274 0.065* 
p66 846 
(626.5 – 1106) 
891 
(790.4 – 1322) 
8010 
(7652 – 8655) 
842.3 
(720.1 – 1029) 
1079 
(957.8 – 1478) 
9654  
(8361 – 11372) 
0.965 0.274 0.034* 
p24 356.5 
(140.5 – 434.5) 
576 
(487 – 738) 
498 
(149 – 1595) 
434.5 
(49 – 637.5) 
518 
(482.5 – 662.5) 
731 
(250 – 3361) 
> 0.999 0.639 0.751 
6 months 
 median (IQR) TFV (n=23) median (IQR) Placebo (n=25) P - value 
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 17.6 
(5.05 – 27.95) 
1.32 
(1.32 – 1.32) 
668.4 
(293.9 – 1868) 
29.6 
(10.7 -64.8) 
1.32 
(1.135 – 1.345) 
436.4  
(318.6 – 783.4) 
0.144 0.907 0.682 
 
gp41 718 
(591 – 853.5) 
1797 
(1430 – 2103) 
2905 
(1590 – 2905) 
666 
(421 – 842.8) 
1727 
(1240 – 2051) 
2905  
(1766- 2905) 
0.486 0.614 0.510 
p66 754.5 
(615.3 – 931.3) 
1043 
(783.5 – 1221) 
8568 
(8108 – 9041) 
824 
(729.7 – 957.5) 
1088 
(750.5 – 1221) 
8784 
 (8174 – 10591) 
0.361 >0.999 0.424 
p24 189.5 
(86 – 628) 
538 
(502 – 857.5) 
654 
(367 – 2306) 
131.5 
(72.75 – 370.3) 
478.5 
(448.3 – 559) 
2426 
 (396.8 – 3361) 
0.357 0.026* 0.302 
12 months 
 median (IQR) TFV (n=17) median (IQR)Placebo (n=22) P - value 
 CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β CD107a IFN-γ MIP-1β 
gp120 15.95 
(7.5 – 37.73) 
1.32 
(1.32 – 1.32) 
599.9 
(316.3 – 1245) 
23.9 
(2.4 – 33.4) 
1.32 
(0.75 – 1.32) 
318.6  
(318.6 – 1869) 
0.962 0.434 0.756 
gp41 753.3 
(415.5 – 1317) 
1410 (1238 – 2020) 2905 
(2055 – 2905) 
697 
(355.8 – 1019) 
1914 
(1401 – 2672) 
2155 
 (389 -2905) 
0.628 0.228 0.081* 
p66 691.5 
(575.5 – 801.5) 
954.8 (687.9 -1135) 8244 
(6793 – 9255) 
691.5 
(575.5 – 801.5) 
1198 
(948.8 – 1525) 
7953 
 (7145 – 9973) 
0.034* 0.082* >0.999 
p24 70 
(37.5 – 354.5) 
536 (481.5 – 734) 451.5 
(257.3 – 2707) 
175.5 
(91.25 – 541.3) 
577.5 
(466.3 – 882.3) 
3361  
(161.5 – 3361) 
0.298 0.881 0.453 
*indicates values that trended towards significance, defined as P < 0.1 
**indicates significant values defined as P ≤ 0.05 
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SUPPLEMENTARY TABLE 6: Comparison analyses of ADCP and ADCC (CD107a) activities in the plasma of women in the tenofovir and placebo arms, for HIV-gp2120, gp41, p66 and p24.  
3 months 
 Tenofovir   Placebo 
 median (IQR) (n=15)  median (IQR) (n=16) 
 ADCC activity (CD107a) Phagocytic Scores P - value ADCC activity (CD107a) Phagocytic Scores P - value 
HIV proteins       
gp120 2.8 (2.325 – 5.01) 27.12 (18.49 – 38.85) < 0.0001** 3.67 (2.729 – 4.435) 26.52 (10.08 – 29.56) < 0.0001** 
gp41 9.245 (2.42 – 9.52) 43.85 (29.48 – 66.04) 0.0003** 8.413 (1.456 – 11.55) 
47.26 (44.08 – 71.82) 
< 0.0001** 
p66 6.29 (0.63 – 26.45) 42.35 (27.4 -62.37) 0.003** 8.08 (4.135 – 17.02) 47.16 (32.4 – 77.85) 0.0001** 
p24 5.1 (4.63 – 7.435) 27.01 (6.26 – 80.82) 0.0001** 6.52 (5.075 – 8.585) 59.78 (10.59 – 93.42) 0.0004** 
6 months 
 median (IQR) (n = 23) median (IQR) (n = 25) 
 ADCC activity CD107a   Phagocytic Scores  P - value ADCC activity (CD107a) Phagocytic Scores  P - value 
HIV proteins       
gp120 3.705 (2.505 – 8.69) 27.12 (21.32 – 49.47) < 0.0001** 3.85 (3 – 6.065) 27.12 (18.14 – 39.65) < 0.0001** 
gp41 7.62 (1.89 – 9.385) 51.52 (37.26 – 71.69) < 0.0001** 9.25 (1.875 – 11.98) 49 (39.18 – 62.56) < 0.0001** 
p66 5.25 (0.655 -24.05) 62.76 (50.15 – 84.48) < 0.0001** 10.74 (2.686 – 20.72) 42.41 (24.87 – 80.24) < 0.0001** 
p24 6.25 (5.275 – 8.595) 41.51 (8.018 – 71.99) < 0.0001** 6.53 (5.556 – 7.093) 52.79 (18.71 – 79.68) 0.0004** 
12 months 
median (IQR) (n = 17) median (IQR) (n = 22) 
HIV proteins ADCC activity CD107a – median 
(IQR) 
Phagocytic Scores  P - value ADCC activity (CD107a) Phagocytic Scores  P - value 
Gp120 4.375 (2.883 – 12.31) 41.99 (25.17 – 65.51) < 0.0001** 4.348 (2.529 – 10.99) 37.52 (28 – 49.11) < 0.0001** 
Gp41 8.855 (2.305 -9.903) 64.1 (41.91 – 71.59) < 0.0001** 9.08 (1.756 – 10.21) 54.74 (38.35 – 71.13) < 0.0001** 
P66 3.82 (0.755 – 13.87) 79.01 (60.21 – 107.5) < 0.0001** 9.2 (6.33 – 33.51) 80.89 (56.81 – 101.9) < 0.0001** 
P24 7.17 (5 – 9.555) 69.16 – 15.63 – 96.35) 0.0002** 6.88 (5.02 – 9.253) 53.48 (16.24 – 76.11) < 0.0001** 
*indicates values that trend towards significance, defined as P < 0.1 
** indicates values that are significant, defined as P ≤ 0.05 
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SUPPLEMENTARY TABLE 7: Comparison analyses of ADCP and ADCC (CD107a) activities in the genital tracts of women in the tenofovir and placebo arms, for HIV-gp2120, gp41, p66 and p24.  
3 months 
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 Tenofovir   Placebo 
 median (IQR) TFV ^ (n = 12)  median (IQR) TFV ^ (n=12) 
 ADCC activity (CD107a) Phagocytic Scores  P - value ADCC activity (CD107) Phagocytic Scores  P - value 
HIV proteins       
gp120 24.8 (14.95 – 31.25) 9.952 (3.831 – 14.72) 0.004** 16.35 (5.475 – 49.28) 9.544 (7.298 – 20.35) 0.742 
gp41 808 (667 – 1113) 19.4 (5.243 – 74.55) 0.002** 1096 (614.4 – 1663) 23.04 (5.942 – 41.09) 0.008** 
p66 846 (626.5 – 1106) 62.56 (12.24 – 78.28) 0.002** 842.3 (720.1 -1029) 34.01 (22.82 – 65.93) 0.008** 
p24 356.5 (140.5 – 434.5) 25.67(10.54 – 40.76) 0.016** 434.5 (49 – 637.5) 18.71 (10.32 – 33.13) 0.063* 
6 months 
Median (IQR) ^ (n = 17) Median ^(IQR) (n = 18) 
 ADCC activity CD107a Phagocytic Scores  P - value ADCC activity (CD107a) Phagocytic Scores  P - value 
HIV proteins       
gp120 20 (10.45 – 29.43) 11.81 (6.073 – 21.1) 0.193 29.6 (10.7 – 64.8) 9.725 (3.431 – 14.23) 0.039** 
gp41 718 (591 – 853.5) 37.92 (19.4 – 65.6) 0.0001** 666 (421 -842.8) 19.4 (9.43 – 28.93) 0.0005** 
p66 754.5  
(615.3 – 931.3) 
32.33  
(14.68 – 67.99) 
0.0002** 824 (729.7 – 957.5) 22.98 (13.37 – 62.46) 0.001** 
p24 189.5 (86 – 628) 25.4 (14.2 – 36.81) 0.004** 131.5 (72.75 – 370.3) 19.81 (9.989 – 35.65) 0.008** 
12 months 
Median (IQR) ^ (n = 14) Median ^ (IQR) (n =15) 
HIV proteins ADCC activity CD107a – 
median (IQR) 
Phagocytic Scores  P - value ADCC activity (CD107a) Phagocytic Scores  P - value 
Gp120 15.95 (7.5 – 37.73_ 9.499 (4.123 – 19.44) 0.432 23.9 (2.4 – 33.4) 11.21 (6.712 – 18.45) > 0.999 
Gp41 753.3 (415.5 – 1317) 19.4 (7.691 – 53.4) 0.001** 697 (355.8 – 1019) 19.4 (16.39 -23.75) 0.002** 
P66 903.3 (774.6 – 1061) 63.58 (33.48 – 83.09) 0.001** 691.5 (575.5 – 801.5) 24.03 (17.44 – 54.16) 0.004** 
P24 70 (37.5 – 354.5) 20.15 (16.61 – 30.61) 0.023** 122.5 (65 – 331.5) 13.41 (4.16 – 18.11) 0.063* 
*indicates values that trend towards significance, defined as P < 0.1 
** indicates values that are significant, defined as P ≤ 0.05 
^ CVL was not available for some participants in the tenofovir and placebo arms. Therefore, the sample sizes (n) represented were the average number of participant CVL samples available to test for each protein. 
SUPPLEMENTARY TABLE 8: Spearman R correlation analyses of ADCP and ADCC (CD107a) activities in the plasma of women in the tenofovir and placebo arms, at 3, 6 and 12 months post-infection, for all HIV-
proteins.  
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 3 months Tenofovir 3 months Placebo 6 months Tenofovir 6 months Placebo 12 months Tenofovir 12 months Placebo 
 R-value P-value R-value P-value R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 0.132 0.639 0.442 0.087* 0.443 0.034** 0.155 0.461 -0.174 0.503 -0.058 0.797 
gp41 0.090 0.749 0.260 0.331 0.523 0.011** 0.003 0.988 0.767 0.0005 0.566 0.006** 
p66 -0.216 0.440 0.231 0.408 -0.153 0.485 -0.002 0.994 0.708 0.002** 0.166 0.471 
p24 0.391 0.151 -0.082 0.772 0.316 0.142 0.187 0.381 0.348 0.171 0.239 0.297 
*indicates values that trend towards significance, defined as P < 0.1 
** indicates values that are significant, defined as P ≤ 0.05 
SUPPLEMENTARY TABLE 9: Spearman R correlation analyses of ADCP and ADCC (CD107a) activities in the genital tracts of women in the tenofovir and placebo arms, at 3, 6 and 12 months post-infection, for all 
HIV-proteins.  
 
 3 months Tenofovir 3 months Placebo 6 months Tenofovir 6 months Placebo 12 months Tenofovir 12 months Placebo 
 R-value P-value R-value P-value R-value P-value R-value P-value R-value P-value R-value P-value 
gp120 0.355 0.349 -0.436 0.280 -0.311 0.379 0.433 0.250 -0.350 0.324 -0.036 0.964 
gp41 0.128 0.726 0.170 0.688 - 0.429 0.113 -0.088 0.788 0.042 0.904 0.200 0.584 
p66 0.54 0.107 0.184 0.663 0.049 0.878 0.182 0.595 -0.459 0.135 0.167 0.678 
p24 0.072 0.878 0.032 0.959 0.183 0.644 -0.072 0.872 0.381 0.360 0.500 0.450 
*indicates values that trend towards significance, defined as P < 0.1 
** indicates values that are significant, defined as P ≤ 0.05 
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